Aortic Valve Stenosis

Cardiovascular Disease MONDO:0042981 Pathograph 53 Show in embeddings browser

Aortic valve stenosis is obstruction of left ventricular outflow at the valve. Adult calcific disease involves leaflet lipid accumulation, inflammation, fibrosis and mineralization; congenital valve morphology and rheumatic commissural fusion provide other routes to obstruction. Ventricular pressure overload can lead to hypertrophy, fibrosis, impaired filling, myocardial ischemia and heart failure. Symptoms and valve severity, ventricular consequences, anatomy, procedural risk and patient preferences guide intervention. Mechanistic evidence from tissue associations and experimental models does not establish one obligatory sequence in every patient.

Ask OpenScientist

Ask a research question about Aortic Valve Stenosis. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

👪

Inheritance

◆

Subtypes

Calcific stenosis of a tricuspid aortic valve

Age-associated leaflet fibrosis and calcification are a common adult presentation; the molecular and genetic association studies largely address this spectrum.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/ SUPPORT REVIEW SYNTHESIS Human Clinical

"Etiologies include congenital (bicuspid/unicuspid), calcific, and rheumatic disease."

Clinical etiologic synthesis; no subtype frequency is inferred.

Congenital valve-associated stenosis

Bicuspid or unicuspid anatomy can cause valvular obstruction and predispose to later calcification. Bicuspid valves may coexist with aortopathy; only a minority of familial disease is explained by recognized NOTCH1 variants.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/ SUPPORT REVIEW SYNTHESIS Human Clinical

"Etiologies include congenital (bicuspid/unicuspid), calcific, and rheumatic disease."

Clinical etiologic synthesis; no subtype frequency is inferred.

Rheumatic aortic stenosis

Post-rheumatic commissural fusion narrows the valve. This route is distinct from the dominant adult calcific mechanism and often accompanies other rheumatic valve disease.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/ SUPPORT REVIEW SYNTHESIS Human Clinical

"The commissures of the leaflets fuse to leave a small central orifice."

Clinical etiologic synthesis; no subtype frequency is inferred.

◈

Mechanistic Hypotheses

Inflammatory and osteogenic contribution to calcific valve disease

calcific_inflammatory_osteogenic_model EMERGING

Evidence balance 3 support

Surface lesions, lipid accumulation, inflammatory cells and osteogenic markers support a proposed interacting disease process. Human cross-sectional histology does not establish a required temporal order, a single indispensable cytokine or a self-sustaining lipid-independent commitment switch.

Pathograph links

Valvular Surface Barrier Injury -> Valvular Lipid Accumulation INDIRECT UNKNOWN INTERMEDIATES Surface disruption may facilitate lipid accumulation; coexistence in human histology supports a proposed route rather than a demonstrated temporal sequence.

Valvular Lipid Accumulation -> Valvular Inflammatory Infiltration INDIRECT UNKNOWN INTERMEDIATES Lipid-rich lesions recruit or retain inflammatory cells in the proposed calcific disease process; the cited autopsy observations alone do not establish directionality.

Valvular Inflammatory Infiltration -> Valvular Osteogenic Program INDIRECT UNKNOWN INTERMEDIATES Inflammatory and osteogenic features participate in the proposed calcific process. These human tissue studies do not establish a single inflammatory mediator or an obligatory sequence.

Valvular Osteogenic Program -> Aortic Leaflet Calcification INDIRECT UNKNOWN INTERMEDIATES Osteogenic activity is a proposed contributor to mineral deposition; associated markers alone do not prove that this is the only route.

Show evidence (3 references)

PMID:7519131 SUPPORT INDIRECT PRIMARY RESULT Human Clinical

"disruption of the basement membrane overlying the lesion."

Cross-sectional autopsy histology documents a surface lesion; it does not establish the temporal initiating injury.

PMID:7519131 SUPPORT INDIRECT PRIMARY RESULT Human Clinical

"early lesions were characterized by the presence of an inflammatory infiltrate composed of non-foam cell and foam cell macrophages, occasional T cells, and rare alpha-actin-positive cells."

Macrophages were also scattered in normal valves; the lesion-associated infiltrate is a quantitative and contextual change.

PMID:12719282 SUPPORT INDIRECT PRIMARY RESULT Human Clinical

"aortic valve calcification is not a random degenerative process but an active regulated process associated with an osteoblast-like phenotype."

Human surgical tissue association supports an osteogenic phenotype, not lineage tracing or irreversible commitment.

Reduced NOTCH-dependent RUNX2 restraint

notch_runx2_restraint EMERGING

Evidence balance 2 support

Rare familial NOTCH1 disease and experimental Hrt–RUNX2 repression support a molecular route to calcification. Loss of this restraint in patient valve cells is inferred; penetrance and the complete developmental sequence remain unresolved.

Pathograph links

NOTCH1 Loss of Function -> Reduced NOTCH-Dependent RUNX2 Repression INDIRECT UNKNOWN INTERMEDIATES Loss of upstream signaling is inferred to diminish the experimentally observed repression.

Reduced NOTCH-Dependent RUNX2 Repression -> Valvular Osteogenic Program INDIRECT UNKNOWN INTERMEDIATES Loss of RUNX2 restraint provides an experimentally motivated route to an osteogenic program; the complete patient-cell sequence is unresolved.

Show evidence (2 references)

PMID:16025100 SUPPORT PRIMARY RESULT Human Clinical

"mutations in the signalling and transcriptional regulator NOTCH1 cause a spectrum of developmental aortic valve anomalies and severe valve calcification in non-syndromic autosomal-dominant human pedigrees."

Rare familial NOTCH1 disease; this does not explain all congenital or acquired stenosis.

PMID:16025100 SUPPORT INDIRECT PRIMARY RESULT In Vitro

"The hairy-related family of transcriptional repressors (Hrt), which are activated by Notch1 signalling, physically interacted with Runx2 and repressed Runx2 transcriptional activity independent of histone deacetylase activity."

Experimental transcriptional repression reported in the abstract; loss of this restraint in patient valves is an inferred disease mechanism.

Lipoprotein(a)-related valve disease susceptibility

lipoprotein_a_specific_pathway EMERGING

Evidence balance 2 support

Genetic associations and Mendelian randomization support a causal contribution under instrument assumptions. The biochemical route and benefit from selective lowering remain under investigation. Failure of statin-based regimens does not directly test selective Lp(a) lowering.

Pathograph links

Elevated Lipoprotein(a) Exposure -> Aortic Leaflet Calcification INDIRECT UNKNOWN INTERMEDIATES Genetic and Mendelian-randomization evidence supports a contribution to valve calcium under instrumental-variable assumptions, without resolving the biochemical intermediates.

Show evidence (2 references)

PMID:23388002 SUPPORT PRIMARY RESULT Human Clinical

"One SNP in the lipoprotein(a) (LPA) locus (rs10455872) reached genomewide significance for the presence of aortic-valve calcification"

The discovery outcome was CT calcium; clinical incident stenosis was assessed in separate cohorts.

PMID:23388002 SUPPORT INDIRECT PRIMARY RESULT Human Clinical

"Further studies are needed to evaluate whether lowering Lp(a) levels will reduce the incidence or progression of aortic-valve disease."

The genetic result motivates, but does not establish, therapeutic Lp(a) lowering.

Discussions and Knowledge Gaps

Which processes mediate valve dysfunction in experimental anti-calcification interventions?

HUMAN MODEL MISMATCH OPEN as_calcification_function_mediation

Attached to

pathophysiology#Aortic Leaflet Calcification animal_models#Osteoprotegerin-treated Western-diet LA mouse animal_models#Notch1-haploinsufficient mouse with Htr2b perturbation

OPG reduces calcification and partly preserves older-mouse valve function without reducing fibrosis, lipids or superoxide. This coresponse does not isolate calcification as the mediator. Htr2b deletion improves hemodynamics without significant measured fibrosis or osteogenic-marker changes, while its tested antagonist regimen is negative. Cell-specific and temporally controlled perturbations with mechanical and tissue readouts are needed before assigning one necessary pathway.

Show evidence (2 references)

PMID:23762316 SUPPORT PRIMARY RESULT Model Organism

"Thus, the association between attenuation of valve calcification and protection of aortic valve function by OPG may not necessarily indicate mechanistic linkage between the two findings."

The authors explicitly distinguish associated intervention responses from demonstrated mediation.

PMID:33237915 SUPPORT PRIMARY RESULT Model Organism

"5-HT2B receptor antagonism, however, did not affect hemodynamic progression."

The tested SB204741 regimen was negative; lifelong gene deletion and pharmacologic treatment are not equivalent.

Why have mechanistically motivated medical therapies not yet modified established valve disease in trials?

KNOWLEDGE GAP OPEN as_medical_modification

Attached to

pathophysiology#Valvular Lipid Accumulation pathophysiology#Valvular Osteogenic Program clinical_trials#NCT02132026

Null statin-based trials in established stenosis do not prove that lipids are irrelevant to initiation or that osteogenic commitment makes the lesion autonomous. SALTIRE2 did not show imaging benefit from denosumab or alendronic acid in its mostly mild/moderate cohort despite lower bone-turnover markers. Its interventions, species context and disease timing differ from the OPG mouse experiment. Selective Lp(a) lowering remains under prospective evaluation; genetic evidence alone does not establish efficacy.

Show evidence (3 references)

PMID:15944423 SUPPORT PRIMARY RESULT Human Clinical

"Intensive lipid-lowering therapy does not halt the progression of calcific aortic stenosis or induce its regression."

Null tested regimen in established disease, not a test of every lipid mechanism.

PMID:33913339 SUPPORT PRIMARY RESULT Human Clinical

"There were no differences in 24-month change in aortic valve calcium score between denosumab and placebo"

The randomized imaging comparison was negative within the tested population and detectable effect size.

PMID:23388002 SUPPORT INDIRECT PRIMARY RESULT Human Clinical

"Further studies are needed to evaluate whether lowering Lp(a) levels will reduce the incidence or progression of aortic-valve disease."

The genetic result motivates, but does not establish, therapeutic Lp(a) lowering.

Does fibrosis burden identify patients who derive greater benefit from early intervention?

KNOWLEDGE GAP OPEN as_fibrosis_treatment_selection

Attached to

pathophysiology#Diffuse Myocardial Fibrosis pathophysiology#Replacement Myocardial Fibrosis clinical_trials#NCT03094143

The 2017 baseline CMR study associates extracellular expansion and LGE with clinical status but lacks enough deaths for multivariable mortality analysis and does not establish serial fibrosis transitions. EVOLVED did not significantly improve its primary outcome. The subsequent fibrosis-burden analysis is available here only as an abstract/repository duplicate: greater burden was associated with composite events and hospitalization, but no randomization-arm interaction was demonstrated. Prognostic association therefore does not establish a treatment-selection threshold or irreversible injury.

Show evidence (3 references)

PMID:28017384 SUPPORT PRIMARY RESULT Human Clinical

"There were insufficient deaths to perform multivariate analysis."

Limits the original mortality comparison.

PMID:41984459 SUPPORT PRIMARY RESULT Human Clinical

"There were no interactions between randomization arm and the midwall fibrosis burden for the primary (P for interaction = .39) or secondary end points."

The post hoc abstract does not demonstrate differential treatment benefit by fibrosis burden.

PMID:39466640 SUPPORT PRIMARY RESULT Human Clinical

"The primary end point occurred in 20 of 113 patients (18%) in the early intervention group and 25 of 111 patients (23%) in the guideline-directed conservative management group (hazard ratio, 0.79 [95% CI, 0.44-1.43]; P = .44; between-group difference, -4.82% [95% CI, -15.31% to 5.66%])."

The primary comparison was nonsignificant with a wide confidence interval, not proof of equivalence.

Which statistically nominated susceptibility genes are causal in valve cells?

KNOWLEDGE GAP OPEN as_gwas_candidates

Attached to

genetic#TWIST1 genetic#PALMD genetic#NAV1

European-ancestry GWAS, valve eQTL, colocalization and Mendelian randomization prioritize expression candidates, but selected surgical bulk tissue and instrumental-variable assumptions limit mechanistic inference. TWIST1 genotype-stratified RNA sequencing compared already severe-stenosis cases, rather than perturbing TWIST1 or measuring endothelial-to-mesenchymal conversion. Candidate genes require cell-specific functional validation; neither genetic overlap nor pathway enrichment proves a causal comorbidity.

Show evidence (1 reference)

PMID:38494474 SUPPORT INDIRECT PRIMARY RESULT Human Clinical

"After removing genes with a low probability for colocalization of the GWAS and eQTL signals (PP4 < 0.75, n = 20), with no MR instrument (n = 3) or with high heterogeneity of the instrument (n = 2), ten genes remained (PALMD, NAV1, PRRX1, ATP13A3, BCL10, TWIST1, RAD9A, NRBP1, FES and AFAP1)."

Statistical prioritization of ten expression candidates; no corresponding gene-rescue experiment is reported.

⚙

Pathophysiology

NOTCH1 Loss of Function

Rare pathogenic NOTCH1 variants alter valve development and predispose to calcification. The disease spectrum and incomplete penetrance differ among families.

Reduced NOTCH-dependent RUNX2 restraint

NOTCH1 hgnc:7881 ⇓ LOSS OF FUNCTION

Downstream

Reduced NOTCH-Dependent RUNX2 Repression Loss of upstream signaling is inferred to diminish the experimentally observed repression.

Congenital Bicuspid Valve Morphology Developmental valve abnormalities can result from rare NOTCH1 variants, with unresolved developmental intermediates and variable penetrance.

Show evidence (1 reference)

PMID:16025100 SUPPORT PRIMARY RESULT Human Clinical

Rare familial NOTCH1 disease; this does not explain all congenital or acquired stenosis.

Reduced NOTCH-Dependent RUNX2 Repression

Mechanism confidence: Provisional

NOTCH-activated Hrt proteins repress RUNX2 in experimental assays. Reduced repression is a proposed molecular consequence of loss of NOTCH1 signaling; the cited abstract does not quantify this event in patient valve cells.

Reduced NOTCH-dependent RUNX2 restraint

RUNX2 hgnc:10472

Downstream

Valvular Osteogenic Program Loss of RUNX2 restraint provides an experimentally motivated route to an osteogenic program; the complete patient-cell sequence is unresolved.

Show evidence (1 reference)

PMID:16025100 SUPPORT INDIRECT PRIMARY RESULT In Vitro

Experimental transcriptional repression reported in the abstract; loss of this restraint in patient valves is an inferred disease mechanism.

Congenital Bicuspid Valve Morphology

A two-leaflet valve alters valve anatomy and predisposes to earlier stenosis. NOTCH1 explains only a minority of inherited valve disease; anatomy is not equivalent to an identified molecular defect.

aortic valve UBERON:0002137

Downstream

Bicuspid Aortic Valve The mechanism node represents the congenital structural phenotype.

Aortic Leaflet Calcification Congenital anatomy can acquire superimposed calcification through incompletely resolved mechanical and cellular intermediates.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/ SUPPORT REVIEW SYNTHESIS Human Clinical

"A congenitally abnormal valve with superimposed calcification can cause aortic stenosis."

Congenital anatomy is an etiologic substrate in a subset.

Elevated Lipoprotein(a) Exposure

Genetically influenced circulating Lp(a) is associated with valve calcium and later clinical stenosis. Mendelian randomization strengthens a causal interpretation under instrument assumptions, but the molecular mediators and treatment responsiveness remain incompletely resolved.

Lipoprotein(a)-related valve disease susceptibility

LPA hgnc:6667

Downstream

Aortic Leaflet Calcification Genetic and Mendelian-randomization evidence supports a contribution to valve calcium under instrumental-variable assumptions, without resolving the biochemical intermediates.

Show evidence (2 references)

PMID:23388002 SUPPORT PRIMARY RESULT Human Clinical

"One SNP in the lipoprotein(a) (LPA) locus (rs10455872) reached genomewide significance for the presence of aortic-valve calcification"

The discovery outcome was CT calcium; clinical incident stenosis was assessed in separate cohorts.

PMID:23388002 SUPPORT INDIRECT PRIMARY RESULT Human Clinical

"Further studies are needed to evaluate whether lowering Lp(a) levels will reduce the incidence or progression of aortic-valve disease."

The genetic result motivates, but does not establish, therapeutic Lp(a) lowering.

Valvular Surface Barrier Injury

Disruption of the basement membrane overlies some early calcific valve lesions. Hemodynamic injury is a proposed contributor, but the founding human study was cross-sectional and did not measure shear stress or prove which lesion came first.

Inflammatory and osteogenic contribution to calcific valve disease

valve endothelial cell CL:4030033

aortic valve UBERON:0002137

Downstream

Valvular Lipid Accumulation Surface disruption may facilitate lipid accumulation; coexistence in human histology supports a proposed route rather than a demonstrated temporal sequence.

Show evidence (1 reference)

PMID:7519131 SUPPORT PRIMARY RESULT Human Clinical

"disruption of the basement membrane overlying the lesion."

Cross-sectional autopsy histology documents a surface lesion; it does not establish the temporal initiating injury.

Valvular Lipid Accumulation

Intracellular and extracellular lipid accumulates in the aortic-side leaflet lesion and adjacent fibrosa. This is valvular rather than arterial-intimal disease.

Inflammatory and osteogenic contribution to calcific valve disease

aortic valve UBERON:0002137

Downstream

Valvular Inflammatory Infiltration Lipid-rich lesions recruit or retain inflammatory cells in the proposed calcific disease process; the cited autopsy observations alone do not establish directionality.

Show evidence (1 reference)

PMID:7519131 SUPPORT PRIMARY RESULT Human Clinical

"the presence of large amounts of intracellular and extracellular neutral lipids (oil red O) and fine, stippled mineralization (von Kossa)"

Lipid and mineral were observed in the same early lesions; temporal or molecular necessity is not established.

Valvular Inflammatory Infiltration

Macrophages, foam cells and occasional T lymphocytes accumulate in early and advanced lesions. Their presence supports inflammatory involvement but does not establish a uniform sequence or one indispensable cytokine.

Inflammatory and osteogenic contribution to calcific valve disease

macrophage CL:0000235 T cell CL:0000084

Downstream

Valvular Osteogenic Program Inflammatory and osteogenic features participate in the proposed calcific process. These human tissue studies do not establish a single inflammatory mediator or an obligatory sequence.

Show evidence (1 reference)

PMID:7519131 SUPPORT PRIMARY RESULT Human Clinical

"early lesions were characterized by the presence of an inflammatory infiltrate composed of non-foam cell and foam cell macrophages, occasional T cells, and rare alpha-actin-positive cells."

Macrophages were also scattered in normal valves; the lesion-associated infiltrate is a quantitative and contextual change.

Valvular Osteogenic Program

Mechanism confidence: Provisional

Calcified human valves express an osteoblast-like marker pattern, including RUNX2/Cbfa1 and bone matrix proteins. Marker expression and experimental differentiation support an osteogenic program, while conversion of every interstitial cell into a mature osteoblast and a lipid-independent commitment point remain unproven.

Inflammatory and osteogenic contribution to calcific valve disease

valve interstitial cell CL:4030032

Downstream

Aortic Leaflet Calcification Osteogenic activity is a proposed contributor to mineral deposition; associated markers alone do not prove that this is the only route.

Show evidence (1 reference)

PMID:12719282 SUPPORT INDIRECT PRIMARY RESULT Human Clinical

"aortic valve calcification is not a random degenerative process but an active regulated process associated with an osteoblast-like phenotype."

Human surgical tissue association supports an osteogenic phenotype, not lineage tracing or irreversible commitment.

Aortic Leaflet Calcification

Mineral deposits accumulate within the leaflets. Calcification contributes to stiffness and restricted opening, although the relative contribution of fibrosis varies by valve morphology and etiology.

aortic valve UBERON:0002137

Experimental models

Baboon valve-interstitial-cell mineralization culture PRIMARY CELL CULTURE Glucose enhanced cellular-matrix mineral deposition under elevated phosphate.

Animal models

Osteoprotegerin-treated Western-diet LA mouse Mouse perturbs OPG reduced valve calcium deposition.

Downstream

Aortic Valve Calcification The tissue event is the structural calcification finding.

Reduced Aortic Valve Opening Accumulating mineral contributes to restricted opening together with fibrosis and anatomy.

Show evidence (2 references)

PMID:7519131 SUPPORT PRIMARY RESULT Human Clinical

"the presence of large amounts of intracellular and extracellular neutral lipids (oil red O) and fine, stippled mineralization (von Kossa)"

Lipid and mineral were observed in the same early lesions; temporal or molecular necessity is not established.

PMID:12719282 SUPPORT INDIRECT PRIMARY RESULT Human Clinical

"aortic valve calcification is not a random degenerative process but an active regulated process associated with an osteoblast-like phenotype."

Human surgical tissue association supports an osteogenic phenotype, not lineage tracing or irreversible commitment.

Rheumatic Commissural Fusion

Rheumatic injury can fuse the aortic leaflet commissures, reducing the effective opening. This is an alternative etiologic branch, not a required step in adult calcific disease.

Downstream

Reduced Aortic Valve Opening Commissural fusion directly narrows the opening.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/ SUPPORT REVIEW SYNTHESIS Human Clinical

"The commissures of the leaflets fuse to leave a small central orifice."

Rheumatic anatomical mechanism.

Reduced Aortic Valve Opening

Restricted leaflet opening creates a fixed valvular outflow obstruction. Fibrosis, calcification and congenital or rheumatic morphology contribute in different proportions.

aortic valve UBERON:0002137

Animal models

Combined metabolic-diet LA mouse Mouse partially recapitulates Higher transvalvular jet velocity provides a functional stenosis readout.

Osteoprotegerin-treated Western-diet LA mouse Mouse perturbs Cusp separation declined less under OPG in the older cohort.

Notch1-haploinsufficient mouse with Htr2b perturbation Mouse perturbs Complete genetic deletion reduced jet velocity and pressure gradient, without establishing a specific leaflet-cell mediator.

Downstream

Aortic Valve Stenosis Reduced valvular opening creates the stenotic lesion.

Left Ventricular Pressure Overload Outflow obstruction increases the pressure required for ejection.

Limited Exertional Cardiac Output Fixed obstruction limits cardiac reserve during exercise.

Loss of High-Molecular-Weight von Willebrand Factor Multimers High-shear flow provides the proposed route; the clinical association and postoperative correction support it without isolating every proteolytic intermediate.

Midsystolic murmur Systolic flow through the narrowed valve produces an ejection murmur, with intensity dependent on flow.

Slow-rising low-amplitude carotid pulse Restricted ejection contributes to a delayed low-amplitude arterial pulse.

Sudden cardiac death Severe stenosis is associated with sudden-death risk through incompletely resolved hemodynamic and arrhythmic intermediates; this is not an inevitable outcome.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/ SUPPORT REVIEW SYNTHESIS Human Clinical

"Left ventricular (LV) obstruction caused by the stenosis of the valve increases LV systolic pressure."

Clinical hemodynamic synthesis.

Left Ventricular Pressure Overload

The ventricle must generate greater systolic pressure to eject through the stenotic valve. The gradient is flow-dependent, so severe low-flow disease can have a low measured gradient.

heart left ventricle UBERON:0002084

Downstream

Cardiomyocyte Hypertrophic Growth Sustained pressure loading induces hypertrophic adaptation.

Diffuse Myocardial Fibrosis Chronic loading may contribute to myocardial injury and matrix remodeling; the full causal intermediates and patient-specific sequence are unresolved.

Replacement Myocardial Fibrosis Chronic loading may contribute to myocardial injury and matrix remodeling; the full causal intermediates and patient-specific sequence are unresolved.

Impaired Left Ventricular Systolic Function Excessive afterload can produce systolic mismatch.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/ SUPPORT REVIEW SYNTHESIS Human Clinical

"Left ventricular (LV) obstruction caused by the stenosis of the valve increases LV systolic pressure."

Clinical hemodynamic synthesis.

Cardiomyocyte Hypertrophic Growth

Increased ventricular muscle mass helps normalize wall stress during pressure loading. Hypertrophy can coexist with impaired relaxation, ischemia and fibrosis without a uniform transition to reduced ejection fraction.

cardiac muscle cell CL:0000746

heart left ventricle UBERON:0002084

Downstream

Left Ventricular Hypertrophy The cellular remodeling event produces increased ventricular muscle mass.

Impaired Left Ventricular Relaxation Altered myocardial structure can impair filling through incompletely resolved physiological intermediates.

Myocardial Oxygen Supply-Demand Imbalance Hypertrophy increases demand and can reduce effective coronary perfusion.

Show evidence (1 reference)

PMID:12732812 SUPPORT REVIEW SYNTHESIS Human Clinical

"With severe aortic stenosis left ventricular hypertrophy occurs, decreasing wall stress and supporting the left ventricular ejection fraction."

Clinical physiological review; the degree of adaptation varies.

Diffuse Myocardial Fibrosis

Interstitial extracellular-matrix expansion accompanies ventricular remodeling. CMR extracellular volume is an imperfect surrogate, and the cited baseline study does not directly demonstrate serial fibrosis progression or reversal.

heart left ventricle UBERON:0002084

Downstream

Myocardial Fibrosis The tissue event contributes to the clinical fibrosis finding.

Impaired Left Ventricular Relaxation Altered myocardial structure can impair filling through incompletely resolved physiological intermediates.

Show evidence (2 references)

PMID:28017384 SUPPORT BACKGROUND Human Clinical

"Diffuse fibrosis is associated with extracellular volume expansion that is detectable by T1 mapping, whereas late gadolinium enhancement (LGE) detects replacement fibrosis."

Clinical imaging framework; ECV may also reflect vascular expansion or infiltration.

PMID:12732812 SUPPORT INDIRECT REVIEW SYNTHESIS Human Clinical

"However, with pathologic hypertrophy there is a dropout of myocardial cells, subendocardial ischemia, and fibrosis."

Review synthesis of maladaptive remodeling; not an obligatory ordered sequence.

Replacement Myocardial Fibrosis

Focal replacement fibrosis accompanies myocardial injury in some patients. Midwall LGE identifies a different imaging pattern from infarct-related scarring; conversion from diffuse fibrosis is a hypothesis requiring longitudinal evidence.

heart left ventricle UBERON:0002084

Downstream

Myocardial Fibrosis The tissue event contributes to the clinical fibrosis finding.

Impaired Left Ventricular Relaxation Altered myocardial structure can impair filling through incompletely resolved physiological intermediates.

Show evidence (2 references)

PMID:28017384 SUPPORT BACKGROUND Human Clinical

"Diffuse fibrosis is associated with extracellular volume expansion that is detectable by T1 mapping, whereas late gadolinium enhancement (LGE) detects replacement fibrosis."

Clinical imaging framework; ECV may also reflect vascular expansion or infiltration.

PMID:12732812 SUPPORT INDIRECT REVIEW SYNTHESIS Human Clinical

"However, with pathologic hypertrophy there is a dropout of myocardial cells, subendocardial ischemia, and fibrosis."

Review synthesis of maladaptive remodeling; not an obligatory ordered sequence.

Impaired Left Ventricular Relaxation

Hypertrophy and matrix changes can impair ventricular filling while global ejection fraction remains preserved.

Downstream

Left ventricular diastolic dysfunction The organ dysfunction corresponds to the clinical filling abnormality.

Elevated Pulmonary Venous Pressure Impaired filling can elevate upstream pulmonary venous pressure.

Congestive Heart Failure Ventricular dysfunction can contribute to clinical heart failure with varying ejection fraction.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/ SUPPORT REVIEW SYNTHESIS Human Clinical

"Diastolic dysfunction develops secondary to hypertrophy and fibrosis and often persists even after AVR."

Clinical mechanism synthesis, not a guarantee of persistence in every patient.

Impaired Left Ventricular Systolic Function

Afterload mismatch and myocardial disease can reduce ejection performance. Reduced function is not synonymous with irreversible scar.

Downstream

Left ventricular systolic dysfunction Reduced ejection performance corresponds to the clinical finding.

Congestive Heart Failure Ventricular dysfunction can contribute to clinical heart failure with varying ejection fraction.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/ SUPPORT REVIEW SYNTHESIS Human Clinical

"some patients can present with systolic dysfunction secondary to the afterload mismatch, resulting in a low ejection fraction."

Systolic dysfunction may reflect reversible loading mismatch as well as myocardial damage.

Myocardial Oxygen Supply-Demand Imbalance

Greater muscle mass and systolic workload increase oxygen demand while perfusion can be constrained. This can produce ischemic symptoms even without obstructive coronary disease.

Downstream

Angina Pectoris Ischemic supply-demand mismatch can produce anginal pain.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/ SUPPORT REVIEW SYNTHESIS Human Clinical

"Angina results from the combination of the need for increased oxygen ... reduction of oxygen ... delivery secondary to the excessive compression of coronary vessels."

Clinical supply-demand mechanism; epicardial coronary disease can contribute independently.

Limited Exertional Cardiac Output

Valvular obstruction can prevent an adequate output increase during exercise. Cerebral perfusion may fall when systemic vasodilation exceeds the compensatory increase in flow.

Downstream

Syncope Reduced reserve can contribute to the symptom, with other causes and intervening physiology remaining relevant.

Exercise intolerance Reduced reserve can contribute to the symptom, with other causes and intervening physiology remaining relevant.

Fatigue Reduced reserve can contribute to the symptom, with other causes and intervening physiology remaining relevant.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/ SUPPORT REVIEW SYNTHESIS Human Clinical

"Syncope is caused by the decrease in cerebral perfusion ... due to systemic vasodilation and an inadequate increase in cardiac output related to stenosis."

Clinical exertional hemodynamic mechanism; does not exclude other causes of syncope.

Elevated Pulmonary Venous Pressure

Raised left ventricular filling pressure can be transmitted to the pulmonary venous circulation and cause congestion.

Downstream

Pulmonary venous hypertension Pulmonary venous pressure elevation contributes to this finding; it is not universal across stenosis stages.

Exertional Dyspnea Pulmonary venous pressure elevation contributes to this finding; it is not universal across stenosis stages.

Orthopnea Pulmonary venous pressure elevation contributes to this finding; it is not universal across stenosis stages.

Pulmonary edema Pulmonary venous pressure elevation contributes to this finding; it is not universal across stenosis stages.

Show evidence (2 references)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/ SUPPORT REVIEW SYNTHESIS Human Clinical

"Severe exertional dyspnea, paroxysmal nocturnal dyspnea, orthopnea, and pulmonary edema show various degrees of pulmonary venous hypertension."

Post-capillary hemodynamic pathway in left-heart disease.

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/ SUPPORT REVIEW SYNTHESIS Human Clinical

"Severe exertional dyspnea, paroxysmal nocturnal dyspnea, orthopnea, and pulmonary edema show various degrees of pulmonary venous hypertension."

Clinical pulmonary-congestion manifestations.

Loss of High-Molecular-Weight von Willebrand Factor Multimers

High-shear valvular flow is associated with loss of the largest vWF multimers in some severe cases. Abnormalities can improve after replacement and recur with prosthesis-patient mismatch.

Downstream

Impaired Primary Hemostasis Loss of functional large multimers contributes to defective platelet adhesion, with other hemostatic influences unresolved in the clinical cohort.

Show evidence (1 reference)

PMID:12878741 SUPPORT PRIMARY RESULT Human Clinical

"Platelet-function abnormalities under conditions of high shear stress, decreased von Willebrand factor collagen-binding activity and the loss of the largest multimers, or a combination of these was present in 67 to 92 percent of patients with severe aortic stenosis and correlated significantly..."

Fifty consecutive patients were studied, with 42 severe cases undergoing replacement; the range summarizes different assays, not a single population prevalence.

Impaired Primary Hemostasis

Reduced vWF collagen-binding function and abnormal high-shear platelet function contribute to acquired bleeding tendency; laboratory changes and clinical bleeding have different frequencies.

Downstream

Gastrointestinal hemorrhage Acquired vWF abnormalities can promote bleeding, often in conjunction with gastrointestinal vascular lesions.

Show evidence (1 reference)

PMID:12878741 SUPPORT PRIMARY RESULT Human Clinical

Fifty consecutive patients were studied, with 42 severe cases undergoing replacement; the range summarizes different assays, not a single population prevalence.

Aortic Leaflet Fibrosis

Extracellular-matrix expansion and fibrosis in the valve can restrict leaflet motion. Its contribution varies among calcific, congenital and rheumatic contexts; this is distinct from the pressure-loaded ventricular fibrotic response. The cited evidence does not resolve one initiating cellular route in all etiologies.

aortic valve UBERON:0002137

Downstream

Reduced Aortic Valve Opening Leaflet matrix remodeling can contribute to obstruction alongside calcification.

Show evidence (1 reference)

url:https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf SUPPORT REVIEW SYNTHESIS Human Clinical

"Aortic stenosis is a disease slowly evolving from mild to severe valve obstruction as a consequence of increasing valve fibrosis and calcifi- cation"

Clinical pathophysiology synthesis distinguishes valve fibrosis from myocardial fibrosis.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

Blood 1

Gastrointestinal hemorrhage HP:0002239

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/ SUPPORT REVIEW SYNTHESIS Human Clinical

"GI bleeding is observed in patients with severe aortic stenosis and is often associated with angiodysplasia or other vascular malformations."

Clinical review synthesis; no population frequency inferred.

Cardiovascular 13

Aortic Valve Stenosis HP:0001650

Course: PROGRESSIVE

No disease-wide frequency band is inferred from selected clinical cohorts or narrative descriptions.

Show evidence (1 reference)

PMID:10965007 SUPPORT PRIMARY RESULT Human Clinical

"we identified 128 consecutive patients with asymptomatic, severe aortic stenosis"

Identifies the defining lesion in a prospectively assembled clinical cohort.

Aortic Valve Calcification HP:0004380

No disease-wide frequency band is inferred from selected clinical cohorts or narrative descriptions.

Show evidence (1 reference)

PMID:12719282 SUPPORT PRIMARY RESULT Human Clinical

"Microradiography and micro-computerized tomography confirmed the presence of calcification in the valve."

Directly documents leaflet calcification in surgically explanted human valves.

Bicuspid Aortic Valve HP:0001647

No disease-wide frequency band is inferred from selected clinical cohorts or narrative descriptions.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/ SUPPORT REVIEW SYNTHESIS Human Clinical

"Etiologies include congenital (bicuspid/unicuspid), calcific, and rheumatic disease."

Bicuspid morphology is an etiologic substrate in a subset, not an acquired consequence.

Left Ventricular Hypertrophy HP:0001712

No disease-wide frequency band is inferred from selected clinical cohorts or narrative descriptions.

Show evidence (1 reference)

PMID:28017384 SUPPORT PRIMARY RESULT Human Clinical

"There was evidence of increasing hypertrophy, myocardial injury, diastolic dysfunction, and longitudinal systolic dysfunction"

Documents hypertrophy in a phenotyped aortic stenosis cohort.

Myocardial Fibrosis HP:0001685

Course: PROGRESSIVE

No disease-wide frequency band is inferred from selected clinical cohorts or narrative descriptions.

Show evidence (1 reference)

PMID:28017384 SUPPORT BACKGROUND Human Clinical

"Diffuse fibrosis is associated with extracellular volume expansion that is detectable by T1 mapping, whereas late gadolinium enhancement (LGE) detects replacement fibrosis."

Clinical imaging background; extracellular expansion is not specific for collagen alone.

Angina Pectoris HP:0001681

No disease-wide frequency band is inferred from selected clinical cohorts or narrative descriptions.

Show evidence (2 references)

PMID:24104373 SUPPORT REVIEW SYNTHESIS Human Clinical

"Angina, exertional syncope, and heart failure are key symptoms indicating a need for intervention."

Names angina among the symptoms whose appearance indicates a need for intervention.

PMID:12732812 SUPPORT REVIEW SYNTHESIS Human Clinical

"Eventually, symptoms of angina, non-Q wave myocardial infarction, exertional syncope, and heart failure occur."

The review names angina in the clinical course; the accompanying infarction term does not establish its coronary mechanism.

Syncope HP:0001279

No disease-wide frequency band is inferred from selected clinical cohorts or narrative descriptions.

Show evidence (2 references)

PMID:24104373 SUPPORT REVIEW SYNTHESIS Human Clinical

"Angina, exertional syncope, and heart failure are key symptoms indicating a need for intervention."

Names syncope, and specifically its exertional character, among the intervention-triggering symptoms.

PMID:12732812 SUPPORT REVIEW SYNTHESIS Human Clinical

"Eventually, symptoms of angina, non-Q wave myocardial infarction, exertional syncope, and heart failure occur."

Independent source placing exertional syncope in the natural history of valvular aortic stenosis.

Congestive Heart Failure HP:0001635

No disease-wide frequency band is inferred from selected clinical cohorts or narrative descriptions.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/ SUPPORT REVIEW SYNTHESIS Human Clinical

"Heart failure is one of the most common complications of aortic stenosis."

Clinical complication synthesis without a disease-level frequency estimate or inevitable terminal sequence.

Midsystolic murmur HP:0031665

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/ SUPPORT REVIEW SYNTHESIS Human Clinical

"mid-systolic ejection murmur, heard best over the right second intercostal space, with radiation into the right neck."

Clinical review synthesis; no population frequency inferred.

Pulmonary venous hypertension HP:0030950

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/ SUPPORT REVIEW SYNTHESIS Human Clinical

"Severe exertional dyspnea, paroxysmal nocturnal dyspnea, orthopnea, and pulmonary edema show various degrees of pulmonary venous hypertension."

Clinical review synthesis; no population frequency inferred.

Sudden cardiac death HP:0001645

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/ SUPPORT REVIEW SYNTHESIS Human Clinical

"Severe symptomatic aortic stenosis patients are at a high risk of sudden death."

Clinical review synthesis; no population frequency inferred.

Left ventricular diastolic dysfunction HP:0025168

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/ SUPPORT REVIEW SYNTHESIS Human Clinical

"Diastolic dysfunction develops secondary to hypertrophy and fibrosis and often persists even after AVR."

Clinical review synthesis; no population frequency inferred.

Left ventricular systolic dysfunction HP:0025169

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/ SUPPORT REVIEW SYNTHESIS Human Clinical

"some patients can present with systolic dysfunction secondary to the afterload mismatch, resulting in a low ejection fraction."

Clinical review synthesis; no population frequency inferred.

Metabolism 1

Pulmonary edema HP:0100598

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/ SUPPORT REVIEW SYNTHESIS Human Clinical

"Severe exertional dyspnea, paroxysmal nocturnal dyspnea, orthopnea, and pulmonary edema show various degrees of pulmonary venous hypertension."

Clinical review synthesis; no population frequency inferred.

Respiratory 2

Exertional Dyspnea HP:0002875

No disease-wide frequency band is inferred from selected clinical cohorts or narrative descriptions.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/ SUPPORT REVIEW SYNTHESIS Human Clinical

"Patients progressively experience a gradual decrease in exercise tolerance, dyspnea on exertion, and fatigue."

The review directly names exertional breathlessness.

Orthopnea HP:0012764

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/ SUPPORT REVIEW SYNTHESIS Human Clinical

"Severe exertional dyspnea, paroxysmal nocturnal dyspnea, orthopnea, and pulmonary edema show various degrees of pulmonary venous hypertension."

Clinical review synthesis; no population frequency inferred.

Constitutional 2

Fatigue HP:0012378

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/ SUPPORT REVIEW SYNTHESIS Human Clinical

"Patients progressively experience a gradual decrease in exercise tolerance, dyspnea on exertion, and fatigue."

Clinical review synthesis; no population frequency inferred.

Exercise intolerance HP:0003546

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/ SUPPORT REVIEW SYNTHESIS Human Clinical

"Patients progressively experience a gradual decrease in exercise tolerance, dyspnea on exertion, and fatigue."

Clinical review synthesis; no population frequency inferred.

Other 1

Slow-rising low-amplitude carotid pulse

Needs term / NTR: slow-rising low-amplitude carotid pulse (pulsus parvus et tardus).

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/ SUPPORT REVIEW SYNTHESIS Human Clinical

"A slow-rising, late-peaking, and a low-amplitude carotid impulse, ... is an expected finding in severe aortic stenosis and, when present, is specific to aortic stenosis."

Clinical review synthesis; no population frequency inferred.

🧬

Genetic Associations

LPA

Gene: LPA hgnc:6667 gene page relationship_type: SUSCEPTIBILITY

Show evidence (1 reference)

PMID:23388002 SUPPORT PRIMARY RESULT Human Clinical

"One SNP in the lipoprotein(a) (LPA) locus (rs10455872) reached genomewide significance for the presence of aortic-valve calcification"

Genome-wide significant association of the LPA locus with aortic valve calcification.

NOTCH1

Gene: NOTCH1 hgnc:7881 gene page relationship_type: CAUSATIVE

Show evidence (2 references)

PMID:16025100 SUPPORT PRIMARY RESULT Human Clinical

Establishes NOTCH1 as a causal gene for human aortic valve disease.

PMID:35288444 SUPPORT PRIMARY RESULT Human Clinical

"No pathogenic or likely pathogenic NOTCH1 variants were identified in 381 sporadic patients."

Primary sporadic BAV sequencing result, not proof that NOTCH1 can never cause sporadic disease.

PRRX1

Gene: PRRX1 hgnc:9142 gene page relationship_type: SUSCEPTIBILITY

Show evidence (1 reference)

PMID:38494474 SUPPORT INDIRECT PRIMARY RESULT Human Clinical

Ten prioritized genes retained after statistical filtering; causal molecular intermediates require complementary experiments.

ATP13A3

Gene: ATP13A3 hgnc:24113 gene page relationship_type: SUSCEPTIBILITY

Show evidence (1 reference)

PMID:38494474 SUPPORT INDIRECT PRIMARY RESULT Human Clinical

Ten prioritized genes retained after statistical filtering; causal molecular intermediates require complementary experiments.

TWIST1

Gene: TWIST1 hgnc:12428 gene page relationship_type: SUSCEPTIBILITY

Show evidence (1 reference)

PMID:38494474 SUPPORT INDIRECT PRIMARY RESULT Human Clinical

Ten prioritized genes retained after statistical filtering; causal molecular intermediates require complementary experiments.

BCL10

Gene: BCL10 hgnc:989 gene page relationship_type: SUSCEPTIBILITY

Show evidence (1 reference)

PMID:38494474 SUPPORT INDIRECT PRIMARY RESULT Human Clinical

Ten prioritized genes retained after statistical filtering; causal molecular intermediates require complementary experiments.

RAD9A

Gene: RAD9A hgnc:9827 relationship_type: SUSCEPTIBILITY

Show evidence (1 reference)

PMID:38494474 SUPPORT INDIRECT PRIMARY RESULT Human Clinical

Ten prioritized genes retained after statistical filtering; causal molecular intermediates require complementary experiments.

NRBP1

Gene: NRBP1 hgnc:7993 relationship_type: SUSCEPTIBILITY

Show evidence (1 reference)

PMID:38494474 SUPPORT INDIRECT PRIMARY RESULT Human Clinical

Ten prioritized genes retained after statistical filtering; causal molecular intermediates require complementary experiments.

FES

Gene: FES hgnc:3657 relationship_type: SUSCEPTIBILITY

Show evidence (1 reference)

PMID:38494474 SUPPORT INDIRECT PRIMARY RESULT Human Clinical

Ten prioritized genes retained after statistical filtering; causal molecular intermediates require complementary experiments.

AFAP1

Gene: AFAP1 hgnc:24017 relationship_type: SUSCEPTIBILITY

Show evidence (1 reference)

PMID:38494474 SUPPORT INDIRECT PRIMARY RESULT Human Clinical

Ten prioritized genes retained after statistical filtering; causal molecular intermediates require complementary experiments.

PALMD

Gene: PALMD hgnc:15846 relationship_type: SUSCEPTIBILITY

Show evidence (1 reference)

PMID:38494474 SUPPORT INDIRECT PRIMARY RESULT Human Clinical

Ten prioritized genes retained after statistical filtering; causal molecular intermediates require complementary experiments.

NAV1

Gene: NAV1 hgnc:15989 relationship_type: SUSCEPTIBILITY

Show evidence (1 reference)

PMID:38494474 SUPPORT INDIRECT PRIMARY RESULT Human Clinical

Ten prioritized genes retained after statistical filtering; causal molecular intermediates require complementary experiments.

💊

Medical Actions

Surgical aortic valve replacement

Action: Aortic Valve Replacement NCIT:C50815

Replacement relieves severe valvular obstruction. In the 2025 ESC/EACTS adult framework, SAVR is recommended for patients younger than 70 years at low surgical risk and remains the principal approach for many young patients with bicuspid stenosis, associated aortopathy or unfavorable transcatheter anatomy. Prosthesis choice incorporates anticoagulation, durability, future interventions and patient preferences; correction of the valve does not guarantee complete myocardial recovery.

Mechanism Target:

INHIBITS Reduced Aortic Valve Opening — The intervention addresses this clinical or physiological target within the stated eligibility and evidence limits.

Show evidence (2 references)

url:https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf SUPPORT REVIEW SYNTHESIS Other

"SAVR is recommended in patients <70 years of age, if the surgical risk is low."

2025 ESC/EACTS Class I, level B; age is interpreted with Heart Team assessment.

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/ SUPPORT REVIEW SYNTHESIS Human Clinical

"The definitive treatment for aortic stenosis includes aortic valve replacement, either via a surgical or percutaneous approach."

Clinical basis for relieving obstruction.

Show evidence (2 references)

url:https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf SUPPORT REVIEW SYNTHESIS Other

"SAVR is recommended in patients <70 years of age, if the surgical risk is low."

2025 ESC/EACTS Class I, level B; age is interpreted with Heart Team assessment.

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/ SUPPORT REVIEW SYNTHESIS Human Clinical

"The definitive treatment for aortic stenosis includes aortic valve replacement, either via a surgical or percutaneous approach."

Clinical basis for relieving obstruction.

Transcatheter aortic valve implantation

Action: Transcatheter Aortic Valve Replacement NCIT:C158018

The 2025 ESC/EACTS guideline recommends TAVI for patients aged at least 70 years with tricuspid stenosis and suitable anatomy. Transfemoral access, coronary obstruction risk, annular anatomy and lifetime reintervention planning matter. Other candidates require individual Heart Team assessment; TAVI for bicuspid stenosis is a weaker recommendation in selected patients at increased surgical risk. Vascular injury, paravalvular leak and pacemaker risk differ from surgical risks.

Mechanism Target:

INHIBITS Reduced Aortic Valve Opening — The intervention addresses this clinical or physiological target within the stated eligibility and evidence limits.

Show evidence (2 references)

url:https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf SUPPORT REVIEW SYNTHESIS Other

"TAVI is recommended in patients ≥70 years of age with tricuspid AV stenosis, if the anatomy is suitable."

Class I, level A in the 2025 adult guideline; this is not an age-only rule.

url:https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf SUPPORT REVIEW SYNTHESIS Other

"SAVR or TAVI are recommended for all remaining candidates for an aortic BHV according to Heart Team assessment."

Individualized mode selection.

Show evidence (2 references)

url:https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf SUPPORT REVIEW SYNTHESIS Other

"TAVI is recommended in patients ≥70 years of age with tricuspid AV stenosis, if the anatomy is suitable."

Class I, level A in the 2025 adult guideline; this is not an age-only rule.

url:https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf SUPPORT REVIEW SYNTHESIS Other

"SAVR or TAVI are recommended for all remaining candidates for an aortic BHV according to Heart Team assessment."

Individualized mode selection.

Timing intervention in symptomatic severe disease

Action: Aortic Valve Replacement NCIT:C50815

Intervention is recommended for symptomatic severe high-gradient stenosis, and for confirmed severe low-flow low-gradient disease with reduced ejection fraction. With preserved ejection fraction and low flow/gradient, severity confirmation and exclusion of competing explanations are essential. Expected benefit, life expectancy and procedural feasibility determine whether intervention is appropriate.

Show evidence (1 reference)

url:https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf SUPPORT REVIEW SYNTHESIS Other

"Intervention is recommended in symptomatic patients with severe, high-gradient AS"

Class I, level B recommendation; the complete clinical and hemodynamic context is required.

Early intervention in selected asymptomatic severe disease

Action: Aortic Valve Replacement NCIT:C50815

The 2025 guideline supports intervention as an alternative to close surveillance in asymptomatic severe high-gradient stenosis with ejection fraction ≥50% and low procedural risk (Class IIa, A). Ejection fraction <50% without another cause is a Class I indication. Very severe hemodynamics, rapid progression with heavy calcification, markedly elevated natriuretic peptides or abnormal exercise blood pressure strengthen selection. Trials differ in age, valve anatomy, fibrosis enrichment, procedures and outcome definitions; there is no uniform mortality benefit across all asymptomatic populations.

Show evidence (2 references)

url:https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf SUPPORT REVIEW SYNTHESIS Other

"Intervention should be considered in asymptomatic patients (confirmed by a normal exercise test, if feasible) with severe, high-gradient AS and LVEF ≥50%, as an alternative to close active surveillance, if the procedural risk is low. IIa A"

The 2025 conditional early-intervention recommendation, not a mandate to replace every asymptomatic valve.

url:https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf SUPPORT REVIEW SYNTHESIS Other

"Intervention is recommended in asymptomatic patients with severe AS and LVEF <50% without another cause."

Class I, level B ventricular-function indication.

Active surveillance and symptom education

For patients managed without immediate intervention, educate patients and caregivers to report symptoms promptly and reassess severity and ventricular function. The 2025 guideline recommends at least six-monthly follow-up for asymptomatic severe disease, annual reassessment for moderate degenerative stenosis, and potentially two- to three-year intervals for younger patients with mild disease and little leaflet calcium. New symptoms prompt earlier reassessment.

Show evidence (1 reference)

url:https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf SUPPORT REVIEW SYNTHESIS Other

"Asymptomatic pa- tients with severe AS should be followed up at least every 6 months to allow detection of early symptoms"

Regular clinical and echocardiographic surveillance in the guideline.

Balloon aortic valvotomy as a bridge

In the adult severe-stenosis guideline, balloon valvotomy may be considered as a temporary bridge to SAVR or TAVI in hemodynamic instability or urgent high-risk noncardiac surgery (Class IIb, C). Benefits are limited and severe regurgitation is a risk; it is not a durable substitute for replacement in calcific adult disease. Pediatric congenital-valve decisions require their own clinical context.

Mechanism Target:

INHIBITS Reduced Aortic Valve Opening — The intervention addresses this clinical or physiological target within the stated eligibility and evidence limits.

Show evidence (1 reference)

url:https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf SUPPORT REVIEW SYNTHESIS Other

"Balloon aortic valvotomy may be considered as a bridge to SAVR or TAVI in haemodynamically unstable patients, and (if feasible) in those with severe AS who require urgent high-risk NCS."

Explicit bridge indication in the adult 2025 guideline.

Show evidence (1 reference)

url:https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf SUPPORT REVIEW SYNTHESIS Other

"Balloon aortic valvotomy may be considered as a bridge to SAVR or TAVI in haemodynamically unstable patients, and (if feasible) in those with severe AS who require urgent high-risk NCS."

Explicit bridge indication in the adult 2025 guideline.

Treatment of hypertension

Action: Pharmacotherapy NCIT:C15986

Agent: ACE Inhibitor NCIT:C247 Angiotensin II Receptor Antagonist NCIT:C66930

Treat coexisting hypertension with careful titration, commonly using renin-angiotensin-system therapy. Blood-pressure management addresses comorbidity and additional ventricular load; it has not been established to reverse the valve lesion and must not delay indicated replacement.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/ SUPPORT REVIEW SYNTHESIS Human Clinical

"Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are preferentially considered."

Clinical hypertension management in aortic stenosis.

Relief of congestion

Action: Pharmacotherapy NCIT:C15986

Agent: Diuretic NCIT:C448

Diuretics can relieve volume overload while definitive valve evaluation proceeds. Dosing must account for hemodynamics and renal function; symptomatic treatment does not remove fixed obstruction.

Mechanism Target:

INHIBITS Elevated Pulmonary Venous Pressure — The intervention addresses this clinical or physiological target within the stated eligibility and evidence limits.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/ SUPPORT REVIEW SYNTHESIS Human Clinical

"AVR is indicated in patients with heart failure and volume overload, but diuretics can help decrease congestion and provide symptomatic relief before surgery."

Symptom relief while addressing severe valve disease.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/ SUPPORT REVIEW SYNTHESIS Human Clinical

"AVR is indicated in patients with heart failure and volume overload, but diuretics can help decrease congestion and provide symptomatic relief before surgery."

Symptom relief while addressing severe valve disease.

Cardiovascular lipid management

Action: Pharmacotherapy NCIT:C15986

Agent: HMG-CoA Reductase Inhibitor NCIT:C1655

Use lipid-lowering therapy for established cardiovascular indications. SALTIRE and SEAS did not demonstrate slowing of established valve disease with the tested statin-based regimens. This does not refute lipid involvement in initiation, prove an autonomous osteogenic switch, or establish the efficacy of selective Lp(a) lowering.

Show evidence (2 references)

PMID:15944423 SUPPORT PRIMARY RESULT Human Clinical

"Intensive lipid-lowering therapy does not halt the progression of calcific aortic stenosis or induce its regression."

SALTIRE tested atorvastatin in established calcific stenosis; it could not exclude smaller effects.

PMID:18765433 SUPPORT PRIMARY RESULT Human Clinical

"Simvastatin and ezetimibe did not reduce the composite outcome of combined aortic-valve events and ischemic events in patients with aortic stenosis."

SEAS did not improve its primary composite or valve outcomes, despite a separate reduction in ischemic events.

Post-replacement surveillance and rehabilitation

Obtain a baseline echocardiogram within the first weeks after replacement and continue annual clinical/echocardiographic review of bioprostheses, with earlier evaluation for symptoms or suspected dysfunction. Rehabilitation may improve functional recovery. Mechanical prostheses require lifelong anticoagulation; the antithrombotic regimen for other prostheses depends on valve type and concurrent indications.

Show evidence (2 references)

url:https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf SUPPORT REVIEW SYNTHESIS Other

"After valve intervention, an early echocardiographic examination within the first weeks after valve replacement is recommended to document base- line prosthetic valve function."

Post-intervention baseline assessment.

url:https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf SUPPORT REVIEW SYNTHESIS Other

"Cardiological evaluations and echocardio- graphic examinations are recommended annually in patients with a bioprosthesis, and whenever changes in clinical symptoms or signs sug- gestive of valve dysfunction are noted."

Longitudinal prosthesis surveillance.

Palliative care when intervention offers insufficient benefit

For advanced valve disease unsuitable for surgical or transcatheter treatment, coordinate symptom-directed heart-failure treatment and multidisciplinary palliative care with the patient and family. The decision is based on expected benefit and goals, rather than age alone.

Show evidence (1 reference)

url:https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf SUPPORT REVIEW SYNTHESIS Other

"In some patients with advanced VHD not qualifying for surgical or transcatheter therapies, medical HF treatment remains the only, and sometimes best, available option."

Guideline care for advanced disease without a feasible beneficial valve intervention.

Secondary rheumatic-fever prevention

Action: Pharmacotherapy NCIT:C15986

Agent: Penicillin G Benzathine NCIT:C47657

Patients with established rheumatic heart disease may require long-term penicillin prophylaxis to prevent recurrent rheumatic fever. This is specific to the rheumatic subtype and does not treat calcific stenosis or mechanically reopen fused commissures.

Show evidence (1 reference)

url:https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf SUPPORT REVIEW SYNTHESIS Other

"In patients with established RHD, secondary long-term prophylaxis with benzathine benzyl penicillin 1.2 million international units (IU) every 3–4 weeks over 10 years is recom- mended to prevent recurrent episodes, especially in children and ado- lescents."

Etiology-specific recurrent-rheumatic-fever prevention.

🔬

Biochemical Markers

BNP and NT-proBNP

Show evidence (1 reference)

url:https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf SUPPORT REVIEW SYNTHESIS Human Clinical

"Natriuretic peptides can be used to arbitrate the sources of symp- toms in patients with multiple potential causes and help to identify those with high-risk asymptomatic AS who may benefit from early intervention."

Guideline synthesis supports adjunctive risk assessment, not a stand-alone diagnosis or a universally causal biomarker.

von Willebrand factor multimer and collagen-binding abnormalities

Show evidence (1 reference)

PMID:12878741 SUPPORT PRIMARY RESULT Human Clinical

Fifty consecutive patients were studied, with 42 severe cases undergoing replacement; the range summarizes different assays, not a single population prevalence.

Lipoprotein(a)

Show evidence (2 references)

PMID:23388002 SUPPORT PRIMARY RESULT Human Clinical

"One SNP in the lipoprotein(a) (LPA) locus (rs10455872) reached genomewide significance for the presence of aortic-valve calcification"

The discovery outcome was CT calcium; clinical incident stenosis was assessed in separate cohorts.

PMID:23388002 SUPPORT INDIRECT PRIMARY RESULT Human Clinical

"Further studies are needed to evaluate whether lowering Lp(a) levels will reduce the incidence or progression of aortic-valve disease."

The genetic result motivates, but does not establish, therapeutic Lp(a) lowering.

🔬

Diagnosis

Transthoracic echocardiography

First-line assessment of valve morphology, peak jet velocity, mean gradient, valve area, flow and ventricular response. High-gradient severe stenosis is generally characterized by mean gradient ≥40 mmHg, peak velocity ≥4 m/s and valve area ≤1 cm², interpreted together. Discordant measurements require technical and hemodynamic review.

Echocardiography Test NCIT:C16525

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/ SUPPORT REVIEW SYNTHESIS Human Clinical

"Echocardiography remains the standard approach method to evaluate and follow-up patients with aortic stenosis and stratify them for surgery."

Clinical diagnostic synthesis.

Assessment of low-flow and discordant-gradient stenosis

A low gradient does not exclude severe stenosis. Stroke-volume index, ejection fraction, blood pressure, Doppler quality and alternative high- or low-flow causes should be integrated. Low-dose dobutamine stress echocardiography and CT calcium scoring can help distinguish true severe from pseudo-severe disease, particularly with reduced ejection fraction.

Echocardiography Test NCIT:C16525

Show evidence (1 reference)

url:https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf SUPPORT REVIEW SYNTHESIS Other

"Intervention is recommended in symptomatic patients with low-flow (SVi ≤35 mL/m 2 ), low-gradient (<40 mmHg) AS with reduced LVEF (<50%) after careful confirmation that AS is severe. I B"

The 2025 recommendation requires careful confirmation of severity; it is not an instruction to treat every small calculated area.

CT valve calcium and procedural anatomy

CT calcium scoring helps adjudicate discordant stenosis; sex-specific thresholds are supportive rather than universal. Bicuspid, amyloid-associated, post-rheumatic or radiation-related fibrotic disease may be severe with relatively little calcium. CT also evaluates annulus, coronary obstruction risk and access anatomy before TAVI.

Show evidence (1 reference)

url:https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf SUPPORT REVIEW SYNTHESIS Other

"The need for a meticulous CT-based anatomical analysis is para- mount in patients with an estimated life expectancy exceeding the assumed valve durability to anticipate future risks at the time of the index valve intervention."

CT informs procedural and lifetime planning.

Exercise stress testing in apparently asymptomatic disease

Supervised testing can reveal symptoms or an abnormal blood-pressure response in patients reporting no symptoms. It should not be used to provoke symptoms in already symptomatic severe disease. The 2026 EARLY TAVR screening registry found 146 positive tests among 962 eligible tested patients, but positivity included hypotension and only 105 consented to registry follow-up; this is not a population symptom frequency.

Exercise Cardiac Stress Test NCIT:C168192

Show evidence (2 references)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/ SUPPORT REVIEW SYNTHESIS Human Clinical

"Exercise testing helps in unmasking symptoms in asymptomatic patients, but it should be avoided in symptomatic patients."

Clinical indication and safety boundary.

PMID:42485012 SUPPORT PRIMARY RESULT Human Clinical

"Of these, 816 (84.8%) had a normal TST result and 146 (15.2%) had a positive TST result."

Selected eligible screening denominator; a positive test is not synonymous with newly elicited symptoms.

CMR assessment of ventricular remodeling

T1 mapping estimates extracellular expansion and LGE detects focal scar patterns. These complement valve assessment; extracellular volume is not specific for collagen, and the 2017 cohort had insufficient deaths for adjusted survival analysis. Fibrosis-guided early intervention did not significantly improve the EVOLVED primary composite, so CMR fibrosis alone is not a validated universal intervention trigger.

Magnetic Resonance Imaging NCIT:C16809

Show evidence (4 references)

PMID:28017384 SUPPORT BACKGROUND Human Clinical

"Diffuse fibrosis is associated with extracellular volume expansion that is detectable by T1 mapping, whereas late gadolinium enhancement (LGE) detects replacement fibrosis."

Clinical imaging framework; ECV may also reflect vascular expansion or infiltration.

PMID:28017384 SUPPORT PRIMARY RESULT Human Clinical

"There were insufficient deaths to perform multivariate analysis."

The mortality association was unadjusted in a small-event cohort.

PMID:39466640 SUPPORT PRIMARY RESULT Human Clinical

"The findings are not definitive, and further research will be required to confirm the trial findings."

EVOLVED had a wide interval around its null primary comparison.

+ 1 more reference

Bleeding and acquired von Willebrand evaluation

In a patient with severe stenosis and bleeding, assess ordinary gastrointestinal and hemostatic causes as well as acquired vWF dysfunction. Specialized multimer, collagen-binding and high-shear platelet-function assays characterized the clinical syndrome; the cited study is not a recommendation to screen every asymptomatic patient.

Show evidence (1 reference)

PMID:12878741 SUPPORT PRIMARY RESULT Human Clinical

"Platelet function under conditions of high shear stress, von Willebrand factor collagen-binding activity and antigen levels, and the multimeric structure of von Willebrand factor were assessed at base line and one day, seven days, and six months postoperatively."

Assays used in the consecutive clinical cohort.

Distinguishing valvular from other outflow obstruction

Aortic sclerosis without important obstruction, subvalvular stenosis, hypertrophic cardiomyopathy and supravalvular stenosis are differential diagnoses. Coronary disease and pulmonary disease can independently explain angina or dyspnea.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/ SUPPORT REVIEW SYNTHESIS Human Clinical

"Other causes of ... with or without LV outflow obstruction include hypertrophic cardiomyopathy, aortic sclerosis, and subvalvular stenosis."

Anatomical and clinical differential diagnosis.

📈

Progression

Variable asymptomatic progression

Symptoms, valve hemodynamics and ventricular consequences can evolve at different rates. The historical 128-person cohort used death or symptom-triggered valve replacement as a composite event; its event-free survival is not a mortality estimate. New randomized evidence informs individualized earlier intervention, rather than a fixed universal asymptomatic duration.

Show evidence (1 reference)

PMID:10965007 SUPPORT PRIMARY RESULT Human Clinical

"The rate of progression of stenosis, as reflected by the aortic-jet velocity, was significantly higher in patients who had cardiac events"

Historical prospective cohort association; event definition included intervention.

📊

Prevalence

GBD world-standardized population, non-rheumatic calcific aortic valve disease, 2021

Point Prevalence 158.35 per 100,000 (135.92–181.0) >1 in 1,000

Age-standardized model estimate with 95% uncertainty interval, not a crude population proportion or screened cohort. Estimated prevalent count 13,320,896 (UI 11,422,539–15,249,411). The GBD disease category is not all congenital/rheumatic aortic stenosis; the article uses a broad I35–I35.9 code range. The magnitude band describes this age-standardized rate, not a crude population case fraction.

Show evidence (1 reference)

PMID:42129826 SUPPORT PRIMARY RESULT Human Clinical

"In 2021, the worldwide prevalence of NRCAVD was 13,320,896 (95% UI 11,422,539–15,249,411) cases, with an ASPR of 158.35 (95% UI 135.92–181.00) cases per 100,000 population."

Modelled GBD2021 disease burden, age-standardized to the GBD reference population.

🌍

Epidemiology

🔬

Clinical Trials

NCT03042104 NOT_APPLICABLE ACTIVE_NOT_RECRUITING

EARLY TAVR randomized 901 selected adults aged ≥65 years with transfemoral-compatible asymptomatic severe stenosis to early balloon-expandable TAVR or surveillance. The primary death/stroke/unplanned cardiovascular hospitalization composite was lower (122/455 versus 202/446; HR 0.50), without an established individual mortality or stroke benefit. The hospitalization definition included early surveillance-arm conversion within six months; 87% eventually underwent replacement. The open-label trial had unblinded event adjudication and predominantly White participants; longer follow-up continues.

Show evidence (2 references)

clinicaltrials:NCT03042104 SUPPORT PRIMARY RESULT Other

"This study will evaluate the safety and effectiveness of the Edwards SAPIEN 3/SAPIEN 3 Ultra Transcatheter Heart Valve (THV) compared with clinical surveillance (CS) in asymptomatic patients with severe, calcific aortic stenosis."

Registry study identity/design; status and phase independently checked through the live ClinicalTrials.gov API on 2026-09-21.

PMID:39466903 SUPPORT PRIMARY RESULT Human Clinical

"A primary end-point event occurred in 122 patients (26.8%) in the TAVR group and in 202 patients (45.3%) in the clinical surveillance group"

Published study finding; see description for selected population, endpoint and uncertainty.

NCT03094143 NOT_APPLICABLE ACTIVE_NOT_RECRUITING

EVOLVED analyzed 224 fibrosis-enriched asymptomatic severe-AS patients of 356 planned. Early intervention versus guideline-directed care did not significantly reduce the primary death/AS-hospitalization composite (20/113 versus 25/111; HR 0.79, 95% CI 0.44–1.43). Median intervention timing was 5 versus 20.2 months. Hospitalization and symptom secondary findings were unadjusted for multiplicity and remain hypothesis-generating; the trial does not establish equivalence or a fibrosis-selection threshold. The registry remains active for longer follow-up.

Show evidence (3 references)

clinicaltrials:NCT03094143 SUPPORT PRIMARY RESULT Other

"Aortic stenosis is the most common valvular disease in the Western world."

Registry study identity/design; status and phase independently checked through the live ClinicalTrials.gov API on 2026-09-21.

PMID:39466640 SUPPORT PRIMARY RESULT Human Clinical

"The findings that early intervention was associated with a lower incidence of unplanned aortic stenosis–related hospitalization and improved symptom burden should be considered hypothesis-generating given that the study did not meet the primary end point and was not adjusted for multiple comparisons."

Published study finding; see description for selected population, endpoint and uncertainty.

PMID:39466640 SUPPORT PRIMARY RESULT Human Clinical

The primary comparison was nonsignificant with a wide confidence interval, not proof of equivalence.

NCT01161732 NOT_APPLICABLE COMPLETED

RECOVERY randomized 145 selected relatively young, low-risk patients with very severe stenosis, predominantly bicuspid valves, to early surgery or conservative care. At extended follow-up (overall median 12 years), operative/CV deaths were 2/73 versus 17/72; ten-year cumulative incidence was 1% versus 19%. Results support early surgery in this selected population, not all older severe-AS patients or transcatheter devices. Exercise testing was not routine, and few primary events limit precision.

Show evidence (2 references)

clinicaltrials:NCT01161732 SUPPORT PRIMARY RESULT Other

"The optimal timing of surgical intervention remains controversial in asymptomatic patients with very severe aortic stenosis."

Registry study identity/design; status and phase independently checked through the live ClinicalTrials.gov API on 2026-09-21.

PMID:41880613 SUPPORT PRIMARY RESULT Human Clinical

"A total of 145 patients underwent randomization."

Published study finding; see description for selected population, endpoint and uncertainty.

NCT02436655 NOT_APPLICABLE COMPLETED

AVATAR randomized 157 low-risk patients with severe stenosis, preserved ejection fraction and a negative exercise test. At median 63 months, the death/MI/stroke/HF-hospitalization composite was 18/78 versus 37/79 with early surgery versus surveillance (HR 0.42). Secondary mortality and HF findings were exploratory without multiplicity adjustment. CV death and sudden death were not statistically clearly reduced. Open-label adjudication, small size and COVID-era follow-up constrain generalization.

Show evidence (2 references)

clinicaltrials:NCT02436655 SUPPORT PRIMARY RESULT Other

"Whether to intervene in asymptomatic patients with severe aortic stenosis and normal left ventricular ejection fraction remains controversial."

Registry study identity/design; status and phase independently checked through the live ClinicalTrials.gov API on 2026-09-21.

PMID:39217448 SUPPORT PRIMARY RESULT Human Clinical

"All patients had negative exercise stress testing."

Published study finding; see description for selected population, endpoint and uncertainty.

NCT02132026 PHASE_II COMPLETED

SALTIRE2 randomized 152 and analyzed 150 treated patients; 136 contributed the primary calculated 24-month CT calcium-change endpoint. Denosumab and alendronic acid lowered bone-turnover markers but did not significantly reduce CT calcification, Doppler progression or 18F-NaF uptake versus pooled placebo. The single-centre mostly White, male cohort was largely mild/moderate disease; it was powered for a 40% progression effect, not clinical events or smaller benefits. These drugs are not established AS-modifying therapies.

Show evidence (2 references)

clinicaltrials:NCT02132026 SUPPORT PRIMARY RESULT Other

"Aortic stenosis is a condition whereby one of the heart valves (aortic valve) becomes narrowed, due to calcium deposition, over time."

Registry study identity/design; status and phase independently checked through the live ClinicalTrials.gov API on 2026-09-21.

PMID:33913339 SUPPORT PRIMARY RESULT Human Clinical

"There were no differences in 24-month change in aortic valve calcium score between denosumab and placebo"

Published study finding; see description for selected population, endpoint and uncertainty.

NCT05646381 PHASE_II RECRUITING

Lp(a)FRONTIERS CAVS tests monthly pelacarsen versus placebo for progression of calcific stenosis. This ongoing trial addresses whether selective Lp(a) lowering modifies valve disease; its design is not evidence of clinical efficacy.

Show evidence (1 reference)

clinicaltrials:NCT05646381 SUPPORT PRIMARY RESULT Other

"The purpose of this study is to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) administered subcutaneously once monthly compared to placebo in slowing the progression of calcific aortic valve stenosis."

Registry study identity/design; status and phase independently checked through the live ClinicalTrials.gov API on 2026-09-21.

🧫

Experimental Models

Baboon valve-interstitial-cell mineralization culture PRIMARY_CELL_CULTURE

Cultured cells were challenged with 25 versus 5.6 mM glucose in normal or high-phosphate calcification medium. Elevated glucose enhanced mineral deposition only in calcification medium.

Cell source

Primary baboon aortic valve interstitial cells

Publication

PMID:29539583

Pathograph links

Aortic Leaflet Calcification perturbs fidelity: moderate observes: cellular Glucose enhanced cellular-matrix mineral deposition under elevated phosphate.

Limitations: Baboon primary-cell culture is not a human clinical model. The calcium assay used high-phosphate medium (2.6 mM versus 1.0 mM in normal medium) and does not identify an indispensable intracellular pathway. No osmotic-control result is reported in the available Methods.

Readouts

Culture calcium content in high-phosphate medium

Direction: INCREASED

Interpretation: Glucose enhanced cellular-matrix mineral deposition under elevated phosphate.

Show evidence (2 references)

PMID:29539583 SUPPORT PRIMARY RESULT In Vitro

"Addition of 25 mM glucose (hyperglycemic level) to the calcification medium enhanced VIC mineralization by ~2 folds compared to 5.6 mM glucose cultures."

Glucose enhanced mineralization in high-phosphate medium; the culture used baboon valve interstitial cells.

+ 1 more reference

Show evidence (2 references)

PMID:29539583 SUPPORT PRIMARY RESULT In Vitro

"Addition of 25 mM glucose (hyperglycemic level) to the calcification medium enhanced VIC mineralization by ~2 folds compared to 5.6 mM glucose cultures."

Glucose enhanced mineralization in high-phosphate medium; the culture used baboon valve interstitial cells.

+ 1 more reference

Baboon primary-cell culture is not a human clinical model. The calcium assay used high-phosphate medium (2.6 mM versus 1.0 mM in normal medium) and does not identify an indispensable intracellular pathway. No osmotic-control result is reported in the available Methods.

Show evidence (2 references)

PMID:29539583 SUPPORT PRIMARY RESULT In Vitro

"Addition of 25 mM glucose (hyperglycemic level) to the calcification medium enhanced VIC mineralization by ~2 folds compared to 5.6 mM glucose cultures."

Glucose enhanced mineralization in high-phosphate medium; the culture used baboon valve interstitial cells.

PMID:29539583 SUPPORT PRIMARY RESULT In Vitro

"No effect of glucose was found in VIC grown in normal media."

Glucose alone was not sufficient under the normal-medium conditions.

🐁

Animal Models

Combined metabolic-diet LA mouse

A diabetogenic and procalcific diet increased valve jet velocities and lesion burden compared with normal chow in a hyperlipidemic male-mouse background. This model addresses a selected metabolic context of calcific valve disease.

Species

Mouse

Genotype

Ldlr-null; Apob100/100

Publication

PMID:29539583

Pathograph links

Reduced Aortic Valve Opening partially recapitulates fidelity: moderate observes: tissue Higher transvalvular jet velocity provides a functional stenosis readout.

Limitations: The combined diet changes glycemia, lipids, minerals and body weight; it does not isolate glucose as the in-vivo cause. Fibrosis occurred with both diets. Whole-group ejection fraction and fractional shortening differences were nonsignificant; a post hoc stenosis subgroup showed larger functional differences. No neoangiogenesis, large calcified nodules or bone metaplasia was observed.

Readouts

Aortic jet velocity

Direction: INCREASED

Interpretation: Higher transvalvular jet velocity provides a functional stenosis readout.

Show evidence (1 reference)

PMID:29539583 SUPPORT PRIMARY RESULT Model Organism

"At 14 months of age, LDLr−/−ApoB100/100 mice DB fed showed a significantly greater proportion of AS than NC fed mice, as indicated by aortic jet velocities greater than 1600 mm/s (10/13=77% versus 5/13=38%, respectively, p=.048)"

Thirteen male mice per diet group; this threshold and selected model are not human severity criteria.

Show evidence (1 reference)

PMID:29539583 SUPPORT PRIMARY RESULT Model Organism

Thirteen male mice per diet group; this threshold and selected model are not human severity criteria.

The combined diet changes glycemia, lipids, minerals and body weight; it does not isolate glucose as the in-vivo cause. Fibrosis occurred with both diets. Whole-group ejection fraction and fractional shortening differences were nonsignificant; a post hoc stenosis subgroup showed larger functional differences. No neoangiogenesis, large calcified nodules or bone metaplasia was observed.

Show evidence (1 reference)

PMID:29539583 SUPPORT PRIMARY RESULT Model Organism

Thirteen male mice per diet group; this threshold and selected model are not human severity criteria.

Osteoprotegerin-treated Western-diet LA mouse

Exogenous osteoprotegerin reduced valve calcification and osteogenic markers in Western-diet LA mice; older mice also had partial preservation of cusp separation. These findings inform experimental intervention, not established clinical treatment.

Species

Mouse

Genotype

Ldlr-null; Apob100/100

Publication

PMID:23762316

Pathograph links

Aortic Leaflet Calcification perturbs fidelity: moderate observes: tissue OPG reduced valve calcium deposition.

Limitations: Treatment began before overt disease; young mice were treated from 2 to 8 months and older mice from 6 to 12 months, with 12 planned per group and assay-specific subsets. Lipid deposition, fibrosis and superoxide were not reduced. Young-mouse function showed only a nonsignificant trend. Parallel improvements in calcification and function do not establish that one mediates the other.

Readouts

Valve calcium deposition

Direction: DECREASED

Interpretation: OPG reduced valve calcium deposition.

Show evidence (1 reference)

PMID:23762316 SUPPORT PRIMARY RESULT Model Organism

"OPG attenuated calcification of valve tissue in Young mice and in Older mice by about 70% (Figure 4)."

Partial reduction in selected Western-diet LA mice, not a human treatment effect.

Show evidence (1 reference)

PMID:23762316 SUPPORT PRIMARY RESULT Model Organism

"OPG attenuated calcification of valve tissue in Young mice and in Older mice by about 70% (Figure 4)."

Partial reduction in selected Western-diet LA mice, not a human treatment effect.

Reduced Aortic Valve Opening perturbs fidelity: moderate observes: tissue Cusp separation declined less under OPG in the older cohort.

Readouts

Preservation of systolic cusp separation

Direction: INCREASED

Interpretation: Cusp separation declined less under OPG in the older cohort.

Show evidence (1 reference)

PMID:23762316 SUPPORT PRIMARY RESULT Model Organism

"Following 6 months of treatment with OPG or vehicle, aortic cusp separation decreased in both Veh-LA mice and OPG-LA mice. However, the decrease in aortic valve function was significantly attenuated in OPG-LA mice, compared to Veh-LA mice"

The older treatment group had partial preservation rather than reversal of valve dysfunction.

Show evidence (1 reference)

PMID:23762316 SUPPORT PRIMARY RESULT Model Organism

The older treatment group had partial preservation rather than reversal of valve dysfunction.

Treatment began before overt disease; young mice were treated from 2 to 8 months and older mice from 6 to 12 months, with 12 planned per group and assay-specific subsets. Lipid deposition, fibrosis and superoxide were not reduced. Young-mouse function showed only a nonsignificant trend. Parallel improvements in calcification and function do not establish that one mediates the other.

Show evidence (2 references)

PMID:23762316 SUPPORT PRIMARY RESULT Model Organism

"OPG attenuated calcification of valve tissue in Young mice and in Older mice by about 70% (Figure 4)."

Partial reduction in selected Western-diet LA mice, not a human treatment effect.

PMID:23762316 SUPPORT PRIMARY RESULT Model Organism

The older treatment group had partial preservation rather than reversal of valve dysfunction.

Notch1-haploinsufficient mouse with Htr2b perturbation

Complete Htr2b deletion improved valve hemodynamics on the Notch1-haploinsufficient high-cholesterol background. A separate antagonist regimen did not reproduce the improvement. The tissue mechanism remains unresolved.

Species

Mouse

Genotype

Notch1+/− with Htr2b+/+, Htr2b+/− or Htr2b−/−; separate antagonist arm

Publication

PMID:33237915

Pathograph links

Reduced Aortic Valve Opening perturbs fidelity: moderate observes: tissue Complete genetic deletion reduced jet velocity and pressure gradient, without establishing a specific leaflet-cell mediator.

Limitations: Notch1-haploinsufficient mice received a 1% cholesterol diet from 2.5 to 6 months. The separate drug arm used SB204741 1 mg/kg/day from 4 to 6 months. Heterozygous Htr2b loss produced only nonsignificant improvement. Collagen density, leaflet thickness, alpha-SMA and Runx2 did not significantly change, and calcification was limited. Neither an antifibrotic nor an anticalcific mediator was established; left ventricular mass and ejection fraction were unchanged.

Readouts

Aortic jet velocity with complete Htr2b deletion

Direction: DECREASED

Interpretation: Complete genetic deletion reduced jet velocity and pressure gradient, without establishing a specific leaflet-cell mediator.

Show evidence (2 references)

PMID:33237915 SUPPORT PRIMARY RESULT Model Organism

"Ablation of Htr2b from Notch1+/- mice decreases the average peak velocity during the cardiac cycle with a corresponding decrease in mean pressure gradient across the AV, relative to Notch1+/-;Htr2b+/+"

Significant hemodynamic differences occurred with complete Htr2b deletion on the Notch1-haploinsufficient background.

+ 1 more reference

Show evidence (2 references)

PMID:33237915 SUPPORT PRIMARY RESULT Model Organism

Significant hemodynamic differences occurred with complete Htr2b deletion on the Notch1-haploinsufficient background.

+ 1 more reference

Notes

Notch1-haploinsufficient mice received a 1% cholesterol diet from 2.5 to 6 months. The separate drug arm used SB204741 1 mg/kg/day from 4 to 6 months. Heterozygous Htr2b loss produced only nonsignificant improvement. Collagen density, leaflet thickness, alpha-SMA and Runx2 did not significantly change, and calcification was limited. Neither an antifibrotic nor an anticalcific mediator was established; left ventricular mass and ejection fraction were unchanged.

Show evidence (2 references)

PMID:33237915 SUPPORT PRIMARY RESULT Model Organism

Significant hemodynamic differences occurred with complete Htr2b deletion on the Notch1-haploinsufficient background.

PMID:33237915 SUPPORT PRIMARY RESULT Model Organism

"5-HT2B receptor antagonism, however, did not affect hemodynamic progression."

The tested SB204741 regimen was negative; lifelong gene deletion and pharmacologic treatment are not equivalent.

{ }

Source YAML

click to show

name: Aortic Valve Stenosis
creation_date: '2026-08-10T13:40:00Z'
disease_term:
  preferred_term: aortic valve stenosis
  term:
    id: MONDO:0042981
    label: aortic valve stenosis
category: Cardiovascular Disease
description: Aortic valve stenosis is obstruction of left ventricular outflow at the valve. Adult calcific disease involves leaflet lipid accumulation, inflammation, fibrosis and mineralization; congenital valve morphology and rheumatic commissural fusion provide other routes to obstruction. Ventricular pressure overload can lead to hypertrophy, fibrosis, impaired filling, myocardial ischemia and heart failure. Symptoms and valve severity, ventricular consequences, anatomy, procedural risk and patient preferences guide intervention. Mechanistic evidence from tissue associations and experimental models does not establish one obligatory sequence in every patient.
synonyms:
- aortic stenosis
- valvular aortic stenosis
notes: This entry covers valvular obstruction, with most molecular evidence concerning adult calcific disease. Calcific aortic valve disease also includes sclerosis without important obstruction and is not an exact synonym for every form of aortic stenosis. Subvalvular and supravalvular stenosis are anatomically distinct. No applicable GeneReviews chapter was identified; the StatPearls aortic stenosis chapter (PMID:32491560; NBK557628) provides a clinical baseline, while intervention timing and mode use the 2025 ESC/EACTS guideline. Older categorical age, survival and procedure claims are not adopted. The valve fibrosa does not satisfy the arterial-intima boundary of the atherogenesis module; lipid and inflammatory similarities alone do not justify conformance. Live Cell Ontology lookup identified CL:4030032 valve interstitial cell and CL:4030033 valve endothelial cell, replacing the previous claimed ontology gap. The 2025 ESC/EACTS guideline is cited by its publisher URL (PMID:40878295, DOI:10.1093/eurheartj/ehaf194) because canonical PMID retrieval returned unavailable content. The AVATAR follow-up (PMID:39217448), EARLY TAVR (PMID:39466903), and RECOVERY ten-year follow-up (PMID:41880613)
  are cited by PMID; their full texts were read during review, and every quoted sentence is present in the corresponding generated abstract.
has_subtypes:
- name: Calcific stenosis of a tricuspid aortic valve
  description: Age-associated leaflet fibrosis and calcification are a common adult presentation; the molecular and genetic association studies largely address this spectrum.
  review_notes: Etiologic grouping; live MONDO searches did not identify an exact acquired calcific or rheumatic subtype. Congenital stenosis MONDO:0017735 does not cover every later acquired stenosis on congenital anatomy.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/
    reference_title: Aortic Stenosis - StatPearls - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: Etiologies include congenital (bicuspid/unicuspid), calcific, and rheumatic disease.
    explanation: Clinical etiologic synthesis; no subtype frequency is inferred.
- name: Congenital valve-associated stenosis
  description: Bicuspid or unicuspid anatomy can cause valvular obstruction and predispose to later calcification. Bicuspid valves may coexist with aortopathy; only a minority of familial disease is explained by recognized NOTCH1 variants.
  review_notes: Etiologic grouping; live MONDO searches did not identify an exact acquired calcific or rheumatic subtype. Congenital stenosis MONDO:0017735 does not cover every later acquired stenosis on congenital anatomy.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/
    reference_title: Aortic Stenosis - StatPearls - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: Etiologies include congenital (bicuspid/unicuspid), calcific, and rheumatic disease.
    explanation: Clinical etiologic synthesis; no subtype frequency is inferred.
- name: Rheumatic aortic stenosis
  description: Post-rheumatic commissural fusion narrows the valve. This route is distinct from the dominant adult calcific mechanism and often accompanies other rheumatic valve disease.
  review_notes: Etiologic grouping; live MONDO searches did not identify an exact acquired calcific or rheumatic subtype. Congenital stenosis MONDO:0017735 does not cover every later acquired stenosis on congenital anatomy.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/
    reference_title: Aortic Stenosis - StatPearls - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: The commissures of the leaflets fuse to leave a small central orifice.
    explanation: Clinical etiologic synthesis; no subtype frequency is inferred.
inheritance:
- name: Autosomal dominant NOTCH1-related aortic valve disease
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  description: Some NOTCH1-related aortic valve disease follows autosomal dominant inheritance with variable expressivity and incomplete penetrance. This mode does not describe all bicuspid valves or acquired calcific stenosis, which also has common-variant susceptibility.
  evidence:
  - reference: PMID:16025100
    reference_title: Mutations in NOTCH1 cause aortic valve disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: we show that mutations in the signalling and transcriptional regulator NOTCH1 cause a spectrum of developmental aortic valve anomalies and severe valve calcification in non-syndromic autosomal-dominant human pedigrees.
    explanation: States the autosomal-dominant, non-syndromic pedigree transmission that this block records, and confines it to the NOTCH1 arm.
    quote_role: PRIMARY_RESULT
genetic:
- name: LPA
  gene_term:
    preferred_term: LPA
    term:
      id: hgnc:6667
      label: LPA
  relationship_type: SUSCEPTIBILITY
  notes: LPA rs10455872 was associated with CT-detected aortic valve calcium in a 6,942-person European-ancestry discovery analysis, with separate prospective clinical-stenosis associations. Replication was positive in several ancestry groups but not significant in the small Chinese-American analysis. Mendelian randomization supports a causal contribution of circulating Lp(a) under instrument assumptions; it does not demonstrate drug efficacy or a resolved molecular pathway.
  evidence:
  - reference: PMID:23388002
    reference_title: Genetic associations with valvular calcification and aortic stenosis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: One SNP in the lipoprotein(a) (LPA) locus (rs10455872) reached genomewide significance for the presence of aortic-valve calcification
    explanation: Genome-wide significant association of the LPA locus with aortic valve calcification.
    quote_role: PRIMARY_RESULT
- name: NOTCH1
  gene_term:
    preferred_term: NOTCH1
    term:
      id: hgnc:7881
      label: NOTCH1
  relationship_type: CAUSATIVE
  notes: Rare loss-of-function variants cause familial aortic valve developmental anomalies and calcification. A 2022 sequencing/systematic study found a pathogenic variant in one of eight recruited pedigrees and none in 381 sporadic BAV patients. Its approximately 2% familial and <0.1% sporadic literature estimates use heterogeneous congenital-heart-disease denominators, mainly of White ancestry; they are not population fractions of all aortic stenosis. Incomplete penetrance and uncertain variants remain important.
  evidence:
  - reference: PMID:16025100
    reference_title: Mutations in NOTCH1 cause aortic valve disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: mutations in the signalling and transcriptional regulator NOTCH1 cause a spectrum of developmental aortic valve anomalies and severe valve calcification in non-syndromic autosomal-dominant human pedigrees.
    explanation: Establishes NOTCH1 as a causal gene for human aortic valve disease.
    quote_role: PRIMARY_RESULT
  - reference: PMID:35288444
    reference_title: Contribution of NOTCH1 genetic variants to bicuspid aortic valve and other congenital lesions.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: No pathogenic or likely pathogenic NOTCH1 variants were identified in 381 sporadic patients.
    explanation: Primary sporadic BAV sequencing result, not proof that NOTCH1 can never cause sporadic disease.
- name: PRRX1
  gene_term:
    preferred_term: PRRX1
    term:
      id: hgnc:9142
      label: PRRX1
  relationship_type: SUSCEPTIBILITY
  notes: Candidate expression-mediated susceptibility from 2024 GWAS, valve eQTL, colocalization and Mendelian randomization. The study associated higher valve expression with risk; this is statistical nomination, not a patient pathogenic-variant series or gene perturbation/rescue. The GWAS included 14,819 cases and 927,044 European-ancestry controls; 484 selected surgical/transplant valve samples passed expression QC. Bulk tissue, ancestry restriction and instrument assumptions limit interpretation.
  evidence:
  - reference: PMID:38494474
    reference_title: Integrative genomic analyses identify candidate causal genes for calcific aortic valve stenosis involving tissue-specific regulation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: After removing genes with a low probability for colocalization of the GWAS and eQTL signals (PP4 < 0.75, n = 20), with no MR instrument (n = 3) or with high heterogeneity of the instrument (n = 2), ten genes remained (PALMD, NAV1, PRRX1, ATP13A3, BCL10, TWIST1, RAD9A, NRBP1, FES and AFAP1).
    explanation: Ten prioritized genes retained after statistical filtering; causal molecular intermediates require complementary experiments.
    directness: INDIRECT
- name: ATP13A3
  gene_term:
    preferred_term: ATP13A3
    term:
      id: hgnc:24113
      label: ATP13A3
  relationship_type: SUSCEPTIBILITY
  notes: Candidate expression-mediated susceptibility from 2024 GWAS, valve eQTL, colocalization and Mendelian randomization. The study associated higher valve expression with risk; this is statistical nomination, not a patient pathogenic-variant series or gene perturbation/rescue. The GWAS included 14,819 cases and 927,044 European-ancestry controls; 484 selected surgical/transplant valve samples passed expression QC. Bulk tissue, ancestry restriction and instrument assumptions limit interpretation.
  evidence:
  - reference: PMID:38494474
    reference_title: Integrative genomic analyses identify candidate causal genes for calcific aortic valve stenosis involving tissue-specific regulation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: After removing genes with a low probability for colocalization of the GWAS and eQTL signals (PP4 < 0.75, n = 20), with no MR instrument (n = 3) or with high heterogeneity of the instrument (n = 2), ten genes remained (PALMD, NAV1, PRRX1, ATP13A3, BCL10, TWIST1, RAD9A, NRBP1, FES and AFAP1).
    explanation: Ten prioritized genes retained after statistical filtering; causal molecular intermediates require complementary experiments.
    directness: INDIRECT
- name: TWIST1
  gene_term:
    preferred_term: TWIST1
    term:
      id: hgnc:12428
      label: TWIST1
  relationship_type: SUSCEPTIBILITY
  notes: Candidate expression-mediated susceptibility from 2024 GWAS, valve eQTL, colocalization and Mendelian randomization. The study associated higher valve expression with risk; this is statistical nomination, not a patient pathogenic-variant series or gene perturbation/rescue. The GWAS included 14,819 cases and 927,044 European-ancestry controls; 484 selected surgical/transplant valve samples passed expression QC. Bulk tissue, ancestry restriction and instrument assumptions limit interpretation.
  evidence:
  - reference: PMID:38494474
    reference_title: Integrative genomic analyses identify candidate causal genes for calcific aortic valve stenosis involving tissue-specific regulation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: After removing genes with a low probability for colocalization of the GWAS and eQTL signals (PP4 < 0.75, n = 20), with no MR instrument (n = 3) or with high heterogeneity of the instrument (n = 2), ten genes remained (PALMD, NAV1, PRRX1, ATP13A3, BCL10, TWIST1, RAD9A, NRBP1, FES and AFAP1).
    explanation: Ten prioritized genes retained after statistical filtering; causal molecular intermediates require complementary experiments.
    directness: INDIRECT
- name: BCL10
  gene_term:
    preferred_term: BCL10
    term:
      id: hgnc:989
      label: BCL10
  relationship_type: SUSCEPTIBILITY
  notes: Candidate expression-mediated susceptibility from 2024 GWAS, valve eQTL, colocalization and Mendelian randomization. The study associated higher valve expression with risk; this is statistical nomination, not a patient pathogenic-variant series or gene perturbation/rescue. The GWAS included 14,819 cases and 927,044 European-ancestry controls; 484 selected surgical/transplant valve samples passed expression QC. Bulk tissue, ancestry restriction and instrument assumptions limit interpretation.
  evidence:
  - reference: PMID:38494474
    reference_title: Integrative genomic analyses identify candidate causal genes for calcific aortic valve stenosis involving tissue-specific regulation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: After removing genes with a low probability for colocalization of the GWAS and eQTL signals (PP4 < 0.75, n = 20), with no MR instrument (n = 3) or with high heterogeneity of the instrument (n = 2), ten genes remained (PALMD, NAV1, PRRX1, ATP13A3, BCL10, TWIST1, RAD9A, NRBP1, FES and AFAP1).
    explanation: Ten prioritized genes retained after statistical filtering; causal molecular intermediates require complementary experiments.
    directness: INDIRECT
- name: RAD9A
  gene_term:
    preferred_term: RAD9A
    term:
      id: hgnc:9827
      label: RAD9A
  relationship_type: SUSCEPTIBILITY
  notes: Candidate expression-mediated susceptibility from 2024 GWAS, valve eQTL, colocalization and Mendelian randomization. The study associated higher valve expression with risk; this is statistical nomination, not a patient pathogenic-variant series or gene perturbation/rescue. The GWAS included 14,819 cases and 927,044 European-ancestry controls; 484 selected surgical/transplant valve samples passed expression QC. Bulk tissue, ancestry restriction and instrument assumptions limit interpretation.
  evidence:
  - reference: PMID:38494474
    reference_title: Integrative genomic analyses identify candidate causal genes for calcific aortic valve stenosis involving tissue-specific regulation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: After removing genes with a low probability for colocalization of the GWAS and eQTL signals (PP4 < 0.75, n = 20), with no MR instrument (n = 3) or with high heterogeneity of the instrument (n = 2), ten genes remained (PALMD, NAV1, PRRX1, ATP13A3, BCL10, TWIST1, RAD9A, NRBP1, FES and AFAP1).
    explanation: Ten prioritized genes retained after statistical filtering; causal molecular intermediates require complementary experiments.
    directness: INDIRECT
- name: NRBP1
  gene_term:
    preferred_term: NRBP1
    term:
      id: hgnc:7993
      label: NRBP1
  relationship_type: SUSCEPTIBILITY
  notes: Candidate expression-mediated susceptibility from 2024 GWAS, valve eQTL, colocalization and Mendelian randomization. The study associated higher valve expression with risk; this is statistical nomination, not a patient pathogenic-variant series or gene perturbation/rescue. The GWAS included 14,819 cases and 927,044 European-ancestry controls; 484 selected surgical/transplant valve samples passed expression QC. Bulk tissue, ancestry restriction and instrument assumptions limit interpretation.
  evidence:
  - reference: PMID:38494474
    reference_title: Integrative genomic analyses identify candidate causal genes for calcific aortic valve stenosis involving tissue-specific regulation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: After removing genes with a low probability for colocalization of the GWAS and eQTL signals (PP4 < 0.75, n = 20), with no MR instrument (n = 3) or with high heterogeneity of the instrument (n = 2), ten genes remained (PALMD, NAV1, PRRX1, ATP13A3, BCL10, TWIST1, RAD9A, NRBP1, FES and AFAP1).
    explanation: Ten prioritized genes retained after statistical filtering; causal molecular intermediates require complementary experiments.
    directness: INDIRECT
- name: FES
  gene_term:
    preferred_term: FES
    term:
      id: hgnc:3657
      label: FES
  relationship_type: SUSCEPTIBILITY
  notes: Candidate expression-mediated susceptibility from 2024 GWAS, valve eQTL, colocalization and Mendelian randomization. The study associated lower valve expression with risk; this is statistical nomination, not a patient pathogenic-variant series or gene perturbation/rescue. The GWAS included 14,819 cases and 927,044 European-ancestry controls; 484 selected surgical/transplant valve samples passed expression QC. Bulk tissue, ancestry restriction and instrument assumptions limit interpretation.
  evidence:
  - reference: PMID:38494474
    reference_title: Integrative genomic analyses identify candidate causal genes for calcific aortic valve stenosis involving tissue-specific regulation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: After removing genes with a low probability for colocalization of the GWAS and eQTL signals (PP4 < 0.75, n = 20), with no MR instrument (n = 3) or with high heterogeneity of the instrument (n = 2), ten genes remained (PALMD, NAV1, PRRX1, ATP13A3, BCL10, TWIST1, RAD9A, NRBP1, FES and AFAP1).
    explanation: Ten prioritized genes retained after statistical filtering; causal molecular intermediates require complementary experiments.
    directness: INDIRECT
- name: AFAP1
  gene_term:
    preferred_term: AFAP1
    term:
      id: hgnc:24017
      label: AFAP1
  relationship_type: SUSCEPTIBILITY
  notes: Candidate expression-mediated susceptibility from 2024 GWAS, valve eQTL, colocalization and Mendelian randomization. The study associated lower valve expression with risk; this is statistical nomination, not a patient pathogenic-variant series or gene perturbation/rescue. The GWAS included 14,819 cases and 927,044 European-ancestry controls; 484 selected surgical/transplant valve samples passed expression QC. Bulk tissue, ancestry restriction and instrument assumptions limit interpretation.
  evidence:
  - reference: PMID:38494474
    reference_title: Integrative genomic analyses identify candidate causal genes for calcific aortic valve stenosis involving tissue-specific regulation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: After removing genes with a low probability for colocalization of the GWAS and eQTL signals (PP4 < 0.75, n = 20), with no MR instrument (n = 3) or with high heterogeneity of the instrument (n = 2), ten genes remained (PALMD, NAV1, PRRX1, ATP13A3, BCL10, TWIST1, RAD9A, NRBP1, FES and AFAP1).
    explanation: Ten prioritized genes retained after statistical filtering; causal molecular intermediates require complementary experiments.
    directness: INDIRECT
- name: PALMD
  gene_term:
    preferred_term: PALMD
    term:
      id: hgnc:15846
      label: PALMD
  relationship_type: SUSCEPTIBILITY
  notes: Candidate expression-mediated susceptibility from 2024 GWAS, valve eQTL, colocalization and Mendelian randomization. The study associated genetically predicted valve expression with risk; this is statistical nomination, not a patient pathogenic-variant series or gene perturbation/rescue. The GWAS included 14,819 cases and 927,044 European-ancestry controls; 484 selected surgical/transplant valve samples passed expression QC. Bulk tissue, ancestry restriction and instrument assumptions limit interpretation.
  evidence:
  - reference: PMID:38494474
    reference_title: Integrative genomic analyses identify candidate causal genes for calcific aortic valve stenosis involving tissue-specific regulation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: After removing genes with a low probability for colocalization of the GWAS and eQTL signals (PP4 < 0.75, n = 20), with no MR instrument (n = 3) or with high heterogeneity of the instrument (n = 2), ten genes remained (PALMD, NAV1, PRRX1, ATP13A3, BCL10, TWIST1, RAD9A, NRBP1, FES and AFAP1).
    explanation: Ten prioritized genes retained after statistical filtering; causal molecular intermediates require complementary experiments.
    directness: INDIRECT
- name: NAV1
  gene_term:
    preferred_term: NAV1
    term:
      id: hgnc:15989
      label: NAV1
  relationship_type: SUSCEPTIBILITY
  notes: Candidate expression-mediated susceptibility from 2024 GWAS, valve eQTL, colocalization and Mendelian randomization. The study associated genetically predicted valve expression with risk; this is statistical nomination, not a patient pathogenic-variant series or gene perturbation/rescue. The GWAS included 14,819 cases and 927,044 European-ancestry controls; 484 selected surgical/transplant valve samples passed expression QC. Bulk tissue, ancestry restriction and instrument assumptions limit interpretation.
  evidence:
  - reference: PMID:38494474
    reference_title: Integrative genomic analyses identify candidate causal genes for calcific aortic valve stenosis involving tissue-specific regulation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: After removing genes with a low probability for colocalization of the GWAS and eQTL signals (PP4 < 0.75, n = 20), with no MR instrument (n = 3) or with high heterogeneity of the instrument (n = 2), ten genes remained (PALMD, NAV1, PRRX1, ATP13A3, BCL10, TWIST1, RAD9A, NRBP1, FES and AFAP1).
    explanation: Ten prioritized genes retained after statistical filtering; causal molecular intermediates require complementary experiments.
    directness: INDIRECT
phenotypes:
- category: Cardiovascular
  name: Aortic Valve Stenosis
  description: Restricted valvular opening produces outflow obstruction. Severity and flow state vary; symptoms are not required for diagnosis.
  phenotype_term:
    preferred_term: Aortic valve stenosis
    term:
      id: HP:0001650
      label: Aortic valve stenosis
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:10965007
    reference_title: Predictors of outcome in severe, asymptomatic aortic stenosis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: we identified 128 consecutive patients with asymptomatic, severe aortic stenosis
    explanation: Identifies the defining lesion in a prospectively assembled clinical cohort.
    quote_role: PRIMARY_RESULT
  notes: No disease-wide frequency band is inferred from selected clinical cohorts or narrative descriptions.
- category: Cardiovascular
  name: Aortic Valve Calcification
  description: Leaflet calcification characterizes calcific stenosis but is less dominant in some congenital, rheumatic or radiation-associated fibrotic lesions.
  phenotype_term:
    preferred_term: Aortic valve calcification
    term:
      id: HP:0004380
      label: Aortic valve calcification
  evidence:
  - reference: PMID:12719282
    reference_title: Human aortic valve calcification is associated with an osteoblast phenotype.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Microradiography and micro-computerized tomography confirmed the presence of calcification in the valve.
    explanation: Directly documents leaflet calcification in surgically explanted human valves.
    quote_role: PRIMARY_RESULT
  notes: No disease-wide frequency band is inferred from selected clinical cohorts or narrative descriptions.
- category: Cardiovascular
  name: Bicuspid Aortic Valve
  description: A congenital substrate in a subset of patients, rather than a consequence or universal feature of aortic stenosis.
  phenotype_term:
    preferred_term: Bicuspid aortic valve
    term:
      id: HP:0001647
      label: Bicuspid aortic valve
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/
    reference_title: Aortic Stenosis - StatPearls - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: Etiologies include congenital (bicuspid/unicuspid), calcific, and rheumatic disease.
    explanation: Bicuspid morphology is an etiologic substrate in a subset, not an acquired consequence.
  notes: No disease-wide frequency band is inferred from selected clinical cohorts or narrative descriptions.
- category: Cardiovascular
  name: Left Ventricular Hypertrophy
  description: Ventricular hypertrophy is an adaptive response to pressure loading; its extent varies with loading conditions and other disease.
  phenotype_term:
    preferred_term: Left ventricular hypertrophy
    term:
      id: HP:0001712
      label: Left ventricular hypertrophy
  evidence:
  - reference: PMID:28017384
    reference_title: Myocardial Fibrosis and Cardiac Decompensation in Aortic Stenosis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: There was evidence of increasing hypertrophy, myocardial injury, diastolic dysfunction, and longitudinal systolic dysfunction
    explanation: Documents hypertrophy in a phenotyped aortic stenosis cohort.
    quote_role: PRIMARY_RESULT
  notes: No disease-wide frequency band is inferred from selected clinical cohorts or narrative descriptions.
- category: Cardiovascular
  name: Myocardial Fibrosis
  description: Diffuse extracellular expansion and focal replacement fibrosis may accompany ventricular remodeling. The 2017 CMR cohort is cross-sectional at baseline and does not establish inevitable serial conversion or independently adjusted mortality prediction.
  phenotype_term:
    preferred_term: Myocardial fibrosis
    term:
      id: HP:0001685
      label: Myocardial fibrosis
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:28017384
    reference_title: Myocardial Fibrosis and Cardiac Decompensation in Aortic Stenosis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    snippet: Diffuse fibrosis is associated with extracellular volume expansion that is detectable by T1 mapping, whereas late gadolinium enhancement (LGE) detects replacement fibrosis.
    explanation: Clinical imaging background; extracellular expansion is not specific for collagen alone.
  notes: No disease-wide frequency band is inferred from selected clinical cohorts or narrative descriptions.
- category: Cardiovascular
  name: Exertional Dyspnea
  description: Exertional breathlessness can reflect increased filling pressures and limited cardiac reserve; competing pulmonary or cardiac causes should be considered.
  phenotype_term:
    preferred_term: Exertional dyspnea
    term:
      id: HP:0002875
      label: Exertional dyspnea
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/
    reference_title: Aortic Stenosis - StatPearls - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: Patients progressively experience a gradual decrease in exercise tolerance, dyspnea on exertion, and fatigue.
    explanation: The review directly names exertional breathlessness.
  notes: No disease-wide frequency band is inferred from selected clinical cohorts or narrative descriptions.
- category: Cardiovascular
  name: Angina Pectoris
  description: Angina can accompany myocardial oxygen supply-demand imbalance even without obstructive epicardial coronary disease.
  phenotype_term:
    preferred_term: Angina pectoris
    term:
      id: HP:0001681
      label: Angina pectoris
  evidence:
  - reference: PMID:24104373
    reference_title: 'Asymptomatic aortic stenosis in the elderly: a clinical review.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Angina, exertional syncope, and heart failure are key symptoms indicating a need for intervention.
    explanation: Names angina among the symptoms whose appearance indicates a need for intervention.
    quote_role: REVIEW_SYNTHESIS
  - reference: PMID:12732812
    reference_title: Pathophysiology of valvular aortic stenosis in the elderly.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Eventually, symptoms of angina, non-Q wave myocardial infarction, exertional syncope, and heart failure occur.
    explanation: The review names angina in the clinical course; the accompanying infarction term does not establish its coronary mechanism.
    quote_role: REVIEW_SYNTHESIS
  notes: No disease-wide frequency band is inferred from selected clinical cohorts or narrative descriptions.
- category: Cardiovascular
  name: Syncope
  description: Exertional cerebral hypoperfusion can occur when output fails to meet vasodilatory demand; other causes of syncope remain possible.
  phenotype_term:
    preferred_term: Syncope
    term:
      id: HP:0001279
      label: Syncope
  evidence:
  - reference: PMID:24104373
    reference_title: 'Asymptomatic aortic stenosis in the elderly: a clinical review.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Angina, exertional syncope, and heart failure are key symptoms indicating a need for intervention.
    explanation: Names syncope, and specifically its exertional character, among the intervention-triggering symptoms.
    quote_role: REVIEW_SYNTHESIS
  - reference: PMID:12732812
    reference_title: Pathophysiology of valvular aortic stenosis in the elderly.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Eventually, symptoms of angina, non-Q wave myocardial infarction, exertional syncope, and heart failure occur.
    explanation: Independent source placing exertional syncope in the natural history of valvular aortic stenosis.
    quote_role: REVIEW_SYNTHESIS
  notes: No disease-wide frequency band is inferred from selected clinical cohorts or narrative descriptions.
- category: Cardiovascular
  name: Congestive Heart Failure
  description: Advanced stenosis may cause clinical heart failure with preserved or reduced ejection fraction.
  phenotype_term:
    preferred_term: Congestive heart failure
    term:
      id: HP:0001635
      label: Congestive heart failure
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/
    reference_title: Aortic Stenosis - StatPearls - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: Heart failure is one of the most common complications of aortic stenosis.
    explanation: Clinical complication synthesis without a disease-level frequency estimate or inevitable terminal sequence.
  notes: No disease-wide frequency band is inferred from selected clinical cohorts or narrative descriptions.
- name: Midsystolic murmur
  category: Cardiovascular
  description: The murmur may soften when stroke volume falls; intensity alone does not determine severity.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/
    reference_title: Aortic Stenosis - StatPearls - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: mid-systolic ejection murmur, heard best over the right second intercostal space, with radiation into the right neck.
    explanation: Clinical review synthesis; no population frequency inferred.
  phenotype_term:
    preferred_term: Midsystolic murmur
    term:
      id: HP:0031665
      label: Midsystolic murmur
- name: Fatigue
  category: Systemic
  description: Exertional fatigue is a clinical symptom, not specific to valvular disease.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/
    reference_title: Aortic Stenosis - StatPearls - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: Patients progressively experience a gradual decrease in exercise tolerance, dyspnea on exertion, and fatigue.
    explanation: Clinical review synthesis; no population frequency inferred.
  phenotype_term:
    preferred_term: Fatigue
    term:
      id: HP:0012378
      label: Fatigue
- name: Exercise intolerance
  category: Cardiovascular
  description: Reduced exercise capacity may develop gradually and may be underestimated by self-report.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/
    reference_title: Aortic Stenosis - StatPearls - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: Patients progressively experience a gradual decrease in exercise tolerance, dyspnea on exertion, and fatigue.
    explanation: Clinical review synthesis; no population frequency inferred.
  phenotype_term:
    preferred_term: Exercise intolerance
    term:
      id: HP:0003546
      label: Exercise intolerance
- name: Orthopnea
  category: Cardiovascular
  description: A congestion-related symptom in decompensated disease.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/
    reference_title: Aortic Stenosis - StatPearls - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: Severe exertional dyspnea, paroxysmal nocturnal dyspnea, orthopnea, and pulmonary edema show various degrees of pulmonary venous hypertension.
    explanation: Clinical review synthesis; no population frequency inferred.
  phenotype_term:
    preferred_term: Orthopnea
    term:
      id: HP:0012764
      label: Orthopnea
- name: Pulmonary edema
  category: Cardiovascular
  description: Acute pulmonary congestion is a complication, not a universal presenting feature.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/
    reference_title: Aortic Stenosis - StatPearls - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: Severe exertional dyspnea, paroxysmal nocturnal dyspnea, orthopnea, and pulmonary edema show various degrees of pulmonary venous hypertension.
    explanation: Clinical review synthesis; no population frequency inferred.
  phenotype_term:
    preferred_term: Pulmonary edema
    term:
      id: HP:0100598
      label: Pulmonary edema
- name: Pulmonary venous hypertension
  category: Cardiovascular
  description: Post-capillary pressure elevation may complicate left ventricular filling dysfunction; this is not an assertion of primary pulmonary arterial hypertension.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/
    reference_title: Aortic Stenosis - StatPearls - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: Severe exertional dyspnea, paroxysmal nocturnal dyspnea, orthopnea, and pulmonary edema show various degrees of pulmonary venous hypertension.
    explanation: Clinical review synthesis; no population frequency inferred.
  phenotype_term:
    preferred_term: Pulmonary venous hypertension
    term:
      id: HP:0030950
      label: Pulmonary venous hypertension
- name: Gastrointestinal hemorrhage
  category: Gastrointestinal
  description: Bleeding can accompany acquired von Willebrand abnormalities and gastrointestinal vascular lesions; other bleeding causes still require evaluation.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/
    reference_title: Aortic Stenosis - StatPearls - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: GI bleeding is observed in patients with severe aortic stenosis and is often associated with angiodysplasia or other vascular malformations.
    explanation: Clinical review synthesis; no population frequency inferred.
  phenotype_term:
    preferred_term: Gastrointestinal hemorrhage
    term:
      id: HP:0002239
      label: Gastrointestinal hemorrhage
- name: Sudden cardiac death
  category: Cardiovascular
  description: A possible severe complication; this narrative source does not provide a transferable frequency.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/
    reference_title: Aortic Stenosis - StatPearls - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: Severe symptomatic aortic stenosis patients are at a high risk of sudden death.
    explanation: Clinical review synthesis; no population frequency inferred.
  phenotype_term:
    preferred_term: Sudden cardiac death
    term:
      id: HP:0001645
      label: Sudden cardiac death
- name: Left ventricular diastolic dysfunction
  category: Cardiovascular
  description: Impaired ventricular filling may occur while global ejection fraction remains preserved.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/
    reference_title: Aortic Stenosis - StatPearls - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: Diastolic dysfunction develops secondary to hypertrophy and fibrosis and often persists even after AVR.
    explanation: Clinical review synthesis; no population frequency inferred.
  phenotype_term:
    preferred_term: Left ventricular diastolic dysfunction
    term:
      id: HP:0025168
      label: Left ventricular diastolic dysfunction
- name: Left ventricular systolic dysfunction
  category: Cardiovascular
  description: Reduced systolic function occurs in a subset and need not imply irreversible myocardial loss.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/
    reference_title: Aortic Stenosis - StatPearls - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: some patients can present with systolic dysfunction secondary to the afterload mismatch, resulting in a low ejection fraction.
    explanation: Clinical review synthesis; no population frequency inferred.
  phenotype_term:
    preferred_term: Left ventricular systolic dysfunction
    term:
      id: HP:0025169
      label: Left ventricular systolic dysfunction
- name: Slow-rising low-amplitude carotid pulse
  category: Cardiovascular
  description: Physical finding of advanced obstruction; live HPO search found no sufficiently specific term, so no broader misleading binding is assigned.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/
    reference_title: Aortic Stenosis - StatPearls - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: A slow-rising, late-peaking, and a low-amplitude carotid impulse, ... is an expected finding in severe aortic stenosis and, when present, is specific to aortic stenosis.
    explanation: Clinical review synthesis; no population frequency inferred.
  notes: 'Needs term / NTR: slow-rising low-amplitude carotid pulse (pulsus parvus et tardus).'
pathophysiology:
- name: NOTCH1 Loss of Function
  description: Rare pathogenic NOTCH1 variants alter valve development and predispose to calcification. The disease spectrum and incomplete penetrance differ among families.
  biological_scale: MOLECULAR
  evidence:
  - &id027
    reference: PMID:16025100
    reference_title: Mutations in NOTCH1 cause aortic valve disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: mutations in the signalling and transcriptional regulator NOTCH1 cause a spectrum of developmental aortic valve anomalies and severe valve calcification in non-syndromic autosomal-dominant human pedigrees.
    explanation: Rare familial NOTCH1 disease; this does not explain all congenital or acquired stenosis.
  gene:
    preferred_term: NOTCH1
    term:
      id: hgnc:7881
      label: NOTCH1
    modifier: LOSS_OF_FUNCTION
  role: trigger
  downstream:
  - target: Reduced NOTCH-Dependent RUNX2 Repression
    description: Loss of upstream signaling is inferred to diminish the experimentally observed repression.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - &id001
      reference: PMID:16025100
      reference_title: Mutations in NOTCH1 cause aortic valve disease.
      supports: SUPPORT
      evidence_source: IN_VITRO
      quote_role: PRIMARY_RESULT
      snippet: The hairy-related family of transcriptional repressors (Hrt), which are activated by Notch1 signalling, physically interacted with Runx2 and repressed Runx2 transcriptional activity independent of histone deacetylase activity.
      explanation: Experimental transcriptional repression reported in the abstract; loss of this restraint in patient valves is an inferred disease mechanism.
      directness: INDIRECT
    hypothesis_groups:
    - notch_runx2_restraint
  - target: Congenital Bicuspid Valve Morphology
    description: Developmental valve abnormalities can result from rare NOTCH1 variants, with unresolved developmental intermediates and variable penetrance.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:16025100
      reference_title: Mutations in NOTCH1 cause aortic valve disease.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: PRIMARY_RESULT
      snippet: mutations in the signalling and transcriptional regulator NOTCH1 cause a spectrum of developmental aortic valve anomalies and severe valve calcification in non-syndromic autosomal-dominant human pedigrees.
      explanation: Rare familial NOTCH1 disease; this does not explain all congenital or acquired stenosis.
      directness: INDIRECT
- name: Reduced NOTCH-Dependent RUNX2 Repression
  description: NOTCH-activated Hrt proteins repress RUNX2 in experimental assays. Reduced repression is a proposed molecular consequence of loss of NOTCH1 signaling; the cited abstract does not quantify this event in patient valve cells.
  biological_scale: MOLECULAR
  evidence:
  - *id001
  gene:
    preferred_term: RUNX2
    term:
      id: hgnc:10472
      label: RUNX2
  mechanism_confidence: PROVISIONAL
  downstream:
  - target: Valvular Osteogenic Program
    description: Loss of RUNX2 restraint provides an experimentally motivated route to an osteogenic program; the complete patient-cell sequence is unresolved.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - *id001
    - &id003
      reference: PMID:12719282
      reference_title: Human aortic valve calcification is associated with an osteoblast phenotype.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: PRIMARY_RESULT
      snippet: aortic valve calcification is not a random degenerative process but an active regulated process associated with an osteoblast-like phenotype.
      explanation: Human surgical tissue association supports an osteogenic phenotype, not lineage tracing or irreversible commitment.
      directness: INDIRECT
    hypothesis_groups:
    - notch_runx2_restraint
- name: Congenital Bicuspid Valve Morphology
  description: A two-leaflet valve alters valve anatomy and predisposes to earlier stenosis. NOTCH1 explains only a minority of inherited valve disease; anatomy is not equivalent to an identified molecular defect.
  biological_scale: TISSUE
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/
    reference_title: Aortic Stenosis - StatPearls - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: A congenitally abnormal valve with superimposed calcification can cause aortic stenosis.
    explanation: Congenital anatomy is an etiologic substrate in a subset.
  locations:
  - preferred_term: aortic valve
    term:
      id: UBERON:0002137
      label: aortic valve
  role: trigger
  downstream:
  - target: Bicuspid Aortic Valve
    description: The mechanism node represents the congenital structural phenotype.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/
      reference_title: Aortic Stenosis - StatPearls - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: The bicuspid aortic valve is the most common cause of aortic stenosis in patients less than the age of 70 years in developed countries.
      explanation: Clinical review description of a congenital substrate; no prevalence imported.
  - target: Aortic Leaflet Calcification
    description: Congenital anatomy can acquire superimposed calcification through incompletely resolved mechanical and cellular intermediates.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/
      reference_title: Aortic Stenosis - StatPearls - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: A congenitally abnormal valve with superimposed calcification can cause aortic stenosis.
      explanation: Clinical synthesis; no universal NOTCH1 attribution.
- name: Elevated Lipoprotein(a) Exposure
  description: Genetically influenced circulating Lp(a) is associated with valve calcium and later clinical stenosis. Mendelian randomization strengthens a causal interpretation under instrument assumptions, but the molecular mediators and treatment responsiveness remain incompletely resolved.
  biological_scale: MOLECULAR
  evidence:
  - &id026
    reference: PMID:23388002
    reference_title: Genetic associations with valvular calcification and aortic stenosis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: One SNP in the lipoprotein(a) (LPA) locus (rs10455872) reached genomewide significance for the presence of aortic-valve calcification
    explanation: The discovery outcome was CT calcium; clinical incident stenosis was assessed in separate cohorts.
  - &id002
    reference: PMID:23388002
    reference_title: Genetic associations with valvular calcification and aortic stenosis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: Further studies are needed to evaluate whether lowering Lp(a) levels will reduce the incidence or progression of aortic-valve disease.
    explanation: The genetic result motivates, but does not establish, therapeutic Lp(a) lowering.
    directness: INDIRECT
  gene:
    preferred_term: LPA
    term:
      id: hgnc:6667
      label: LPA
  role: trigger
  downstream:
  - target: Aortic Leaflet Calcification
    description: Genetic and Mendelian-randomization evidence supports a contribution to valve calcium under instrumental-variable assumptions, without resolving the biochemical intermediates.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:23388002
      reference_title: Genetic associations with valvular calcification and aortic stenosis.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: PRIMARY_RESULT
      snippet: One SNP in the lipoprotein(a) (LPA) locus (rs10455872) reached genomewide significance for the presence of aortic-valve calcification
      explanation: The discovery outcome was CT calcium; clinical incident stenosis was assessed in separate cohorts.
      directness: INDIRECT
    - *id002
    hypothesis_groups:
    - lipoprotein_a_specific_pathway
- name: Valvular Surface Barrier Injury
  description: Disruption of the basement membrane overlies some early calcific valve lesions. Hemodynamic injury is a proposed contributor, but the founding human study was cross-sectional and did not measure shear stress or prove which lesion came first.
  biological_scale: TISSUE
  evidence:
  - reference: PMID:7519131
    reference_title: Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: disruption of the basement membrane overlying the lesion.
    explanation: Cross-sectional autopsy histology documents a surface lesion; it does not establish the temporal initiating injury.
  locations:
  - preferred_term: aortic valve
    term:
      id: UBERON:0002137
      label: aortic valve
  cell_types:
  - preferred_term: valve endothelial cell
    term:
      id: CL:4030033
      label: valve endothelial cell
  downstream:
  - target: Valvular Lipid Accumulation
    description: Surface disruption may facilitate lipid accumulation; coexistence in human histology supports a proposed route rather than a demonstrated temporal sequence.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:7519131
      reference_title: Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: PRIMARY_RESULT
      snippet: disruption of the basement membrane overlying the lesion.
      explanation: Cross-sectional autopsy histology documents a surface lesion; it does not establish the temporal initiating injury.
      directness: INDIRECT
    - reference: PMID:7519131
      reference_title: Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: PRIMARY_RESULT
      snippet: the presence of large amounts of intracellular and extracellular neutral lipids (oil red O) and fine, stippled mineralization (von Kossa)
      explanation: Lipid and mineral were observed in the same early lesions; temporal or molecular necessity is not established.
      directness: INDIRECT
    hypothesis_groups:
    - calcific_inflammatory_osteogenic_model
- name: Valvular Lipid Accumulation
  description: Intracellular and extracellular lipid accumulates in the aortic-side leaflet lesion and adjacent fibrosa. This is valvular rather than arterial-intimal disease.
  biological_scale: TISSUE
  evidence:
  - &id004
    reference: PMID:7519131
    reference_title: Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: the presence of large amounts of intracellular and extracellular neutral lipids (oil red O) and fine, stippled mineralization (von Kossa)
    explanation: Lipid and mineral were observed in the same early lesions; temporal or molecular necessity is not established.
  locations:
  - preferred_term: aortic valve
    term:
      id: UBERON:0002137
      label: aortic valve
  downstream:
  - target: Valvular Inflammatory Infiltration
    description: Lipid-rich lesions recruit or retain inflammatory cells in the proposed calcific disease process; the cited autopsy observations alone do not establish directionality.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:7519131
      reference_title: Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: PRIMARY_RESULT
      snippet: the presence of large amounts of intracellular and extracellular neutral lipids (oil red O) and fine, stippled mineralization (von Kossa)
      explanation: Lipid and mineral were observed in the same early lesions; temporal or molecular necessity is not established.
      directness: INDIRECT
    - reference: PMID:7519131
      reference_title: Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: PRIMARY_RESULT
      snippet: early lesions were characterized by the presence of an inflammatory infiltrate composed of non-foam cell and foam cell macrophages, occasional T cells, and rare alpha-actin-positive cells.
      explanation: Macrophages were also scattered in normal valves; the lesion-associated infiltrate is a quantitative and contextual change.
      directness: INDIRECT
    hypothesis_groups:
    - calcific_inflammatory_osteogenic_model
- name: Valvular Inflammatory Infiltration
  description: Macrophages, foam cells and occasional T lymphocytes accumulate in early and advanced lesions. Their presence supports inflammatory involvement but does not establish a uniform sequence or one indispensable cytokine.
  biological_scale: CELLULAR
  evidence:
  - reference: PMID:7519131
    reference_title: Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: early lesions were characterized by the presence of an inflammatory infiltrate composed of non-foam cell and foam cell macrophages, occasional T cells, and rare alpha-actin-positive cells.
    explanation: Macrophages were also scattered in normal valves; the lesion-associated infiltrate is a quantitative and contextual change.
  cell_types:
  - preferred_term: macrophage
    term:
      id: CL:0000235
      label: macrophage
  - preferred_term: T cell
    term:
      id: CL:0000084
      label: T cell
  downstream:
  - target: Valvular Osteogenic Program
    description: Inflammatory and osteogenic features participate in the proposed calcific process. These human tissue studies do not establish a single inflammatory mediator or an obligatory sequence.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:7519131
      reference_title: Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: PRIMARY_RESULT
      snippet: early lesions were characterized by the presence of an inflammatory infiltrate composed of non-foam cell and foam cell macrophages, occasional T cells, and rare alpha-actin-positive cells.
      explanation: Macrophages were also scattered in normal valves; the lesion-associated infiltrate is a quantitative and contextual change.
      directness: INDIRECT
    - *id003
    hypothesis_groups:
    - calcific_inflammatory_osteogenic_model
- name: Valvular Osteogenic Program
  description: Calcified human valves express an osteoblast-like marker pattern, including RUNX2/Cbfa1 and bone matrix proteins. Marker expression and experimental differentiation support an osteogenic program, while conversion of every interstitial cell into a mature osteoblast and a lipid-independent commitment point remain unproven.
  biological_scale: CELLULAR
  evidence:
  - *id003
  cell_types:
  - preferred_term: valve interstitial cell
    term:
      id: CL:4030032
      label: valve interstitial cell
  mechanism_confidence: PROVISIONAL
  downstream:
  - target: Aortic Leaflet Calcification
    description: Osteogenic activity is a proposed contributor to mineral deposition; associated markers alone do not prove that this is the only route.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - *id003
    hypothesis_groups:
    - calcific_inflammatory_osteogenic_model
- name: Aortic Leaflet Calcification
  description: Mineral deposits accumulate within the leaflets. Calcification contributes to stiffness and restricted opening, although the relative contribution of fibrosis varies by valve morphology and etiology.
  biological_scale: TISSUE
  evidence:
  - *id004
  - *id003
  locations:
  - preferred_term: aortic valve
    term:
      id: UBERON:0002137
      label: aortic valve
  downstream:
  - target: Aortic Valve Calcification
    description: The tissue event is the structural calcification finding.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - *id004
  - target: Reduced Aortic Valve Opening
    description: Accumulating mineral contributes to restricted opening together with fibrosis and anatomy.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/
      reference_title: Aortic Stenosis - StatPearls - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: A congenitally abnormal valve with superimposed calcification can cause aortic stenosis.
      explanation: Clinical structure-function synthesis.
    - *id003
- name: Rheumatic Commissural Fusion
  description: Rheumatic injury can fuse the aortic leaflet commissures, reducing the effective opening. This is an alternative etiologic branch, not a required step in adult calcific disease.
  biological_scale: TISSUE
  evidence:
  - &id005
    reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/
    reference_title: Aortic Stenosis - StatPearls - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: The commissures of the leaflets fuse to leave a small central orifice.
    explanation: Rheumatic anatomical mechanism.
  role: trigger
  downstream:
  - target: Reduced Aortic Valve Opening
    description: Commissural fusion directly narrows the opening.
    causal_link_type: DIRECT
    evidence:
    - *id005
- name: Reduced Aortic Valve Opening
  description: Restricted leaflet opening creates a fixed valvular outflow obstruction. Fibrosis, calcification and congenital or rheumatic morphology contribute in different proportions.
  biological_scale: TISSUE
  evidence:
  - &id006
    reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/
    reference_title: Aortic Stenosis - StatPearls - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: Left ventricular (LV) obstruction caused by the stenosis of the valve increases LV systolic pressure.
    explanation: Clinical hemodynamic synthesis.
  locations:
  - preferred_term: aortic valve
    term:
      id: UBERON:0002137
      label: aortic valve
  downstream:
  - target: Aortic Valve Stenosis
    description: Reduced valvular opening creates the stenotic lesion.
    causal_link_type: DIRECT
    evidence:
    - *id006
  - target: Left Ventricular Pressure Overload
    description: Outflow obstruction increases the pressure required for ejection.
    causal_link_type: DIRECT
    evidence:
    - *id006
  - target: Limited Exertional Cardiac Output
    description: Fixed obstruction limits cardiac reserve during exercise.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - &id013
      reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/
      reference_title: Aortic Stenosis - StatPearls - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: Syncope is caused by the decrease in cerebral perfusion ... due to systemic vasodilation and an inadequate increase in cardiac output related to stenosis.
      explanation: Clinical exertional hemodynamic mechanism; does not exclude other causes of syncope.
  - target: Loss of High-Molecular-Weight von Willebrand Factor Multimers
    description: High-shear flow provides the proposed route; the clinical association and postoperative correction support it without isolating every proteolytic intermediate.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:12878741
      reference_title: Acquired von Willebrand syndrome in aortic stenosis.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: PRIMARY_RESULT
      snippet: Platelet-function abnormalities under conditions of high shear stress, decreased von Willebrand factor collagen-binding activity and the loss of the largest multimers, or a combination of these was present in 67 to 92 percent of patients with severe aortic stenosis and correlated significantly with the severity of valve stenosis.
      explanation: Fifty consecutive patients were studied, with 42 severe cases undergoing replacement; the range summarizes different assays, not a single population prevalence.
      directness: INDIRECT
  - target: Midsystolic murmur
    description: Systolic flow through the narrowed valve produces an ejection murmur, with intensity dependent on flow.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/
      reference_title: Aortic Stenosis - StatPearls - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: mid-systolic ejection murmur, heard best over the right second intercostal space, with radiation into the right neck.
      explanation: Clinical auscultatory finding.
  - target: Slow-rising low-amplitude carotid pulse
    description: Restricted ejection contributes to a delayed low-amplitude arterial pulse.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/
      reference_title: Aortic Stenosis - StatPearls - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: A slow-rising, late-peaking, and a low-amplitude carotid impulse, ... is an expected finding in severe aortic stenosis and, when present, is specific to aortic stenosis.
      explanation: Clinical physical-examination synthesis.
  - target: Sudden cardiac death
    description: Severe stenosis is associated with sudden-death risk through incompletely resolved hemodynamic and arrhythmic intermediates; this is not an inevitable outcome.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/
      reference_title: Aortic Stenosis - StatPearls - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: Severe symptomatic aortic stenosis patients are at a high risk of sudden death.
      explanation: Clinical risk association; no event frequency or unique lethal mechanism inferred.
- name: Left Ventricular Pressure Overload
  description: The ventricle must generate greater systolic pressure to eject through the stenotic valve. The gradient is flow-dependent, so severe low-flow disease can have a low measured gradient.
  biological_scale: TISSUE
  evidence:
  - *id006
  locations:
  - preferred_term: heart left ventricle
    term:
      id: UBERON:0002084
      label: heart left ventricle
  downstream:
  - target: Cardiomyocyte Hypertrophic Growth
    description: Sustained pressure loading induces hypertrophic adaptation.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - &id008
      reference: PMID:12732812
      reference_title: Pathophysiology of valvular aortic stenosis in the elderly.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: With severe aortic stenosis left ventricular hypertrophy occurs, decreasing wall stress and supporting the left ventricular ejection fraction.
      explanation: Clinical physiological review; the degree of adaptation varies.
  - target: Diffuse Myocardial Fibrosis
    description: Chronic loading may contribute to myocardial injury and matrix remodeling; the full causal intermediates and patient-specific sequence are unresolved.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - &id007
      reference: PMID:12732812
      reference_title: Pathophysiology of valvular aortic stenosis in the elderly.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: However, with pathologic hypertrophy there is a dropout of myocardial cells, subendocardial ischemia, and fibrosis.
      explanation: Review synthesis of maladaptive remodeling; not an obligatory ordered sequence.
      directness: INDIRECT
  - target: Replacement Myocardial Fibrosis
    description: Chronic loading may contribute to myocardial injury and matrix remodeling; the full causal intermediates and patient-specific sequence are unresolved.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - *id007
  - target: Impaired Left Ventricular Systolic Function
    description: Excessive afterload can produce systolic mismatch.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - &id011
      reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/
      reference_title: Aortic Stenosis - StatPearls - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: some patients can present with systolic dysfunction secondary to the afterload mismatch, resulting in a low ejection fraction.
      explanation: Systolic dysfunction may reflect reversible loading mismatch as well as myocardial damage.
- name: Cardiomyocyte Hypertrophic Growth
  description: Increased ventricular muscle mass helps normalize wall stress during pressure loading. Hypertrophy can coexist with impaired relaxation, ischemia and fibrosis without a uniform transition to reduced ejection fraction.
  biological_scale: CELLULAR
  evidence:
  - *id008
  locations:
  - preferred_term: heart left ventricle
    term:
      id: UBERON:0002084
      label: heart left ventricle
  cell_types:
  - preferred_term: cardiac muscle cell
    term:
      id: CL:0000746
      label: cardiac muscle cell
  downstream:
  - target: Left Ventricular Hypertrophy
    description: The cellular remodeling event produces increased ventricular muscle mass.
    causal_link_type: DIRECT
    evidence:
    - *id008
  - target: Impaired Left Ventricular Relaxation
    description: Altered myocardial structure can impair filling through incompletely resolved physiological intermediates.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - &id010
      reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/
      reference_title: Aortic Stenosis - StatPearls - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: Diastolic dysfunction develops secondary to hypertrophy and fibrosis and often persists even after AVR.
      explanation: Clinical mechanism synthesis, not a guarantee of persistence in every patient.
  - target: Myocardial Oxygen Supply-Demand Imbalance
    description: Hypertrophy increases demand and can reduce effective coronary perfusion.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - &id012
      reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/
      reference_title: Aortic Stenosis - StatPearls - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: Angina results from the combination of the need for increased oxygen ... reduction of oxygen ... delivery secondary to the excessive compression of coronary vessels.
      explanation: Clinical supply-demand mechanism; epicardial coronary disease can contribute independently.
- name: Diffuse Myocardial Fibrosis
  description: Interstitial extracellular-matrix expansion accompanies ventricular remodeling. CMR extracellular volume is an imperfect surrogate, and the cited baseline study does not directly demonstrate serial fibrosis progression or reversal.
  biological_scale: TISSUE
  evidence:
  - &id009
    reference: PMID:28017384
    reference_title: Myocardial Fibrosis and Cardiac Decompensation in Aortic Stenosis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    snippet: Diffuse fibrosis is associated with extracellular volume expansion that is detectable by T1 mapping, whereas late gadolinium enhancement (LGE) detects replacement fibrosis.
    explanation: Clinical imaging framework; ECV may also reflect vascular expansion or infiltration.
  - *id007
  locations:
  - preferred_term: heart left ventricle
    term:
      id: UBERON:0002084
      label: heart left ventricle
  downstream:
  - target: Myocardial Fibrosis
    description: The tissue event contributes to the clinical fibrosis finding.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - *id009
  - target: Impaired Left Ventricular Relaxation
    description: Altered myocardial structure can impair filling through incompletely resolved physiological intermediates.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - *id010
- name: Replacement Myocardial Fibrosis
  description: Focal replacement fibrosis accompanies myocardial injury in some patients. Midwall LGE identifies a different imaging pattern from infarct-related scarring; conversion from diffuse fibrosis is a hypothesis requiring longitudinal evidence.
  biological_scale: TISSUE
  evidence:
  - *id009
  - *id007
  locations:
  - preferred_term: heart left ventricle
    term:
      id: UBERON:0002084
      label: heart left ventricle
  downstream:
  - target: Myocardial Fibrosis
    description: The tissue event contributes to the clinical fibrosis finding.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - *id009
  - target: Impaired Left Ventricular Relaxation
    description: Altered myocardial structure can impair filling through incompletely resolved physiological intermediates.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - *id010
- name: Impaired Left Ventricular Relaxation
  description: Hypertrophy and matrix changes can impair ventricular filling while global ejection fraction remains preserved.
  biological_scale: TISSUE
  evidence:
  - *id010
  downstream:
  - target: Left ventricular diastolic dysfunction
    description: The organ dysfunction corresponds to the clinical filling abnormality.
    causal_link_type: DIRECT
    evidence:
    - *id010
  - target: Elevated Pulmonary Venous Pressure
    description: Impaired filling can elevate upstream pulmonary venous pressure.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - &id014
      reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/
      reference_title: Aortic Stenosis - StatPearls - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: Severe exertional dyspnea, paroxysmal nocturnal dyspnea, orthopnea, and pulmonary edema show various degrees of pulmonary venous hypertension.
      explanation: Post-capillary hemodynamic pathway in left-heart disease.
  - target: Congestive Heart Failure
    description: Ventricular dysfunction can contribute to clinical heart failure with varying ejection fraction.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/
      reference_title: Aortic Stenosis - StatPearls - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: Heart failure is one of the most common complications of aortic stenosis.
      explanation: Clinical complication synthesis.
    - *id010
- name: Impaired Left Ventricular Systolic Function
  description: Afterload mismatch and myocardial disease can reduce ejection performance. Reduced function is not synonymous with irreversible scar.
  biological_scale: TISSUE
  evidence:
  - *id011
  downstream:
  - target: Left ventricular systolic dysfunction
    description: Reduced ejection performance corresponds to the clinical finding.
    causal_link_type: DIRECT
    evidence:
    - *id011
  - target: Congestive Heart Failure
    description: Ventricular dysfunction can contribute to clinical heart failure with varying ejection fraction.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/
      reference_title: Aortic Stenosis - StatPearls - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: Heart failure is one of the most common complications of aortic stenosis.
      explanation: Clinical complication synthesis.
    - *id011
- name: Myocardial Oxygen Supply-Demand Imbalance
  description: Greater muscle mass and systolic workload increase oxygen demand while perfusion can be constrained. This can produce ischemic symptoms even without obstructive coronary disease.
  biological_scale: TISSUE
  evidence:
  - *id012
  downstream:
  - target: Angina Pectoris
    description: Ischemic supply-demand mismatch can produce anginal pain.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - *id012
- name: Limited Exertional Cardiac Output
  description: Valvular obstruction can prevent an adequate output increase during exercise. Cerebral perfusion may fall when systemic vasodilation exceeds the compensatory increase in flow.
  biological_scale: TISSUE
  evidence:
  - *id013
  downstream:
  - target: Syncope
    description: Reduced reserve can contribute to the symptom, with other causes and intervening physiology remaining relevant.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/
      reference_title: Aortic Stenosis - StatPearls - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: Syncope is caused by the decrease in cerebral perfusion ... due to systemic vasodilation and an inadequate increase in cardiac output related to stenosis.
      explanation: Clinical exertional hemodynamic mechanism; does not exclude other causes of syncope.
      directness: INDIRECT
    - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/
      reference_title: Aortic Stenosis - StatPearls - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: Patients progressively experience a gradual decrease in exercise tolerance, dyspnea on exertion, and fatigue.
      explanation: Clinical symptom synthesis.
  - target: Exercise intolerance
    description: Reduced reserve can contribute to the symptom, with other causes and intervening physiology remaining relevant.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/
      reference_title: Aortic Stenosis - StatPearls - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: Syncope is caused by the decrease in cerebral perfusion ... due to systemic vasodilation and an inadequate increase in cardiac output related to stenosis.
      explanation: Clinical exertional hemodynamic mechanism; does not exclude other causes of syncope.
      directness: INDIRECT
    - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/
      reference_title: Aortic Stenosis - StatPearls - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: Patients progressively experience a gradual decrease in exercise tolerance, dyspnea on exertion, and fatigue.
      explanation: Clinical symptom synthesis.
  - target: Fatigue
    description: Reduced reserve can contribute to the symptom, with other causes and intervening physiology remaining relevant.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/
      reference_title: Aortic Stenosis - StatPearls - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: Syncope is caused by the decrease in cerebral perfusion ... due to systemic vasodilation and an inadequate increase in cardiac output related to stenosis.
      explanation: Clinical exertional hemodynamic mechanism; does not exclude other causes of syncope.
      directness: INDIRECT
    - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/
      reference_title: Aortic Stenosis - StatPearls - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: Patients progressively experience a gradual decrease in exercise tolerance, dyspnea on exertion, and fatigue.
      explanation: Clinical symptom synthesis.
- name: Elevated Pulmonary Venous Pressure
  description: Raised left ventricular filling pressure can be transmitted to the pulmonary venous circulation and cause congestion.
  biological_scale: TISSUE
  evidence:
  - *id014
  - &id015
    reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/
    reference_title: Aortic Stenosis - StatPearls - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: Severe exertional dyspnea, paroxysmal nocturnal dyspnea, orthopnea, and pulmonary edema show various degrees of pulmonary venous hypertension.
    explanation: Clinical pulmonary-congestion manifestations.
  downstream:
  - target: Pulmonary venous hypertension
    description: Pulmonary venous pressure elevation contributes to this finding; it is not universal across stenosis stages.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - *id015
    - *id014
  - target: Exertional Dyspnea
    description: Pulmonary venous pressure elevation contributes to this finding; it is not universal across stenosis stages.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - *id015
    - *id014
  - target: Orthopnea
    description: Pulmonary venous pressure elevation contributes to this finding; it is not universal across stenosis stages.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - *id015
    - *id014
  - target: Pulmonary edema
    description: Pulmonary venous pressure elevation contributes to this finding; it is not universal across stenosis stages.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - *id015
    - *id014
- name: Loss of High-Molecular-Weight von Willebrand Factor Multimers
  description: High-shear valvular flow is associated with loss of the largest vWF multimers in some severe cases. Abnormalities can improve after replacement and recur with prosthesis-patient mismatch.
  biological_scale: MOLECULAR
  evidence:
  - &id016
    reference: PMID:12878741
    reference_title: Acquired von Willebrand syndrome in aortic stenosis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: Platelet-function abnormalities under conditions of high shear stress, decreased von Willebrand factor collagen-binding activity and the loss of the largest multimers, or a combination of these was present in 67 to 92 percent of patients with severe aortic stenosis and correlated significantly with the severity of valve stenosis.
    explanation: Fifty consecutive patients were studied, with 42 severe cases undergoing replacement; the range summarizes different assays, not a single population prevalence.
  downstream:
  - target: Impaired Primary Hemostasis
    description: Loss of functional large multimers contributes to defective platelet adhesion, with other hemostatic influences unresolved in the clinical cohort.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:12878741
      reference_title: Acquired von Willebrand syndrome in aortic stenosis.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: PRIMARY_RESULT
      snippet: Platelet-function abnormalities under conditions of high shear stress, decreased von Willebrand factor collagen-binding activity and the loss of the largest multimers, or a combination of these was present in 67 to 92 percent of patients with severe aortic stenosis and correlated significantly with the severity of valve stenosis.
      explanation: Fifty consecutive patients were studied, with 42 severe cases undergoing replacement; the range summarizes different assays, not a single population prevalence.
      directness: INDIRECT
- name: Impaired Primary Hemostasis
  description: Reduced vWF collagen-binding function and abnormal high-shear platelet function contribute to acquired bleeding tendency; laboratory changes and clinical bleeding have different frequencies.
  biological_scale: ORGANISM
  evidence:
  - *id016
  downstream:
  - target: Gastrointestinal hemorrhage
    description: Acquired vWF abnormalities can promote bleeding, often in conjunction with gastrointestinal vascular lesions.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/
      reference_title: Aortic Stenosis - StatPearls - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: They are also at increased risk of bleeding, especially GI bleeding, due to acquired von Willebrand syndrome.
      explanation: Clinical synthesis of the bleeding complication.
- name: Aortic Leaflet Fibrosis
  description: Extracellular-matrix expansion and fibrosis in the valve can restrict leaflet motion. Its contribution varies among calcific, congenital and rheumatic contexts; this is distinct from the pressure-loaded ventricular fibrotic response. The cited evidence does not resolve one initiating cellular route in all etiologies.
  biological_scale: TISSUE
  evidence:
  - &id017
    reference: url:https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf
    reference_title: https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: Aortic stenosis is a disease slowly evolving from mild to severe valve obstruction as a consequence of increasing valve fibrosis and calcifi- cation
    explanation: Clinical pathophysiology synthesis distinguishes valve fibrosis from myocardial fibrosis.
  locations:
  - preferred_term: aortic valve
    term:
      id: UBERON:0002137
      label: aortic valve
  downstream:
  - target: Reduced Aortic Valve Opening
    description: Leaflet matrix remodeling can contribute to obstruction alongside calcification.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - *id017
diagnosis:
- name: Transthoracic echocardiography
  description: First-line assessment of valve morphology, peak jet velocity, mean gradient, valve area, flow and ventricular response. High-gradient severe stenosis is generally characterized by mean gradient ≥40 mmHg, peak velocity ≥4 m/s and valve area ≤1 cm², interpreted together. Discordant measurements require technical and hemodynamic review.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/
    reference_title: Aortic Stenosis - StatPearls - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: Echocardiography remains the standard approach method to evaluate and follow-up patients with aortic stenosis and stratify them for surgery.
    explanation: Clinical diagnostic synthesis.
  diagnosis_term:
    preferred_term: Echocardiography Test
    term:
      id: NCIT:C16525
      label: Echocardiography Test
- name: Assessment of low-flow and discordant-gradient stenosis
  description: A low gradient does not exclude severe stenosis. Stroke-volume index, ejection fraction, blood pressure, Doppler quality and alternative high- or low-flow causes should be integrated. Low-dose dobutamine stress echocardiography and CT calcium scoring can help distinguish true severe from pseudo-severe disease, particularly with reduced ejection fraction.
  evidence:
  - reference: url:https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf
    reference_title: https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: Intervention is recommended in symptomatic patients with low-flow (SVi ≤35 mL/m 2 ), low-gradient (<40 mmHg) AS with reduced LVEF (<50%) after careful confirmation that AS is severe. I B
    explanation: The 2025 recommendation requires careful confirmation of severity; it is not an instruction to treat every small calculated area.
  diagnosis_term:
    preferred_term: Echocardiography Test
    term:
      id: NCIT:C16525
      label: Echocardiography Test
- name: CT valve calcium and procedural anatomy
  description: CT calcium scoring helps adjudicate discordant stenosis; sex-specific thresholds are supportive rather than universal. Bicuspid, amyloid-associated, post-rheumatic or radiation-related fibrotic disease may be severe with relatively little calcium. CT also evaluates annulus, coronary obstruction risk and access anatomy before TAVI.
  evidence:
  - reference: url:https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf
    reference_title: https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: The need for a meticulous CT-based anatomical analysis is para- mount in patients with an estimated life expectancy exceeding the assumed valve durability to anticipate future risks at the time of the index valve intervention.
    explanation: CT informs procedural and lifetime planning.
- name: Exercise stress testing in apparently asymptomatic disease
  description: Supervised testing can reveal symptoms or an abnormal blood-pressure response in patients reporting no symptoms. It should not be used to provoke symptoms in already symptomatic severe disease. The 2026 EARLY TAVR screening registry found 146 positive tests among 962 eligible tested patients, but positivity included hypotension and only 105 consented to registry follow-up; this is not a population symptom frequency.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/
    reference_title: Aortic Stenosis - StatPearls - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: Exercise testing helps in unmasking symptoms in asymptomatic patients, but it should be avoided in symptomatic patients.
    explanation: Clinical indication and safety boundary.
  - reference: PMID:42485012
    reference_title: 'Treadmill Stress Test in Patients With Asymptomatic Severe Aortic Stenosis: A Prespecified Registry-Based Follow-Up of the EARLY TAVR Randomized Clinical Trial.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: Of these, 816 (84.8%) had a normal TST result and 146 (15.2%) had a positive TST result.
    explanation: Selected eligible screening denominator; a positive test is not synonymous with newly elicited symptoms.
  diagnosis_term:
    preferred_term: Exercise Cardiac Stress Test
    term:
      id: NCIT:C168192
      label: Exercise Cardiac Stress Test
- name: CMR assessment of ventricular remodeling
  description: T1 mapping estimates extracellular expansion and LGE detects focal scar patterns. These complement valve assessment; extracellular volume is not specific for collagen, and the 2017 cohort had insufficient deaths for adjusted survival analysis. Fibrosis-guided early intervention did not significantly improve the EVOLVED primary composite, so CMR fibrosis alone is not a validated universal intervention trigger.
  evidence:
  - *id009
  - reference: PMID:28017384
    reference_title: Myocardial Fibrosis and Cardiac Decompensation in Aortic Stenosis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: There were insufficient deaths to perform multivariate analysis.
    explanation: The mortality association was unadjusted in a small-event cohort.
  - reference: PMID:39466640
    reference_title: 'Early Intervention in Patients With Asymptomatic Severe Aortic Stenosis and Myocardial Fibrosis: The EVOLVED Randomized Clinical Trial.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: The findings are not definitive, and further research will be required to confirm the trial findings.
    explanation: EVOLVED had a wide interval around its null primary comparison.
  - reference: PMID:39466640
    reference_title: 'Early Intervention in Patients With Asymptomatic Severe Aortic Stenosis and Myocardial Fibrosis: The EVOLVED Randomized Clinical Trial.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: The primary end point occurred in 20 of 113 patients (18%) in the early intervention group and 25 of 111 patients (23%) in the guideline-directed conservative management group (hazard ratio, 0.79 [95% CI, 0.44-1.43]; P = .44; between-group difference, -4.82% [95% CI, -15.31% to 5.66%]).
    explanation: The primary comparison was nonsignificant with a wide confidence interval, not proof of equivalence.
  diagnosis_term:
    preferred_term: Magnetic Resonance Imaging
    term:
      id: NCIT:C16809
      label: Magnetic Resonance Imaging
- name: Bleeding and acquired von Willebrand evaluation
  description: In a patient with severe stenosis and bleeding, assess ordinary gastrointestinal and hemostatic causes as well as acquired vWF dysfunction. Specialized multimer, collagen-binding and high-shear platelet-function assays characterized the clinical syndrome; the cited study is not a recommendation to screen every asymptomatic patient.
  evidence:
  - reference: PMID:12878741
    reference_title: Acquired von Willebrand syndrome in aortic stenosis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: Platelet function under conditions of high shear stress, von Willebrand factor collagen-binding activity and antigen levels, and the multimeric structure of von Willebrand factor were assessed at base line and one day, seven days, and six months postoperatively.
    explanation: Assays used in the consecutive clinical cohort.
- name: Distinguishing valvular from other outflow obstruction
  description: Aortic sclerosis without important obstruction, subvalvular stenosis, hypertrophic cardiomyopathy and supravalvular stenosis are differential diagnoses. Coronary disease and pulmonary disease can independently explain angina or dyspnea.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/
    reference_title: Aortic Stenosis - StatPearls - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: Other causes of ... with or without LV outflow obstruction include hypertrophic cardiomyopathy, aortic sclerosis, and subvalvular stenosis.
    explanation: Anatomical and clinical differential diagnosis.
treatments:
- name: Surgical aortic valve replacement
  description: Replacement relieves severe valvular obstruction. In the 2025 ESC/EACTS adult framework, SAVR is recommended for patients younger than 70 years at low surgical risk and remains the principal approach for many young patients with bicuspid stenosis, associated aortopathy or unfavorable transcatheter anatomy. Prosthesis choice incorporates anticoagulation, durability, future interventions and patient preferences; correction of the valve does not guarantee complete myocardial recovery.
  evidence:
  - reference: url:https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf
    reference_title: https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: SAVR is recommended in patients <70 years of age, if the surgical risk is low.
    explanation: 2025 ESC/EACTS Class I, level B; age is interpreted with Heart Team assessment.
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/
    reference_title: Aortic Stenosis - StatPearls - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: The definitive treatment for aortic stenosis includes aortic valve replacement, either via a surgical or percutaneous approach.
    explanation: Clinical basis for relieving obstruction.
  treatment_term: &id018
    preferred_term: Aortic Valve Replacement
    term:
      id: NCIT:C50815
      label: Aortic Valve Replacement
  target_mechanisms:
  - target: Reduced Aortic Valve Opening
    treatment_effect: INHIBITS
    description: The intervention addresses this clinical or physiological target within the stated eligibility and evidence limits.
    evidence:
    - reference: url:https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf
      reference_title: https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf
      supports: SUPPORT
      evidence_source: OTHER
      quote_role: REVIEW_SYNTHESIS
      snippet: SAVR is recommended in patients <70 years of age, if the surgical risk is low.
      explanation: 2025 ESC/EACTS Class I, level B; age is interpreted with Heart Team assessment.
    - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/
      reference_title: Aortic Stenosis - StatPearls - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: The definitive treatment for aortic stenosis includes aortic valve replacement, either via a surgical or percutaneous approach.
      explanation: Clinical basis for relieving obstruction.
- name: Transcatheter aortic valve implantation
  description: The 2025 ESC/EACTS guideline recommends TAVI for patients aged at least 70 years with tricuspid stenosis and suitable anatomy. Transfemoral access, coronary obstruction risk, annular anatomy and lifetime reintervention planning matter. Other candidates require individual Heart Team assessment; TAVI for bicuspid stenosis is a weaker recommendation in selected patients at increased surgical risk. Vascular injury, paravalvular leak and pacemaker risk differ from surgical risks.
  evidence:
  - reference: url:https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf
    reference_title: https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: TAVI is recommended in patients ≥70 years of age with tricuspid AV stenosis, if the anatomy is suitable.
    explanation: Class I, level A in the 2025 adult guideline; this is not an age-only rule.
  - reference: url:https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf
    reference_title: https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: SAVR or TAVI are recommended for all remaining candidates for an aortic BHV according to Heart Team assessment.
    explanation: Individualized mode selection.
  treatment_term:
    preferred_term: Transcatheter Aortic Valve Replacement
    term:
      id: NCIT:C158018
      label: Transcatheter Aortic Valve Replacement
  target_mechanisms:
  - target: Reduced Aortic Valve Opening
    treatment_effect: INHIBITS
    description: The intervention addresses this clinical or physiological target within the stated eligibility and evidence limits.
    evidence:
    - reference: url:https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf
      reference_title: https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf
      supports: SUPPORT
      evidence_source: OTHER
      quote_role: REVIEW_SYNTHESIS
      snippet: TAVI is recommended in patients ≥70 years of age with tricuspid AV stenosis, if the anatomy is suitable.
      explanation: Class I, level A in the 2025 adult guideline; this is not an age-only rule.
    - reference: url:https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf
      reference_title: https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf
      supports: SUPPORT
      evidence_source: OTHER
      quote_role: REVIEW_SYNTHESIS
      snippet: SAVR or TAVI are recommended for all remaining candidates for an aortic BHV according to Heart Team assessment.
      explanation: Individualized mode selection.
- name: Timing intervention in symptomatic severe disease
  description: Intervention is recommended for symptomatic severe high-gradient stenosis, and for confirmed severe low-flow low-gradient disease with reduced ejection fraction. With preserved ejection fraction and low flow/gradient, severity confirmation and exclusion of competing explanations are essential. Expected benefit, life expectancy and procedural feasibility determine whether intervention is appropriate.
  evidence:
  - reference: url:https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf
    reference_title: https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: Intervention is recommended in symptomatic patients with severe, high-gradient AS
    explanation: Class I, level B recommendation; the complete clinical and hemodynamic context is required.
  treatment_term: *id018
- name: Early intervention in selected asymptomatic severe disease
  description: The 2025 guideline supports intervention as an alternative to close surveillance in asymptomatic severe high-gradient stenosis with ejection fraction ≥50% and low procedural risk (Class IIa, A). Ejection fraction <50% without another cause is a Class I indication. Very severe hemodynamics, rapid progression with heavy calcification, markedly elevated natriuretic peptides or abnormal exercise blood pressure strengthen selection. Trials differ in age, valve anatomy, fibrosis enrichment, procedures and outcome definitions; there is no uniform mortality benefit across all asymptomatic populations.
  evidence:
  - reference: url:https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf
    reference_title: https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: Intervention should be considered in asymptomatic patients (confirmed by a normal exercise test, if feasible) with severe, high-gradient AS and LVEF ≥50%, as an alternative to close active surveillance, if the procedural risk is low. IIa A
    explanation: The 2025 conditional early-intervention recommendation, not a mandate to replace every asymptomatic valve.
  - reference: url:https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf
    reference_title: https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: Intervention is recommended in asymptomatic patients with severe AS and LVEF <50% without another cause.
    explanation: Class I, level B ventricular-function indication.
  treatment_term: *id018
- name: Active surveillance and symptom education
  description: For patients managed without immediate intervention, educate patients and caregivers to report symptoms promptly and reassess severity and ventricular function. The 2025 guideline recommends at least six-monthly follow-up for asymptomatic severe disease, annual reassessment for moderate degenerative stenosis, and potentially two- to three-year intervals for younger patients with mild disease and little leaflet calcium. New symptoms prompt earlier reassessment.
  evidence:
  - reference: url:https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf
    reference_title: https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: Asymptomatic pa- tients with severe AS should be followed up at least every 6 months to allow detection of early symptoms
    explanation: Regular clinical and echocardiographic surveillance in the guideline.
- name: Balloon aortic valvotomy as a bridge
  description: In the adult severe-stenosis guideline, balloon valvotomy may be considered as a temporary bridge to SAVR or TAVI in hemodynamic instability or urgent high-risk noncardiac surgery (Class IIb, C). Benefits are limited and severe regurgitation is a risk; it is not a durable substitute for replacement in calcific adult disease. Pediatric congenital-valve decisions require their own clinical context.
  evidence:
  - reference: url:https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf
    reference_title: https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: Balloon aortic valvotomy may be considered as a bridge to SAVR or TAVI in haemodynamically unstable patients, and (if feasible) in those with severe AS who require urgent high-risk NCS.
    explanation: Explicit bridge indication in the adult 2025 guideline.
  target_mechanisms:
  - target: Reduced Aortic Valve Opening
    treatment_effect: INHIBITS
    description: The intervention addresses this clinical or physiological target within the stated eligibility and evidence limits.
    evidence:
    - reference: url:https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf
      reference_title: https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf
      supports: SUPPORT
      evidence_source: OTHER
      quote_role: REVIEW_SYNTHESIS
      snippet: Balloon aortic valvotomy may be considered as a bridge to SAVR or TAVI in haemodynamically unstable patients, and (if feasible) in those with severe AS who require urgent high-risk NCS.
      explanation: Explicit bridge indication in the adult 2025 guideline.
- name: Treatment of hypertension
  description: Treat coexisting hypertension with careful titration, commonly using renin-angiotensin-system therapy. Blood-pressure management addresses comorbidity and additional ventricular load; it has not been established to reverse the valve lesion and must not delay indicated replacement.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/
    reference_title: Aortic Stenosis - StatPearls - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are preferentially considered.
    explanation: Clinical hypertension management in aortic stenosis.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: ACE Inhibitor
      term:
        id: NCIT:C247
        label: ACE Inhibitor
    - preferred_term: Angiotensin II Receptor Antagonist
      term:
        id: NCIT:C66930
        label: Angiotensin II Receptor Antagonist
- name: Relief of congestion
  description: Diuretics can relieve volume overload while definitive valve evaluation proceeds. Dosing must account for hemodynamics and renal function; symptomatic treatment does not remove fixed obstruction.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/
    reference_title: Aortic Stenosis - StatPearls - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: AVR is indicated in patients with heart failure and volume overload, but diuretics can help decrease congestion and provide symptomatic relief before surgery.
    explanation: Symptom relief while addressing severe valve disease.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: Diuretic
      term:
        id: NCIT:C448
        label: Diuretic
  target_mechanisms:
  - target: Elevated Pulmonary Venous Pressure
    treatment_effect: INHIBITS
    description: The intervention addresses this clinical or physiological target within the stated eligibility and evidence limits.
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/
      reference_title: Aortic Stenosis - StatPearls - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: AVR is indicated in patients with heart failure and volume overload, but diuretics can help decrease congestion and provide symptomatic relief before surgery.
      explanation: Symptom relief while addressing severe valve disease.
- name: Cardiovascular lipid management
  description: Use lipid-lowering therapy for established cardiovascular indications. SALTIRE and SEAS did not demonstrate slowing of established valve disease with the tested statin-based regimens. This does not refute lipid involvement in initiation, prove an autonomous osteogenic switch, or establish the efficacy of selective Lp(a) lowering.
  evidence:
  - reference: PMID:15944423
    reference_title: A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: Intensive lipid-lowering therapy does not halt the progression of calcific aortic stenosis or induce its regression.
    explanation: SALTIRE tested atorvastatin in established calcific stenosis; it could not exclude smaller effects.
  - reference: PMID:18765433
    reference_title: Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: Simvastatin and ezetimibe did not reduce the composite outcome of combined aortic-valve events and ischemic events in patients with aortic stenosis.
    explanation: SEAS did not improve its primary composite or valve outcomes, despite a separate reduction in ischemic events.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: HMG-CoA Reductase Inhibitor
      term:
        id: NCIT:C1655
        label: HMG-CoA Reductase Inhibitor
- name: Post-replacement surveillance and rehabilitation
  description: Obtain a baseline echocardiogram within the first weeks after replacement and continue annual clinical/echocardiographic review of bioprostheses, with earlier evaluation for symptoms or suspected dysfunction. Rehabilitation may improve functional recovery. Mechanical prostheses require lifelong anticoagulation; the antithrombotic regimen for other prostheses depends on valve type and concurrent indications.
  evidence:
  - reference: url:https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf
    reference_title: https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: After valve intervention, an early echocardiographic examination within the first weeks after valve replacement is recommended to document base- line prosthetic valve function.
    explanation: Post-intervention baseline assessment.
  - reference: url:https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf
    reference_title: https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: Cardiological evaluations and echocardio- graphic examinations are recommended annually in patients with a bioprosthesis, and whenever changes in clinical symptoms or signs sug- gestive of valve dysfunction are noted.
    explanation: Longitudinal prosthesis surveillance.
- name: Palliative care when intervention offers insufficient benefit
  description: For advanced valve disease unsuitable for surgical or transcatheter treatment, coordinate symptom-directed heart-failure treatment and multidisciplinary palliative care with the patient and family. The decision is based on expected benefit and goals, rather than age alone.
  evidence:
  - reference: url:https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf
    reference_title: https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: In some patients with advanced VHD not qualifying for surgical or transcatheter therapies, medical HF treatment remains the only, and sometimes best, available option.
    explanation: Guideline care for advanced disease without a feasible beneficial valve intervention.
- name: Secondary rheumatic-fever prevention
  description: Patients with established rheumatic heart disease may require long-term penicillin prophylaxis to prevent recurrent rheumatic fever. This is specific to the rheumatic subtype and does not treat calcific stenosis or mechanically reopen fused commissures.
  evidence:
  - reference: url:https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf
    reference_title: https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: In patients with established RHD, secondary long-term prophylaxis with benzathine benzyl penicillin 1.2 million international units (IU) every 3–4 weeks over 10 years is recom- mended to prevent recurrent episodes, especially in children and ado- lescents.
    explanation: Etiology-specific recurrent-rheumatic-fever prevention.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: Penicillin G Benzathine
      term:
        id: NCIT:C47657
        label: Penicillin G Benzathine
clinical_trials:
- name: NCT03042104
  phase: NOT_APPLICABLE
  status: ACTIVE_NOT_RECRUITING
  description: EARLY TAVR randomized 901 selected adults aged ≥65 years with transfemoral-compatible asymptomatic severe stenosis to early balloon-expandable TAVR or surveillance. The primary death/stroke/unplanned cardiovascular hospitalization composite was lower (122/455 versus 202/446; HR 0.50), without an established individual mortality or stroke benefit. The hospitalization definition included early surveillance-arm conversion within six months; 87% eventually underwent replacement. The open-label trial had unblinded event adjudication and predominantly White participants; longer follow-up continues.
  notes: Status and phase checked on 2026-09-21. Published analysis size is distinguished from registry planned enrollment and subsequent extension.
  evidence:
  - reference: clinicaltrials:NCT03042104
    reference_title: Evaluation of Transcatheter Aortic Valve Replacement Compared to Surveillance for Patients With Asymptomatic Severe Aortic Stenosis
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: PRIMARY_RESULT
    snippet: This study will evaluate the safety and effectiveness of the Edwards SAPIEN 3/SAPIEN 3 Ultra Transcatheter Heart Valve (THV) compared with clinical surveillance (CS) in asymptomatic patients with severe, calcific aortic stenosis.
    explanation: Registry study identity/design; status and phase independently checked through the live ClinicalTrials.gov API on 2026-09-21.
  - reference: PMID:39466903
    reference_title: Transcatheter Aortic-Valve Replacement for Asymptomatic Severe Aortic Stenosis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: A primary end-point event occurred in 122 patients (26.8%) in the TAVR group and in 202 patients (45.3%) in the clinical surveillance group
    explanation: Published study finding; see description for selected population, endpoint and uncertainty.
- name: NCT03094143
  phase: NOT_APPLICABLE
  status: ACTIVE_NOT_RECRUITING
  description: EVOLVED analyzed 224 fibrosis-enriched asymptomatic severe-AS patients of 356 planned. Early intervention versus guideline-directed care did not significantly reduce the primary death/AS-hospitalization composite (20/113 versus 25/111; HR 0.79, 95% CI 0.44–1.43). Median intervention timing was 5 versus 20.2 months. Hospitalization and symptom secondary findings were unadjusted for multiplicity and remain hypothesis-generating; the trial does not establish equivalence or a fibrosis-selection threshold. The registry remains active for longer follow-up.
  notes: Status and phase checked on 2026-09-21. Published analysis size is distinguished from registry planned enrollment and subsequent extension.
  evidence:
  - reference: clinicaltrials:NCT03094143
    reference_title: Early Valve Replacement Guided by Biomarkers of Left Ventricular Decompensation in Asymptomatic Patients With Severe Aortic Stenosis
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: PRIMARY_RESULT
    snippet: Aortic stenosis is the most common valvular disease in the Western world.
    explanation: Registry study identity/design; status and phase independently checked through the live ClinicalTrials.gov API on 2026-09-21.
  - reference: PMID:39466640
    reference_title: 'Early Intervention in Patients With Asymptomatic Severe Aortic Stenosis and Myocardial Fibrosis: The EVOLVED Randomized Clinical Trial.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: The findings that early intervention was associated with a lower incidence of unplanned aortic stenosis–related hospitalization and improved symptom burden should be considered hypothesis-generating given that the study did not meet the primary end point and was not adjusted for multiple comparisons.
    explanation: Published study finding; see description for selected population, endpoint and uncertainty.
  - reference: PMID:39466640
    reference_title: 'Early Intervention in Patients With Asymptomatic Severe Aortic Stenosis and Myocardial Fibrosis: The EVOLVED Randomized Clinical Trial.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: The primary end point occurred in 20 of 113 patients (18%) in the early intervention group and 25 of 111 patients (23%) in the guideline-directed conservative management group (hazard ratio, 0.79 [95% CI, 0.44-1.43]; P = .44; between-group difference, -4.82% [95% CI, -15.31% to 5.66%]).
    explanation: The primary comparison was nonsignificant with a wide confidence interval, not proof of equivalence.
- name: NCT01161732
  phase: NOT_APPLICABLE
  status: COMPLETED
  description: RECOVERY randomized 145 selected relatively young, low-risk patients with very severe stenosis, predominantly bicuspid valves, to early surgery or conservative care. At extended follow-up (overall median 12 years), operative/CV deaths were 2/73 versus 17/72; ten-year cumulative incidence was 1% versus 19%. Results support early surgery in this selected population, not all older severe-AS patients or transcatheter devices. Exercise testing was not routine, and few primary events limit precision.
  notes: Status and phase checked on 2026-09-21. Published analysis size is distinguished from registry planned enrollment and subsequent extension.
  evidence:
  - reference: clinicaltrials:NCT01161732
    reference_title: Randomized Comparison of Early Surgery Versus Conventional Treatment in Very Severe Aortic Stenosis
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: PRIMARY_RESULT
    snippet: The optimal timing of surgical intervention remains controversial in asymptomatic patients with very severe aortic stenosis.
    explanation: Registry study identity/design; status and phase independently checked through the live ClinicalTrials.gov API on 2026-09-21.
  - reference: PMID:41880613
    reference_title: Early Surgery or Conservative Care for Asymptomatic Aortic Stenosis at 10 Years.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: A total of 145 patients underwent randomization.
    explanation: Published study finding; see description for selected population, endpoint and uncertainty.
- name: NCT02436655
  phase: NOT_APPLICABLE
  status: COMPLETED
  description: AVATAR randomized 157 low-risk patients with severe stenosis, preserved ejection fraction and a negative exercise test. At median 63 months, the death/MI/stroke/HF-hospitalization composite was 18/78 versus 37/79 with early surgery versus surveillance (HR 0.42). Secondary mortality and HF findings were exploratory without multiplicity adjustment. CV death and sudden death were not statistically clearly reduced. Open-label adjudication, small size and COVID-era follow-up constrain generalization.
  notes: Status and phase checked on 2026-09-21. Published analysis size is distinguished from registry planned enrollment and subsequent extension.
  evidence:
  - reference: clinicaltrials:NCT02436655
    reference_title: 'Aortic Valve Replacement Versus Conservative Treatment in Asymptomatic Severe Aortic Stenosis: (AVATAR Trial): A Multicentre Randomized Controlled Trial'
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: PRIMARY_RESULT
    snippet: Whether to intervene in asymptomatic patients with severe aortic stenosis and normal left ventricular ejection fraction remains controversial.
    explanation: Registry study identity/design; status and phase independently checked through the live ClinicalTrials.gov API on 2026-09-21.
  - reference: PMID:39217448
    reference_title: 'Aortic valve replacement vs. conservative treatment in asymptomatic severe aortic stenosis: long-term follow-up of the AVATAR trial.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: All patients had negative exercise stress testing.
    explanation: Published study finding; see description for selected population, endpoint and uncertainty.
- name: NCT02132026
  phase: PHASE_II
  status: COMPLETED
  description: SALTIRE2 randomized 152 and analyzed 150 treated patients; 136 contributed the primary calculated 24-month CT calcium-change endpoint. Denosumab and alendronic acid lowered bone-turnover markers but did not significantly reduce CT calcification, Doppler progression or 18F-NaF uptake versus pooled placebo. The single-centre mostly White, male cohort was largely mild/moderate disease; it was powered for a 40% progression effect, not clinical events or smaller benefits. These drugs are not established AS-modifying therapies.
  notes: Status and phase checked on 2026-09-21. Published analysis size is distinguished from registry planned enrollment and subsequent extension.
  evidence:
  - reference: clinicaltrials:NCT02132026
    reference_title: 'SALTIRE II: Bisphosphonates and RANKL Inhibition in Aortic Stenosis'
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: PRIMARY_RESULT
    snippet: Aortic stenosis is a condition whereby one of the heart valves (aortic valve) becomes narrowed, due to calcium deposition, over time.
    explanation: Registry study identity/design; status and phase independently checked through the live ClinicalTrials.gov API on 2026-09-21.
  - reference: PMID:33913339
    reference_title: 'Effect of Denosumab or Alendronic Acid on the Progression of Aortic Stenosis: A Double-Blind Randomized Controlled Trial.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: There were no differences in 24-month change in aortic valve calcium score between denosumab and placebo
    explanation: Published study finding; see description for selected population, endpoint and uncertainty.
- name: NCT05646381
  phase: PHASE_II
  status: RECRUITING
  description: Lp(a)FRONTIERS CAVS tests monthly pelacarsen versus placebo for progression of calcific stenosis. This ongoing trial addresses whether selective Lp(a) lowering modifies valve disease; its design is not evidence of clinical efficacy.
  notes: Status and phase checked on 2026-09-21. Published analysis size is distinguished from registry planned enrollment and subsequent extension.
  evidence:
  - reference: clinicaltrials:NCT05646381
    reference_title: A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis [Lp(a)FRONTIERS CAVS]
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: PRIMARY_RESULT
    snippet: The purpose of this study is to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) administered subcutaneously once monthly compared to placebo in slowing the progression of calcific aortic valve stenosis.
    explanation: Registry study identity/design; status and phase independently checked through the live ClinicalTrials.gov API on 2026-09-21.
prevalence:
- population: GBD world-standardized population, non-rheumatic calcific aortic valve disease, 2021
  measure_type: POINT_PREVALENCE
  rate_per_100000: 158.35
  rate_low: 135.92
  rate_high: 181.0
  notes: Age-standardized model estimate with 95% uncertainty interval, not a crude population proportion or screened cohort. Estimated prevalent count 13,320,896 (UI 11,422,539–15,249,411). The GBD disease category is not all congenital/rheumatic aortic stenosis; the article uses a broad I35–I35.9 code range. The magnitude band describes this age-standardized rate, not a crude population case fraction.
  evidence:
  - reference: PMID:42129826
    reference_title: 'Global, regional, and national burden of non-rheumatic calcific aortic valve disease from 1990 to 2021, with projections of incidence to 2050: a systematic analysis of the global burden of disease study 2021 and Mendelian randomization analysis.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: In 2021, the worldwide prevalence of NRCAVD was 13,320,896 (95% UI 11,422,539–15,249,411) cases, with an ASPR of 158.35 (95% UI 135.92–181.00) cases per 100,000 population.
    explanation: Modelled GBD2021 disease burden, age-standardized to the GBD reference population.
  prevalence_class: ABOVE_1_IN_1000
epidemiology:
- name: Etiologic and age-related heterogeneity
  description: Calcific disease becomes more common with age; congenital anatomy can produce earlier stenosis, and the contribution of rheumatic disease varies geographically. These groups should not share an assumed single prevalence or mechanism.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/
    reference_title: Aortic Stenosis - StatPearls - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: The causes of aortic stenosis vary geographically as calcific stenosis is more common in North America and Europe, while rheumatic valve disease is more common in developing countries.
    explanation: Broad clinical epidemiologic synthesis; no precise regional rate inferred.
progression:
- phase: Variable asymptomatic progression
  notes: Symptoms, valve hemodynamics and ventricular consequences can evolve at different rates. The historical 128-person cohort used death or symptom-triggered valve replacement as a composite event; its event-free survival is not a mortality estimate. New randomized evidence informs individualized earlier intervention, rather than a fixed universal asymptomatic duration.
  evidence:
  - reference: PMID:10965007
    reference_title: Predictors of outcome in severe, asymptomatic aortic stenosis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: The rate of progression of stenosis, as reflected by the aortic-jet velocity, was significantly higher in patients who had cardiac events
    explanation: Historical prospective cohort association; event definition included intervention.
animal_models:
- name: Combined metabolic-diet LA mouse
  species: Mouse
  genotype: Ldlr-null; Apob100/100
  publication: PMID:29539583
  description: A diabetogenic and procalcific diet increased valve jet velocities and lesion burden compared with normal chow in a hyperlipidemic male-mouse background. This model addresses a selected metabolic context of calcific valve disease.
  notes: The combined diet changes glycemia, lipids, minerals and body weight; it does not isolate glucose as the in-vivo cause. Fibrosis occurred with both diets. Whole-group ejection fraction and fractional shortening differences were nonsignificant; a post hoc stenosis subgroup showed larger functional differences. No neoangiogenesis, large calcified nodules or bone metaplasia was observed.
  evidence:
  - &id019
    reference: PMID:29539583
    reference_title: Increased Calcific Aortic Valve Disease in response to a diabetogenic, procalcific diet in the LDLr(-/-)ApoB(100/100) mouse model.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: PRIMARY_RESULT
    snippet: At 14 months of age, LDLr−/−ApoB100/100 mice DB fed showed a significantly greater proportion of AS than NC fed mice, as indicated by aortic jet velocities greater than 1600 mm/s (10/13=77% versus 5/13=38%, respectively, p=.048)
    explanation: Thirteen male mice per diet group; this threshold and selected model are not human severity criteria.
  modeled_mechanisms:
  - target: Reduced Aortic Valve Opening
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    model_scale: TISSUE
    description: Higher transvalvular jet velocity provides a functional stenosis readout.
    limitations: The combined diet changes glycemia, lipids, minerals and body weight; it does not isolate glucose as the in-vivo cause. Fibrosis occurred with both diets. Whole-group ejection fraction and fractional shortening differences were nonsignificant; a post hoc stenosis subgroup showed larger functional differences. No neoangiogenesis, large calcified nodules or bone metaplasia was observed.
    evidence:
    - *id019
    readouts:
    - name: Aortic jet velocity
      target: Reduced Aortic Valve Opening
      direction: INCREASED
      interpretation: Higher transvalvular jet velocity provides a functional stenosis readout.
      evidence:
      - reference: PMID:29539583
        reference_title: Increased Calcific Aortic Valve Disease in response to a diabetogenic, procalcific diet in the LDLr(-/-)ApoB(100/100) mouse model.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        quote_role: PRIMARY_RESULT
        snippet: At 14 months of age, LDLr−/−ApoB100/100 mice DB fed showed a significantly greater proportion of AS than NC fed mice, as indicated by aortic jet velocities greater than 1600 mm/s (10/13=77% versus 5/13=38%, respectively, p=.048)
        explanation: Thirteen male mice per diet group; this threshold and selected model are not human severity criteria.
- name: Osteoprotegerin-treated Western-diet LA mouse
  species: Mouse
  genotype: Ldlr-null; Apob100/100
  publication: PMID:23762316
  description: Exogenous osteoprotegerin reduced valve calcification and osteogenic markers in Western-diet LA mice; older mice also had partial preservation of cusp separation. These findings inform experimental intervention, not established clinical treatment.
  notes: Treatment began before overt disease; young mice were treated from 2 to 8 months and older mice from 6 to 12 months, with 12 planned per group and assay-specific subsets. Lipid deposition, fibrosis and superoxide were not reduced. Young-mouse function showed only a nonsignificant trend. Parallel improvements in calcification and function do not establish that one mediates the other.
  evidence:
  - &id020
    reference: PMID:23762316
    reference_title: Osteoprotegerin inhibits aortic valve calcification and preserves valve function in hypercholesterolemic mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: PRIMARY_RESULT
    snippet: OPG attenuated calcification of valve tissue in Young mice and in Older mice by about 70% (Figure 4).
    explanation: Partial reduction in selected Western-diet LA mice, not a human treatment effect.
  - &id021
    reference: PMID:23762316
    reference_title: Osteoprotegerin inhibits aortic valve calcification and preserves valve function in hypercholesterolemic mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: PRIMARY_RESULT
    snippet: Following 6 months of treatment with OPG or vehicle, aortic cusp separation decreased in both Veh-LA mice and OPG-LA mice. However, the decrease in aortic valve function was significantly attenuated in OPG-LA mice, compared to Veh-LA mice
    explanation: The older treatment group had partial preservation rather than reversal of valve dysfunction.
  modeled_mechanisms:
  - target: Aortic Leaflet Calcification
    relationship: PERTURBS
    fidelity: MODERATE
    model_scale: TISSUE
    description: OPG reduced valve calcium deposition.
    limitations: Treatment began before overt disease; young mice were treated from 2 to 8 months and older mice from 6 to 12 months, with 12 planned per group and assay-specific subsets. Lipid deposition, fibrosis and superoxide were not reduced. Young-mouse function showed only a nonsignificant trend. Parallel improvements in calcification and function do not establish that one mediates the other.
    evidence:
    - *id020
    readouts:
    - name: Valve calcium deposition
      target: Aortic Leaflet Calcification
      direction: DECREASED
      interpretation: OPG reduced valve calcium deposition.
      evidence:
      - reference: PMID:23762316
        reference_title: Osteoprotegerin inhibits aortic valve calcification and preserves valve function in hypercholesterolemic mice.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        quote_role: PRIMARY_RESULT
        snippet: OPG attenuated calcification of valve tissue in Young mice and in Older mice by about 70% (Figure 4).
        explanation: Partial reduction in selected Western-diet LA mice, not a human treatment effect.
  - target: Reduced Aortic Valve Opening
    relationship: PERTURBS
    fidelity: MODERATE
    model_scale: TISSUE
    description: Cusp separation declined less under OPG in the older cohort.
    limitations: Treatment began before overt disease; young mice were treated from 2 to 8 months and older mice from 6 to 12 months, with 12 planned per group and assay-specific subsets. Lipid deposition, fibrosis and superoxide were not reduced. Young-mouse function showed only a nonsignificant trend. Parallel improvements in calcification and function do not establish that one mediates the other.
    evidence:
    - *id021
    readouts:
    - name: Preservation of systolic cusp separation
      target: Reduced Aortic Valve Opening
      direction: INCREASED
      interpretation: Cusp separation declined less under OPG in the older cohort.
      evidence:
      - reference: PMID:23762316
        reference_title: Osteoprotegerin inhibits aortic valve calcification and preserves valve function in hypercholesterolemic mice.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        quote_role: PRIMARY_RESULT
        snippet: Following 6 months of treatment with OPG or vehicle, aortic cusp separation decreased in both Veh-LA mice and OPG-LA mice. However, the decrease in aortic valve function was significantly attenuated in OPG-LA mice, compared to Veh-LA mice
        explanation: The older treatment group had partial preservation rather than reversal of valve dysfunction.
- name: Notch1-haploinsufficient mouse with Htr2b perturbation
  species: Mouse
  genotype: Notch1+/− with Htr2b+/+, Htr2b+/− or Htr2b−/−; separate antagonist arm
  publication: PMID:33237915
  description: Complete Htr2b deletion improved valve hemodynamics on the Notch1-haploinsufficient high-cholesterol background. A separate antagonist regimen did not reproduce the improvement. The tissue mechanism remains unresolved.
  notes: Notch1-haploinsufficient mice received a 1% cholesterol diet from 2.5 to 6 months. The separate drug arm used SB204741 1 mg/kg/day from 4 to 6 months. Heterozygous Htr2b loss produced only nonsignificant improvement. Collagen density, leaflet thickness, alpha-SMA and Runx2 did not significantly change, and calcification was limited. Neither an antifibrotic nor an anticalcific mediator was established; left ventricular mass and ejection fraction were unchanged.
  evidence:
  - &id022
    reference: PMID:33237915
    reference_title: Genetic ablation of serotonin receptor 2B improves aortic valve hemodynamics of Notch1 heterozygous mice in a high-cholesterol diet model.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: PRIMARY_RESULT
    snippet: Ablation of Htr2b from Notch1+/- mice decreases the average peak velocity during the cardiac cycle with a corresponding decrease in mean pressure gradient across the AV, relative to Notch1+/-;Htr2b+/+
    explanation: Significant hemodynamic differences occurred with complete Htr2b deletion on the Notch1-haploinsufficient background.
  - &id023
    reference: PMID:33237915
    reference_title: Genetic ablation of serotonin receptor 2B improves aortic valve hemodynamics of Notch1 heterozygous mice in a high-cholesterol diet model.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: PRIMARY_RESULT
    snippet: 5-HT2B receptor antagonism, however, did not affect hemodynamic progression.
    explanation: The tested SB204741 regimen was negative; lifelong gene deletion and pharmacologic treatment are not equivalent.
  modeled_mechanisms:
  - target: Reduced Aortic Valve Opening
    relationship: PERTURBS
    fidelity: MODERATE
    model_scale: TISSUE
    description: Complete genetic deletion reduced jet velocity and pressure gradient, without establishing a specific leaflet-cell mediator.
    limitations: Notch1-haploinsufficient mice received a 1% cholesterol diet from 2.5 to 6 months. The separate drug arm used SB204741 1 mg/kg/day from 4 to 6 months. Heterozygous Htr2b loss produced only nonsignificant improvement. Collagen density, leaflet thickness, alpha-SMA and Runx2 did not significantly change, and calcification was limited. Neither an antifibrotic nor an anticalcific mediator was established; left ventricular mass and ejection fraction were unchanged.
    evidence:
    - *id022
    - *id023
    readouts:
    - name: Aortic jet velocity with complete Htr2b deletion
      target: Reduced Aortic Valve Opening
      direction: DECREASED
      interpretation: Complete genetic deletion reduced jet velocity and pressure gradient, without establishing a specific leaflet-cell mediator.
      evidence:
      - reference: PMID:33237915
        reference_title: Genetic ablation of serotonin receptor 2B improves aortic valve hemodynamics of Notch1 heterozygous mice in a high-cholesterol diet model.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        quote_role: PRIMARY_RESULT
        snippet: Ablation of Htr2b from Notch1+/- mice decreases the average peak velocity during the cardiac cycle with a corresponding decrease in mean pressure gradient across the AV, relative to Notch1+/-;Htr2b+/+
        explanation: Significant hemodynamic differences occurred with complete Htr2b deletion on the Notch1-haploinsufficient background.
      - reference: PMID:33237915
        reference_title: Genetic ablation of serotonin receptor 2B improves aortic valve hemodynamics of Notch1 heterozygous mice in a high-cholesterol diet model.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        quote_role: PRIMARY_RESULT
        snippet: 5-HT2B receptor antagonism, however, did not affect hemodynamic progression.
        explanation: The tested SB204741 regimen was negative; lifelong gene deletion and pharmacologic treatment are not equivalent.
experimental_models:
- name: Baboon valve-interstitial-cell mineralization culture
  experimental_model_type: PRIMARY_CELL_CULTURE
  cell_source: Primary baboon aortic valve interstitial cells
  cell_types:
  - preferred_term: valve interstitial cell
    term:
      id: CL:4030032
      label: valve interstitial cell
  publication: PMID:29539583
  description: Cultured cells were challenged with 25 versus 5.6 mM glucose in normal or high-phosphate calcification medium. Elevated glucose enhanced mineral deposition only in calcification medium.
  notes: Baboon primary-cell culture is not a human clinical model. The calcium assay used high-phosphate medium (2.6 mM versus 1.0 mM in normal medium) and does not identify an indispensable intracellular pathway. No osmotic-control result is reported in the available Methods.
  evidence:
  - &id024
    reference: PMID:29539583
    reference_title: Increased Calcific Aortic Valve Disease in response to a diabetogenic, procalcific diet in the LDLr(-/-)ApoB(100/100) mouse model.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    snippet: Addition of 25 mM glucose (hyperglycemic level) to the calcification medium enhanced VIC mineralization by ~2 folds compared to 5.6 mM glucose cultures.
    explanation: Glucose enhanced mineralization in high-phosphate medium; the culture used baboon valve interstitial cells.
  - &id025
    reference: PMID:29539583
    reference_title: Increased Calcific Aortic Valve Disease in response to a diabetogenic, procalcific diet in the LDLr(-/-)ApoB(100/100) mouse model.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    snippet: No effect of glucose was found in VIC grown in normal media.
    explanation: Glucose alone was not sufficient under the normal-medium conditions.
  modeled_mechanisms:
  - target: Aortic Leaflet Calcification
    relationship: PERTURBS
    fidelity: MODERATE
    model_scale: CELLULAR
    description: Glucose enhanced cellular-matrix mineral deposition under elevated phosphate.
    limitations: Baboon primary-cell culture is not a human clinical model. The calcium assay used high-phosphate medium (2.6 mM versus 1.0 mM in normal medium) and does not identify an indispensable intracellular pathway. No osmotic-control result is reported in the available Methods.
    evidence:
    - *id024
    - *id025
    readouts:
    - name: Culture calcium content in high-phosphate medium
      target: Aortic Leaflet Calcification
      direction: INCREASED
      interpretation: Glucose enhanced cellular-matrix mineral deposition under elevated phosphate.
      evidence:
      - reference: PMID:29539583
        reference_title: Increased Calcific Aortic Valve Disease in response to a diabetogenic, procalcific diet in the LDLr(-/-)ApoB(100/100) mouse model.
        supports: SUPPORT
        evidence_source: IN_VITRO
        quote_role: PRIMARY_RESULT
        snippet: Addition of 25 mM glucose (hyperglycemic level) to the calcification medium enhanced VIC mineralization by ~2 folds compared to 5.6 mM glucose cultures.
        explanation: Glucose enhanced mineralization in high-phosphate medium; the culture used baboon valve interstitial cells.
      - reference: PMID:29539583
        reference_title: Increased Calcific Aortic Valve Disease in response to a diabetogenic, procalcific diet in the LDLr(-/-)ApoB(100/100) mouse model.
        supports: SUPPORT
        evidence_source: IN_VITRO
        quote_role: PRIMARY_RESULT
        snippet: No effect of glucose was found in VIC grown in normal media.
        explanation: Glucose alone was not sufficient under the normal-medium conditions.
discussions:
- discussion_id: as_calcification_function_mediation
  prompt: Which processes mediate valve dysfunction in experimental anti-calcification interventions?
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  attaches_to:
  - pathophysiology#Aortic Leaflet Calcification
  - animal_models#Osteoprotegerin-treated Western-diet LA mouse
  - animal_models#Notch1-haploinsufficient mouse with Htr2b perturbation
  rationale: OPG reduces calcification and partly preserves older-mouse valve function without reducing fibrosis, lipids or superoxide. This coresponse does not isolate calcification as the mediator. Htr2b deletion improves hemodynamics without significant measured fibrosis or osteogenic-marker changes, while its tested antagonist regimen is negative. Cell-specific and temporally controlled perturbations with mechanical and tissue readouts are needed before assigning one necessary pathway.
  evidence:
  - reference: PMID:23762316
    reference_title: Osteoprotegerin inhibits aortic valve calcification and preserves valve function in hypercholesterolemic mice.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: PRIMARY_RESULT
    snippet: Thus, the association between attenuation of valve calcification and protection of aortic valve function by OPG may not necessarily indicate mechanistic linkage between the two findings.
    explanation: The authors explicitly distinguish associated intervention responses from demonstrated mediation.
  - *id023
- discussion_id: as_medical_modification
  prompt: Why have mechanistically motivated medical therapies not yet modified established valve disease in trials?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Valvular Lipid Accumulation
  - pathophysiology#Valvular Osteogenic Program
  - clinical_trials#NCT02132026
  rationale: Null statin-based trials in established stenosis do not prove that lipids are irrelevant to initiation or that osteogenic commitment makes the lesion autonomous. SALTIRE2 did not show imaging benefit from denosumab or alendronic acid in its mostly mild/moderate cohort despite lower bone-turnover markers. Its interventions, species context and disease timing differ from the OPG mouse experiment. Selective Lp(a) lowering remains under prospective evaluation; genetic evidence alone does not establish efficacy.
  evidence:
  - reference: PMID:15944423
    reference_title: A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: Intensive lipid-lowering therapy does not halt the progression of calcific aortic stenosis or induce its regression.
    explanation: Null tested regimen in established disease, not a test of every lipid mechanism.
  - reference: PMID:33913339
    reference_title: 'Effect of Denosumab or Alendronic Acid on the Progression of Aortic Stenosis: A Double-Blind Randomized Controlled Trial.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: There were no differences in 24-month change in aortic valve calcium score between denosumab and placebo
    explanation: The randomized imaging comparison was negative within the tested population and detectable effect size.
  - *id002
- discussion_id: as_fibrosis_treatment_selection
  prompt: Does fibrosis burden identify patients who derive greater benefit from early intervention?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Diffuse Myocardial Fibrosis
  - pathophysiology#Replacement Myocardial Fibrosis
  - clinical_trials#NCT03094143
  rationale: 'The 2017 baseline CMR study associates extracellular expansion and LGE with clinical status but lacks enough deaths for multivariable mortality analysis and does not establish serial fibrosis transitions. EVOLVED did not significantly improve its primary outcome. The subsequent fibrosis-burden analysis is available here only as an abstract/repository duplicate: greater burden was associated with composite events and hospitalization, but no randomization-arm interaction was demonstrated. Prognostic association therefore does not establish a treatment-selection threshold or irreversible injury.'
  evidence:
  - reference: PMID:28017384
    reference_title: Myocardial Fibrosis and Cardiac Decompensation in Aortic Stenosis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: There were insufficient deaths to perform multivariate analysis.
    explanation: Limits the original mortality comparison.
  - reference: PMID:41984459
    reference_title: 'Myocardial Fibrosis and Early Intervention in Asymptomatic Patients With Severe Aortic Stenosis: Insights From the EVOLVED Randomized Clinical Trial.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: There were no interactions between randomization arm and the midwall fibrosis burden for the primary (P for interaction = .39) or secondary end points.
    explanation: The post hoc abstract does not demonstrate differential treatment benefit by fibrosis burden.
  - reference: PMID:39466640
    reference_title: 'Early Intervention in Patients With Asymptomatic Severe Aortic Stenosis and Myocardial Fibrosis: The EVOLVED Randomized Clinical Trial.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: The primary end point occurred in 20 of 113 patients (18%) in the early intervention group and 25 of 111 patients (23%) in the guideline-directed conservative management group (hazard ratio, 0.79 [95% CI, 0.44-1.43]; P = .44; between-group difference, -4.82% [95% CI, -15.31% to 5.66%]).
    explanation: The primary comparison was nonsignificant with a wide confidence interval, not proof of equivalence.
- discussion_id: as_gwas_candidates
  prompt: Which statistically nominated susceptibility genes are causal in valve cells?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - genetic#TWIST1
  - genetic#PALMD
  - genetic#NAV1
  rationale: European-ancestry GWAS, valve eQTL, colocalization and Mendelian randomization prioritize expression candidates, but selected surgical bulk tissue and instrumental-variable assumptions limit mechanistic inference. TWIST1 genotype-stratified RNA sequencing compared already severe-stenosis cases, rather than perturbing TWIST1 or measuring endothelial-to-mesenchymal conversion. Candidate genes require cell-specific functional validation; neither genetic overlap nor pathway enrichment proves a causal comorbidity.
  evidence:
  - reference: PMID:38494474
    reference_title: Integrative genomic analyses identify candidate causal genes for calcific aortic valve stenosis involving tissue-specific regulation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: After removing genes with a low probability for colocalization of the GWAS and eQTL signals (PP4 < 0.75, n = 20), with no MR instrument (n = 3) or with high heterogeneity of the instrument (n = 2), ten genes remained (PALMD, NAV1, PRRX1, ATP13A3, BCL10, TWIST1, RAD9A, NRBP1, FES and AFAP1).
    explanation: Statistical prioritization of ten expression candidates; no corresponding gene-rescue experiment is reported.
    directness: INDIRECT
biochemical:
- name: BNP and NT-proBNP
  notes: Natriuretic peptides can inform cardiac-stress and symptom assessment. Markedly elevated repeated values relative to age- and sex-adjusted normal ranges are one guideline risk feature; renal function, rhythm and other cardiac disease affect interpretation. They do not independently define valve severity.
  evidence:
  - reference: url:https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf
    reference_title: https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: Natriuretic peptides can be used to arbitrate the sources of symp- toms in patients with multiple potential causes and help to identify those with high-risk asymptomatic AS who may benefit from early intervention.
    explanation: Guideline synthesis supports adjunctive risk assessment, not a stand-alone diagnosis or a universally causal biomarker.
- name: von Willebrand factor multimer and collagen-binding abnormalities
  notes: Loss of large multimers and impaired collagen binding/high-shear platelet function occurred in a selected consecutive severe-AS cohort. The 67–92% range refers to different laboratory abnormalities, not the prevalence of gastrointestinal bleeding. Correction after replacement and recurrence with mismatch support a shear-related acquired syndrome.
  evidence:
  - *id016
- name: Lipoprotein(a)
  notes: A heritable exposure associated with valve calcium and clinical stenosis, rather than a stand-alone diagnostic marker. Genetic-instrument evidence does not establish a universal threshold, direct cellular mediator or treatment-response biomarker.
  evidence:
  - *id026
  - *id002
mechanistic_hypotheses:
- hypothesis_group_id: calcific_inflammatory_osteogenic_model
  hypothesis_label: Inflammatory and osteogenic contribution to calcific valve disease
  status: EMERGING
  description: Surface lesions, lipid accumulation, inflammatory cells and osteogenic markers support a proposed interacting disease process. Human cross-sectional histology does not establish a required temporal order, a single indispensable cytokine or a self-sustaining lipid-independent commitment switch.
  evidence:
  - reference: PMID:7519131
    reference_title: Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: disruption of the basement membrane overlying the lesion.
    explanation: Cross-sectional autopsy histology documents a surface lesion; it does not establish the temporal initiating injury.
    directness: INDIRECT
  - reference: PMID:7519131
    reference_title: Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: early lesions were characterized by the presence of an inflammatory infiltrate composed of non-foam cell and foam cell macrophages, occasional T cells, and rare alpha-actin-positive cells.
    explanation: Macrophages were also scattered in normal valves; the lesion-associated infiltrate is a quantitative and contextual change.
    directness: INDIRECT
  - *id003
- hypothesis_group_id: notch_runx2_restraint
  hypothesis_label: Reduced NOTCH-dependent RUNX2 restraint
  status: EMERGING
  description: Rare familial NOTCH1 disease and experimental Hrt–RUNX2 repression support a molecular route to calcification. Loss of this restraint in patient valve cells is inferred; penetrance and the complete developmental sequence remain unresolved.
  evidence:
  - *id027
  - *id001
- hypothesis_group_id: lipoprotein_a_specific_pathway
  hypothesis_label: Lipoprotein(a)-related valve disease susceptibility
  status: EMERGING
  description: Genetic associations and Mendelian randomization support a causal contribution under instrument assumptions. The biochemical route and benefit from selective lowering remain under investigation. Failure of statin-based regimens does not directly test selective Lp(a) lowering.
  evidence:
  - *id026
  - *id002
references:
- reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/
  title: Aortic Stenosis - StatPearls - NCBI Bookshelf
  tags:
  - StatPearls
- reference: PMID:16025100
  title: Mutations in NOTCH1 cause aortic valve disease.
- reference: PMID:23388002
  title: Genetic associations with valvular calcification and aortic stenosis.
- reference: PMID:35288444
  title: Contribution of NOTCH1 genetic variants to bicuspid aortic valve and other congenital lesions.
- reference: PMID:38494474
  title: Integrative genomic analyses identify candidate causal genes for calcific aortic valve stenosis involving tissue-specific regulation.
- reference: PMID:10965007
  title: Predictors of outcome in severe, asymptomatic aortic stenosis.
- reference: PMID:12719282
  title: Human aortic valve calcification is associated with an osteoblast phenotype.
- reference: PMID:28017384
  title: Myocardial Fibrosis and Cardiac Decompensation in Aortic Stenosis.
- reference: PMID:24104373
  title: 'Asymptomatic aortic stenosis in the elderly: a clinical review.'
- reference: PMID:12732812
  title: Pathophysiology of valvular aortic stenosis in the elderly.
- reference: PMID:7519131
  title: Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies.
- reference: PMID:12878741
  title: Acquired von Willebrand syndrome in aortic stenosis.
- reference: url:https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf
  title: https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf
- reference: PMID:42485012
  title: 'Treadmill Stress Test in Patients With Asymptomatic Severe Aortic Stenosis: A Prespecified Registry-Based Follow-Up of the EARLY TAVR Randomized Clinical Trial.'
- reference: PMID:39466640
  title: 'Early Intervention in Patients With Asymptomatic Severe Aortic Stenosis and Myocardial Fibrosis: The EVOLVED Randomized Clinical Trial.'
- reference: PMID:15944423
  title: A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis.
- reference: PMID:18765433
  title: Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.
- reference: clinicaltrials:NCT03042104
  title: Evaluation of Transcatheter Aortic Valve Replacement Compared to Surveillance for Patients With Asymptomatic Severe Aortic Stenosis
- reference: PMID:39466903
  title: Transcatheter Aortic-Valve Replacement for Asymptomatic Severe Aortic Stenosis.
- reference: clinicaltrials:NCT03094143
  title: Early Valve Replacement Guided by Biomarkers of Left Ventricular Decompensation in Asymptomatic Patients With Severe Aortic Stenosis
- reference: clinicaltrials:NCT01161732
  title: Randomized Comparison of Early Surgery Versus Conventional Treatment in Very Severe Aortic Stenosis
- reference: PMID:41880613
  title: Early Surgery or Conservative Care for Asymptomatic Aortic Stenosis at 10 Years.
- reference: clinicaltrials:NCT02436655
  title: 'Aortic Valve Replacement Versus Conservative Treatment in Asymptomatic Severe Aortic Stenosis: (AVATAR Trial): A Multicentre Randomized Controlled Trial'
- reference: PMID:39217448
  title: 'Aortic valve replacement vs. conservative treatment in asymptomatic severe aortic stenosis: long-term follow-up of the AVATAR trial.'
- reference: clinicaltrials:NCT02132026
  title: 'SALTIRE II: Bisphosphonates and RANKL Inhibition in Aortic Stenosis'
- reference: PMID:33913339
  title: 'Effect of Denosumab or Alendronic Acid on the Progression of Aortic Stenosis: A Double-Blind Randomized Controlled Trial.'
- reference: clinicaltrials:NCT05646381
  title: A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis [Lp(a)FRONTIERS CAVS]
- reference: PMID:42129826
  title: 'Global, regional, and national burden of non-rheumatic calcific aortic valve disease from 1990 to 2021, with projections of incidence to 2050: a systematic analysis of the global burden of disease study 2021 and Mendelian randomization analysis.'
- reference: PMID:29539583
  title: Increased Calcific Aortic Valve Disease in response to a diabetogenic, procalcific diet in the LDLr(-/-)ApoB(100/100) mouse model.
- reference: PMID:23762316
  title: Osteoprotegerin inhibits aortic valve calcification and preserves valve function in hypercholesterolemic mice.
- reference: PMID:33237915
  title: Genetic ablation of serotonin receptor 2B improves aortic valve hemodynamics of Notch1 heterozygous mice in a high-cholesterol diet model.
- reference: PMID:41984459
  title: 'Myocardial Fibrosis and Early Intervention in Asymptomatic Patients With Severe Aortic Stenosis: Insights From the EVOLVED Randomized Clinical Trial.'

📚

References & Deep Research

References

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK557628/

Aortic Stenosis - StatPearls - NCBI Bookshelf

No top-level findings curated for this source.

PMID:16025100

Mutations in NOTCH1 cause aortic valve disease.

No top-level findings curated for this source.

PMID:23388002

Genetic associations with valvular calcification and aortic stenosis.

No top-level findings curated for this source.

PMID:35288444

Contribution of NOTCH1 genetic variants to bicuspid aortic valve and other congenital lesions.

No top-level findings curated for this source.

PMID:38494474

Integrative genomic analyses identify candidate causal genes for calcific aortic valve stenosis involving tissue-specific regulation.

No top-level findings curated for this source.

PMID:10965007

Predictors of outcome in severe, asymptomatic aortic stenosis.

No top-level findings curated for this source.

PMID:12719282

Human aortic valve calcification is associated with an osteoblast phenotype.

No top-level findings curated for this source.

PMID:28017384

Myocardial Fibrosis and Cardiac Decompensation in Aortic Stenosis.

No top-level findings curated for this source.

PMID:24104373

Asymptomatic aortic stenosis in the elderly: a clinical review.

No top-level findings curated for this source.

PMID:12732812

Pathophysiology of valvular aortic stenosis in the elderly.

No top-level findings curated for this source.

PMID:7519131

Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies.

No top-level findings curated for this source.

PMID:12878741

Acquired von Willebrand syndrome in aortic stenosis.

No top-level findings curated for this source.

url:https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf

https://arrhythmiaclinic.org/wp-content/uploads/2025/08/2025-ESC-Guideline-Valvular-Heart-Disease.pdf

No top-level findings curated for this source.

PMID:42485012

Treadmill Stress Test in Patients With Asymptomatic Severe Aortic Stenosis: A Prespecified Registry-Based Follow-Up of the EARLY TAVR Randomized Clinical Trial.

No top-level findings curated for this source.

PMID:39466640

Early Intervention in Patients With Asymptomatic Severe Aortic Stenosis and Myocardial Fibrosis: The EVOLVED Randomized Clinical Trial.

No top-level findings curated for this source.

PMID:15944423

A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis.

No top-level findings curated for this source.

PMID:18765433

Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.

No top-level findings curated for this source.

clinicaltrials:NCT03042104

Evaluation of Transcatheter Aortic Valve Replacement Compared to Surveillance for Patients With Asymptomatic Severe Aortic Stenosis

No top-level findings curated for this source.

PMID:39466903

Transcatheter Aortic-Valve Replacement for Asymptomatic Severe Aortic Stenosis.

No top-level findings curated for this source.

clinicaltrials:NCT03094143

Early Valve Replacement Guided by Biomarkers of Left Ventricular Decompensation in Asymptomatic Patients With Severe Aortic Stenosis

No top-level findings curated for this source.

clinicaltrials:NCT01161732

Randomized Comparison of Early Surgery Versus Conventional Treatment in Very Severe Aortic Stenosis

No top-level findings curated for this source.

PMID:41880613

Early Surgery or Conservative Care for Asymptomatic Aortic Stenosis at 10 Years.

No top-level findings curated for this source.

clinicaltrials:NCT02436655

Aortic Valve Replacement Versus Conservative Treatment in Asymptomatic Severe Aortic Stenosis: (AVATAR Trial): A Multicentre Randomized Controlled Trial

No top-level findings curated for this source.

PMID:39217448

Aortic valve replacement vs. conservative treatment in asymptomatic severe aortic stenosis: long-term follow-up of the AVATAR trial.

No top-level findings curated for this source.

clinicaltrials:NCT02132026

SALTIRE II: Bisphosphonates and RANKL Inhibition in Aortic Stenosis

No top-level findings curated for this source.

PMID:33913339

Effect of Denosumab or Alendronic Acid on the Progression of Aortic Stenosis: A Double-Blind Randomized Controlled Trial.

No top-level findings curated for this source.

clinicaltrials:NCT05646381

A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis [Lp(a)FRONTIERS CAVS]

No top-level findings curated for this source.

PMID:42129826

Global, regional, and national burden of non-rheumatic calcific aortic valve disease from 1990 to 2021, with projections of incidence to 2050: a systematic analysis of the global burden of disease study 2021 and Mendelian randomization analysis.

No top-level findings curated for this source.

PMID:29539583

Increased Calcific Aortic Valve Disease in response to a diabetogenic, procalcific diet in the LDLr(-/-)ApoB(100/100) mouse model.

No top-level findings curated for this source.

PMID:23762316

Osteoprotegerin inhibits aortic valve calcification and preserves valve function in hypercholesterolemic mice.

No top-level findings curated for this source.

PMID:33237915

Genetic ablation of serotonin receptor 2B improves aortic valve hemodynamics of Notch1 heterozygous mice in a high-cholesterol diet model.

No top-level findings curated for this source.

PMID:41984459

Myocardial Fibrosis and Early Intervention in Asymptomatic Patients With Severe Aortic Stenosis: Insights From the EVOLVED Randomized Clinical Trial.

No top-level findings curated for this source.

Deep Research

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Claude Code ▸

Aortic Valve Stenosis: Comprehensive Disease Characteristics Research Report

claude-haiku-4-5-20251001, claude-sonnet-5 44 citations 2026-08-10T14:13:17.393740

Aortic Valve Stenosis: Comprehensive Disease Characteristics Research Report

1. Disease Information

Overview. Aortic valve stenosis (AS) is the narrowing of the aortic valve orifice that obstructs left ventricular outflow during systole. In adults in industrialized nations it is overwhelmingly an acquired, degenerative/calcific disease — often termed calcific aortic valve disease (CAVD) or calcific aortic valve stenosis (CAVS) — arising from an active, cell-mediated process of lipid deposition, chronic inflammation, fibrosis, and dystrophic calcification of the valve leaflets that is mechanistically distinct from, but shares risk factors with, atherosclerosis (PMID:31912380; PMID:32160774). It is the most common valvular heart disease in high-income countries and the most frequent indication for valve intervention in the elderly. Globally, however, rheumatic heart disease remains an important cause of aortic (and mitral) valve stenosis in low- and middle-income countries, and congenital bicuspid aortic valve (BAV) is the leading cause of AS presenting before age 65.

Key identifiers (verify exact codes at time of KB curation via OAK/authoritative sources before use): - ICD-10-CM: I35.0 (Nonrheumatic aortic (valve) stenosis); I06.0/I06.2 (Rheumatic aortic stenosis, with/without insufficiency); Q23.0 (Congenital stenosis of aortic valve) - ICD-11: BC71.0 (aortic valve stenosis, non-rheumatic) / BC63 rheumatic aortic valve diseases (foundation-layer codes; confirm exact ICD-11 MMS entry) - MeSH: D001024 (Aortic Valve Stenosis); D001022 (Aortic Valve Insufficiency, related) - OMIM: 109730 (Aortic Valve Disease 1; AOVD1 — NOTCH1-related congenital/BAV form); related syndromic entries include 185500 (Williams-Beuren syndrome, associated with supravalvular AS via ELN) and 300363 (Filamin A-related valvulopathy) - Orphanet: rare/syndromic subtypes are separately coded (e.g., isolated supravalvular aortic stenosis, Williams syndrome); degenerative calcific AS in the elderly is a common, non-rare disease and is not itself an Orphanet entry - MONDO: search "aortic valve stenosis" for the current MONDO ID; congenital and syndromic subtypes are separately coded (e.g., NOTCH1-related bicuspid aortic valve) - HPO: phenotype term "Aortic valve stenosis" (confirm exact HP ID via OAK) and "Bicuspid aortic valve" (HP:0004936, confirm)

Common synonyms/alternative names: Calcific aortic stenosis; senile/degenerative aortic stenosis; calcific aortic valve disease (CAVD); aortic sclerosis (the earliest, hemodynamically insignificant stage); valvular aortic stenosis; rheumatic aortic stenosis (etiology-specific); congenital aortic stenosis; bicuspid aortic valve stenosis; aortic valve calcification (AVC, when referring to the imaging/pathologic substrate rather than the hemodynamic lesion).

Data provenance for this report: Findings below are drawn from aggregated disease-level literature (systematic reviews, GWAS meta-analyses, randomized trials, registries such as PARTNER and the Global Burden of Disease study) rather than individual patient-level EHR data, consistent with standard knowledge-base curation sourcing.

2. Etiology

2a. Disease Causal Factors

Three broad etiologic categories converge on the same end-organ lesion (a stenotic, often calcified, aortic valve):

Degenerative/calcific (most common in adults >65): an active biological process — not passive "wear and tear" — involving endothelial injury, lipoprotein infiltration (notably Lp(a) and oxidized LDL), macrophage/T-cell-driven chronic inflammation, valve interstitial cell (VIC) osteoblastic transdifferentiation, and progressive nodular calcification, closely paralleling early atherogenesis but diverging mechanistically in later stages (PMID:31912380; PMID:32160774).
Congenital (bicuspid or, rarely, unicuspid/quadricuspid) valve: an abnormal two- (or one-) cusp valve morphology arising from developmental defects in endocardial cushion/valvulogenesis (notably via NOTCH1 signaling), which is hemodynamically stressed from birth and undergoes accelerated calcific degeneration, typically presenting 1–2 decades earlier than tricuspid degenerative AS.
Rheumatic: post-infectious autoimmune valvulitis following group A Streptococcus pharyngitis (acute rheumatic fever), causing commissural fusion, leaflet fibrosis/retraction and, over years to decades, stenosis — almost always accompanied by mitral valve involvement and typically with mixed stenosis/regurgitation.

Less common causes: radiation-induced valvulopathy (mediastinal radiotherapy, e.g., for Hodgkin lymphoma or breast cancer, years after exposure), chronic kidney disease/dialysis-associated valvular calcification, familial hypercholesterolemia (homozygous, causing severe premature supra/valvular aortic disease), and inborn errors such as Fabry disease (glycosphingolipid deposition in valve tissue).

2b. Risk Factors

Genetic risk factors: - LPA locus / elevated lipoprotein(a) [Lp(a)] — the single strongest and most replicated genetic risk factor. GWAS identified rs10455872 and rs3798220 at the LPA locus, and Kringle IV type-2 copy-number variation, as determinants of plasma Lp(a) and of aortic valve calcium/AS risk (PMID cluster reviewed in PMC6787733, PMC9182826). A large Danish cohort/Mendelian-randomization study found a 10-fold increase in Lp(a) associated with an age/sex-adjusted hazard ratio of ~1.4 for AS, with an instrumental-variable (causal) estimate of ~1.6 — Mendelian randomization supports a causal role, not mere association (JACC 2013, PMID:24291273/doi 10.1016/j.jacc.2013.09.038). - PALMD (1p21) and TEX41 (2q22) loci — identified in the first large AS GWAS (Icelandic discovery cohort, 2,457 cases/349,342 controls, replicated in ~4,850 cases); rs7543130 (PALMD) OR≈1.20, P=1.2×10⁻²²; rs1830321 (TEX41) OR≈1.15, P=1.8×10⁻¹³. Both loci also associate with bicuspid aortic valve; TEX41 additionally associates with coronary artery disease (Nature Communications 2018, PMID:29511194). - NOTCH1 (9q34.3) — the gene with the strongest evidence for Mendelian/familial congenital aortic valve disease (OMIM 109730, Aortic Valve Disease 1/AOVD1, autosomal dominant). NOTCH1 loss-of-function mutations were first described by Garg et al. (2005) causing BAV with severe calcification, and account for an estimated 5–10% of non-syndromic BAV cases (PMC5573733; PMID:32720365). NOTCH1 haploinsufficiency both disrupts valvulogenesis and de-represses osteogenic gene programs (RUNX2, osteopontin) in adult VICs, linking developmental and degenerative calcification mechanisms; associations with osteoprotegerin/RANK/RANKL pathway dysregulation have also been reported (PMC5299165). - Multi-ancestry GWAS expansion — the Million Veteran Program multi-ancestry GWAS and subsequent integrative genomic analyses replicated ALPL, PALMD, TEX41, LPA, IL6, and FADS1, and identified additional novel loci, plus candidate causal genes implicated via tissue-specific regulatory analysis (Circulation 2023; Nature Communications 2024, doi:10.1038/s41467-024-46639-4). IL6, ALPL (tissue-nonspecific alkaline phosphatase, directly relevant to mineralization biochemistry), and NAV1 were highlighted as novel susceptibility genes in an earlier meta-analysis (bioRxiv 515494/subsequently published). - Other Mendelian/syndromic genetic causes: ELN (elastin) haploinsufficiency in Williams-Beuren syndrome (supravalvular AS, OMIM 185500); FLNA (filamin A) in X-linked myxomatous/dysplastic valvulopathy; homozygous familial hypercholesterolemia (LDLR, APOB, PCSK9) causing premature valvular and supravalvular calcific disease.

Environmental / clinical risk factors (largely overlapping with atherosclerotic risk factors, reflecting shared early pathobiology): - Advanced age (strongest non-genetic risk factor; prevalence rises steeply after age 65) - Male sex - Hypertension - Diabetes mellitus / metabolic syndrome - Smoking - Elevated LDL-cholesterol and elevated Lp(a) (also environmentally/dietarily modulated on top of genetic baseline) - Chronic kidney disease and CKD-mineral bone disorder (disordered calcium-phosphate handling promotes ectopic valvular/vascular calcification) - Prior mediastinal radiation therapy - Rheumatic fever history (for rheumatic AS specifically — itself driven by GAS pharyngitis exposure, crowding, and limited access to antibiotics/penicillin prophylaxis) - Bicuspid aortic valve (a structural risk factor rather than classic "environmental" one, but non-Mendelian in most sporadic cases)

Gene-environment interactions: Elevated Lp(a) and LDL act as substrates for the same oxidative and inflammatory processes that also respond to metabolic-syndrome/diabetogenic dietary exposures — demonstrated experimentally in LDLr⁻/⁻ApoB100/100 mice, where a diabetogenic/procalcific diet markedly accelerated valvular calcification beyond genotype alone (PMID:29539583). This models a genotype (LDL/Lp(a) handling) × environment (diet, metabolic syndrome) interaction analogous to atherosclerosis. CKD represents another gene-environment convergence point: uremic mineral dysregulation accelerates calcification in individuals already genetically predisposed via LPA/PALMD/ALPL risk alleles, though large-scale interaction studies specific to AS are less mature than for the general Lp(a)-CVD relationship.

2c. Protective Factors

No robust genetic protective variant is established (in contrast to LDL/PCSK9 loss-of-function protective alleles for coronary disease). Statins/aggressive LDL-lowering, despite strong observational and mechanistic rationale (parallel to atherosclerosis biology), failed to slow AS progression in randomized trials: - SALTIRE (atorvastatin vs placebo, n=155, up to 3 years): no reduction in aortic-jet velocity progression or valvular calcification. - SEAS (simvastatin/ezetimibe vs placebo; NEJM 2008, doi:10.1056/NEJMoa0804602): no significant effect on AS progression; possible signal of increased cancer incidence noted as a trial-specific finding. - ASTRONOMER (intensive rosuvastatin in mild-moderate AS; PMID:20080097): atorvastatin not associated with slowed hemodynamic progression. - Meta-analyses of ~2,344 patients across randomized placebo-controlled lipid-lowering trials concluded current data do not support statins as a disease-modifying therapy for established AS, in contrast to their clear benefit for atherosclerotic events — implying that once calcific remodeling is established, lipid lowering alone cannot reverse the fibro-calcific process, and/or that the intervention window (before overt stenosis) had already closed in enrolled cohorts.

This "statin paradox" is itself a key mechanistic finding: it argues that early lipid-driven initiation and later self-sustaining osteogenic/fibrotic progression are at least partly biologically distinct phases, motivating newer targeted approaches (Lp(a)-lowering agents such as pelacarsen and lepodisiran are in trials for atherosclerotic CVD, with dedicated Lp(a)-AS progression trials also underway; specific trial identifiers should be confirmed against ClinicalTrials.gov at curation time).

3. Phenotypes

Aortic stenosis is characteristically asymptomatic for years to decades (long latent/compensated phase) before symptoms emerge once the valve area falls below a critical threshold (~1 cm²) and left ventricular hypertrophy can no longer compensate.

Cardinal triad of symptoms (classically taught, sign of decompensation and adverse prognosis): - Exertional dyspnea/heart failure symptoms — most common; reflects diastolic dysfunction from concentric LV hypertrophy progressing to systolic dysfunction. HPO: consider "Dyspnea" (HP:0002094), "Exertional dyspnea" (verify HP ID), "Heart failure" (HP:0001635). - Angina — even without epicardial coronary disease, due to increased myocardial oxygen demand (hypertrophy) outstripping supply (reduced coronary flow reserve, shortened diastolic filling time). HPO: "Angina pectoris" (verify ID). - Syncope/presyncope, typically exertional — due to a fixed cardiac output unable to augment with exertion-induced peripheral vasodilation, and/or transient arrhythmia. HPO: "Syncope" (HP:0001279).

Additional clinical signs: - Harsh crescendo-decrescendo systolic ejection murmur, loudest at the right second intercostal space, radiating to the carotids - Diminished and delayed carotid upstroke (pulsus parvus et tardus) - Soft/absent S2 (calcified, immobile leaflets) - S4 gallop (atrial contraction against a stiff, hypertrophied ventricle) - Sustained/heaving apical impulse - Late complications: atrial fibrillation, heart failure with reduced or preserved EF, sudden cardiac death (particularly once symptomatic and untreated), acquired von Willebrand syndrome/Heyde syndrome (GI angiodysplasia bleeding due to shear-induced degradation of high-molecular-weight vWF multimers across the stenotic valve)

Laboratory abnormalities: elevated BNP/NT-proBNP (correlates with symptom onset and prognosis, used to trigger intervention in select asymptomatic patients per guidelines); acquired reduction of high-molecular-weight von Willebrand multimers (Heyde syndrome); no disease-specific routine chemistry abnormality otherwise.

Phenotype characteristics: - Age of onset: congenital (unicuspid, severe neonatal AS) presents in infancy; BAV-related AS typically presents in the 4th–6th decades; degenerative tricuspid calcific AS typically presents ≥65–70 years; rheumatic AS presents variably depending on access to acute rheumatic fever treatment/prophylaxis, often 3rd–5th decade in endemic regions. - Severity: graded echocardiographically as mild, moderate, severe (see Diagnostics), with "very severe" (peak velocity ≥5 m/s) increasingly recognized as an especially high-risk substage. - Progression: typically slow and progressive over years (mean jet-velocity progression roughly 0.1–0.3 m/s/year, mean gradient progression ~7 mmHg/year in some series), but rate is highly variable between individuals and can accelerate with worsening calcification burden, CKD, or in bicuspid valves. - Frequency of individual signs/symptoms among affected individuals: the systolic murmur is present in nearly all clinically significant cases; classic triad symptoms occur in a minority of the (large) asymptomatic population at any given time but portend a roughly 1–2%/year sudden-death risk once truly asymptomatic-but-severe, rising sharply once symptoms appear (~25% one-year mortality untreated, see Outcome/Prognosis).

Quality of life impact: Symptomatic AS substantially reduces functional capacity (NYHA class progression), exercise tolerance, and overall quality of life; validated general instruments (SF-36, EQ-5D) and disease-specific tools (Kansas City Cardiomyopathy Questionnaire, adapted for valve disease) show marked QoL improvement after successful valve replacement (TAVR or SAVR), a major endpoint in the PARTNER trial family.

Suggested HPO terms (verify exact IDs/labels via OAK before KB use): Aortic valve stenosis; Bicuspid aortic valve; Dyspnea; Exertional dyspnea; Syncope; Angina pectoris; Left ventricular hypertrophy; Heart failure; Atrial fibrillation; Sudden cardiac death; Systolic ejection murmur (or "Heart murmur").

4. Genetic/Molecular Information

Causal/high-risk genes (congenital/Mendelian forms): - NOTCH1 (HGNC:7881; OMIM 190198 gene / 109730 phenotype AOVD1) — autosomal dominant BAV and calcific AS; loss-of-function (haploinsufficient) variants; ~5–10% of non-syndromic familial/sporadic BAV (PMC5573733, PMID:32720365). - ELN (elastin) — Williams-Beuren syndrome (contiguous gene deletion, 7q11.23), causing supravalvular aortic stenosis as part of a multisystem elastin-arteriopathy syndrome (OMIM 185500). - FLNA (filamin A) — X-linked valvulo-septal defects with myxomatous, sometimes stenotic valve disease. - GATA4, GATA5, SMAD6, ROBO4, MAT2A, NOS3 and others — additional candidate/lower-penetrance genes reported in BAV cohorts via targeted and exome sequencing (systematic review: MDPI Genes 2024, doi:10.3390/genes15101309).

Common-variant / polygenic risk loci (degenerative CAVS): - LPA (rs10455872, rs3798220, KIV-2 copy number) — determines Lp(a) level; strongest and causally-supported (Mendelian randomization) common risk locus. - PALMD (1p21.2) and TEX41 (2q22.3) — first GWAS-identified non-LPA loci (PMID:29511194), both also linked to BAV. - ALPL (tissue-nonspecific alkaline phosphatase) — direct biochemical role in phosphate/mineralization biology. - IL6 — inflammatory pathway. - FADS1 — lipid/fatty-acid desaturation pathway. - NAV1 — novel candidate from meta-analysis. - Additional loci from the Million Veteran Program multi-ancestry GWAS and 2024 integrative genomics study, which nominated tissue-specific candidate causal genes via valve-tissue expression/regulatory data (Nat Commun 2024, doi:10.1038/s41467-024-46639-4).

Variant classification/frequency resources: ClinVar and ClinGen classify pathogenicity for NOTCH1/ELN/FLNA variants per ACMG/AMP criteria; gnomAD provides population allele frequencies for common-variant loci (LPA, PALMD, TEX41 alleles are common, MAF often >5–20% depending on ancestry, consistent with polygenic-risk rather than rare fully penetrant Mendelian variance for the bulk of adult degenerative AS).

Somatic vs. germline: AS-associated variants are germline; there is no established somatic-mutation driver analogous to clonal hematopoiesis in this disease (though CHIP/clonal hematopoiesis is an active research area for cardiovascular calcification broadly and may be relevant as an emerging modifier — flagged here as an area for further literature confirmation rather than an established causal link specific to AS).

Functional consequences: NOTCH1 variants are predominantly loss-of-function/haploinsufficient, disrupting Notch-mediated repression of osteogenic transcriptional programs in valve interstitial cells (de-repression of RUNX2/osteopontin-driven calcification) as well as impairing endocardial-cushion/valvulogenesis signaling during development — a dual developmental-and-degenerative mechanism (PMC5299165). LPA/Lp(a)-raising alleles act through a gain of circulating pro-atherogenic, pro-inflammatory, and oxidized-phospholipid-carrying lipoprotein particle rather than a coding loss/gain of a single protein's enzymatic function.

Epigenetic information: DNA methylation differences have been studied in Turner syndrome-associated BAV (PMC9194862) as a candidate modifier explaining incomplete penetrance/phenotypic variability of BAV in monosomy X; broader epigenomic studies of valve tissue (histone marks, chromatin accessibility) in sporadic CAVS are an active but less mature area relative to atherosclerosis epigenomics.

Chromosomal abnormalities: Turner syndrome (45,X and mosaic variants) carries markedly elevated BAV prevalence (14–34% across studies, vs. 0.5–2% general population) and consequent elevated AS risk, alongside coarctation of the aorta and aortopathy (meta-analysis, TechScience CHD journal; JACC 2008, PMID:18538181 area). 22q11.2 deletion syndrome and other conotruncal/left-heart developmental syndromes carry increased rates of left-sided obstructive lesions including AS, though BAV/AS is not the dominant cardiac phenotype in 22q11.2DS specifically.

5. Environmental Information

Environmental/toxic factors: No specific environmental toxin is established as a primary AS cause; chronic low-grade systemic inflammation and oxidative stress (shared with atherosclerosis) are the operative environmental-biological axis. Air-pollution/particulate-matter exposure has been studied as a contributor to vascular calcification broadly and is a plausible but not disease-specific established risk modifier for CAVS.
Radiation: Mediastinal/thoracic radiotherapy (Hodgkin lymphoma, breast, lung cancer treatment) is a well-established, dose- and latency-dependent cause of radiation-associated valvular heart disease, including accelerated aortic valve fibrosis and calcification appearing 10–20+ years post-exposure.
Lifestyle factors: Smoking, sedentary lifestyle contributing to metabolic syndrome/diabetes, and diets promoting dyslipidemia and hyperglycemia (mirroring the diabetogenic/procalcific diet used experimentally in LDLr⁻/⁻ApoB100/100 mice, PMID:29539583) are relevant modifiable contributors, primarily through acceleration of the shared lipid-inflammatory-calcific pathway rather than as independent disease initiators.
Infectious agents: Streptococcus pyogenes (Group A Streptococcus) is the infectious trigger for acute rheumatic fever, which via post-streptococcal autoimmune cross-reactivity (molecular mimicry between streptococcal M-protein epitopes and cardiac valve tissue) causes rheumatic valvulitis and, over years of recurrent/chronic disease, rheumatic aortic (and mitral) stenosis. This remains the dominant global cause of valvular AS in low-resource settings (RHD affects an estimated ~41 million people worldwide, causing ~1.4 million premature deaths annually, with the highest childhood cardiovascular DALY burden in ages 10–14; PMC7731852). Infective endocarditis can also cause secondary valve destruction/dysfunction but more typically causes regurgitation than pure stenosis.

6. Mechanism / Pathophysiology

Causal chain (degenerative calcific AS — the dominant adult mechanism)

Initiating endothelial injury/dysfunction at sites of high mechanical shear/turbulent flow on the aortic (outflow) side of the leaflet — analogous to early atherogenesis (GO: response to fluid shear stress, GO:0034405).
Lipoprotein infiltration and retention — LDL and especially Lp(a)-carried oxidized phospholipids (OxPL) accumulate in the subendothelial valve matrix; Lp(a) also delivers autotaxin, which generates lysophosphatidic acid, amplifying local inflammatory/pro-osteogenic signaling.
Chronic inflammatory infiltration — macrophages, T lymphocytes, and mast cells infiltrate the leaflet; pro-inflammatory cytokines (IL-6, TNF-α, IL-1β) and complement activation sustain a self-perpetuating inflammatory microenvironment (GO: inflammatory response, GO:0006954).
Valve interstitial cell (VIC) activation and osteoblastic transdifferentiation — resident VICs (normally quiescent fibroblast-like cells) activate into myofibroblasts and subsequently trans-differentiate into osteoblast-like cells expressing RUNX2, alkaline phosphatase (ALPL), osteopontin, and osteocalcin — a genuine ectopic bone-formation-like program (GO: osteoblast differentiation, GO:0001649; GO: bone mineralization, GO:0030282), counterbalanced physiologically by inhibitors such as osteoprotegerin (loss of which accelerates calcification in hypercholesterolemic mouse models, PMC3675204).
Nodular calcification and matrix remodeling — deposition of calcium-phosphate (hydroxyapatite; CHEBI relevant to calcium phosphate mineral) at leaflet bases progressing toward the free edges, extracellular matrix degradation/remodeling by matrix metalloproteinases, and progressive leaflet stiffening.
Neovascularization and intravalvular microhemorrhage contribute additional inflammatory and calcific stimulus in more advanced lesions.
Mechanical outflow obstruction — leaflet stiffening and calcific bulk progressively reduce effective orifice area, imposing chronic pressure overload on the left ventricle.
Compensatory concentric LV hypertrophy — normalizes wall stress initially (Laplace's law) but over time causes myocardial fibrosis, diastolic dysfunction, reduced coronary flow reserve, and eventually systolic dysfunction/heart failure once compensation fails.
Clinical decompensation — symptom onset (angina, syncope, dyspnea) signals a marked increase in mortality risk absent intervention.

Upstream vs. downstream: Endothelial injury/lipid infiltration and the LPA/NOTCH1/PALMD genetic lesions sit upstream (initiating/predisposing); inflammatory amplification and VIC osteogenic transdifferentiation are the central, self-sustaining mid-pathway "engine" (explaining why upstream lipid-lowering with statins fails once this program is established); mechanical stenosis, LV hypertrophy, and heart failure are downstream consequences.

Cell types involved: valve interstitial cells (VICs; fibroblast-like, myofibroblast, osteoblast-like states), valve endothelial cells (VECs), infiltrating macrophages, T lymphocytes, mast cells, and — for the downstream cardiac remodeling arm — cardiomyocytes undergoing hypertrophy and interstitial cardiac fibroblasts. Suggested CL terms (verify exact IDs): "cardiac valve interstitial cell," "cardiac endothelial cell" (CL:1000487 candidate), "macrophage" (CL:0000235), "myofibroblast" (CL:0000186), "osteoblast" (CL:0000062, used here in an ectopic/trans-differentiated sense), "T cell" (CL:0000084), "cardiac muscle cell"/cardiomyocyte (CL:0000746).

Rheumatic mechanism (distinct pathway)

Group A streptococcal pharyngitis triggers an autoimmune cross-reactive (molecular mimicry) response targeting valvular endothelium and matrix proteins; recurrent/chronic inflammatory valvulitis produces commissural fusion, leaflet thickening/retraction and fibrosis, and secondary calcification — mechanistically an immune-mediated fibrotic process rather than the primarily lipid/osteogenic pathway of degenerative CAVS, though the two can converge on calcification as a final common pathway (dismech's granuloma_formation- and atherogenesis-adjacent, but non-identical, mechanism logic — a rheumatic AS entry would not conforms_to atherogenesis).

Molecular profiling / omics evidence

Transcriptomics: valve-tissue RNA-seq/microarray studies (deposited in GEO) have characterized differential expression of osteogenic (RUNX2, BMP2), inflammatory (IL6, TNF), and matrix-remodeling (MMPs) genes between calcified and normal leaflets, and underpin the tissue-specific regulatory analyses used in recent integrative GWAS follow-up (Nat Commun 2024).
Proteomics: valve and serum proteomic studies have identified osteopontin, osteocalcin, and complement components as enriched in calcified leaflets and, for some markers, in circulation.
Genomic structural features: copy-number variation at the LPA KIV-2 domain directly determines Lp(a) particle number/plasma level and thus genetic AS risk — a structural-genomic (not just SNP) contributor.
Single-cell/spatial approaches: emerging single-cell RNA-seq of human calcific valve tissue is beginning to resolve VIC subpopulation heterogeneity (quiescent vs. activated vs. osteogenic states) and immune cell diversity within lesions; this is a rapidly developing area as of 2025–2026 and specific dataset citations should be pulled from GEO/Human Cell Atlas at curation time.
Functional genomics: CRISPR/RNAi screens in valve interstitial cell culture systems have been used to interrogate osteogenic transdifferentiation regulators (e.g., RUNX2 pathway components), though this remains a smaller literature than for atherosclerosis-focused functional genomics (DepMap/BioGRID ORCS coverage of this specific phenotype should be checked directly if curating this level of detail).

7. Anatomical Structures Affected

Organ level: - Primary: the aortic valve (three leaflets/cusps in the normal tricuspid valve; two in BAV) and, immediately downstream, the left ventricle (concentric hypertrophy, later systolic dysfunction). - Secondary/complications: left atrium (pressure/volume overload contributing to atrial fibrillation), pulmonary vasculature and right heart (pulmonary hypertension, right heart failure in advanced disease), coronary circulation (reduced flow reserve despite often-normal epicardial arteries; concurrent atherosclerotic CAD is also common given shared risk factors), ascending aorta (post-stenotic dilation from turbulent jet, and — especially with BAV — an intrinsic aortopathy with aneurysm risk independent of hemodynamics), and (for BAV) association with aortic coarctation. - Body systems: primarily cardiovascular; secondarily hematologic (acquired von Willebrand syndrome/Heyde syndrome with GI bleeding), and — via reduced cardiac output — renal (cardiorenal interactions) and cerebrovascular (embolic stroke risk from calcific debris or associated atrial fibrillation).

Tissue and cell level: - Valve leaflet fibrosa, spongiosa, and ventricularis layers (trilaminar valve extracellular matrix architecture) undergo disorganization, fibrosis, and calcific nodule formation, predominantly on the fibrosa (aortic/outflow) side. - Cell populations: valve interstitial cells (activated/osteoblast-like), valve endothelial cells (dysfunctional), infiltrating macrophages/T cells/mast cells, and downstream cardiomyocyte hypertrophy plus interstitial myocardial fibroblast activation (fibrosis) in the left ventricle.

Subcellular level: mitochondrial oxidative stress in VICs contributes to osteogenic reprogramming; nuclear transcriptional reprogramming (RUNX2 activation) drives the osteoblast-like phenotype switch; extracellular matrix vesicles (a recognized nucleation site for hydroxyapatite deposition, paralleling bone/vascular calcification biology) are implicated in the mineralization step itself.

Localization/lateralization: Not applicable in the sense of unilateral/bilateral — the aortic valve is a single, midline structure — but calcification classically begins focally at leaflet bases near the commissures/hinge points and progresses toward the free margins, with the degree and distribution differing characteristically between tricuspid (more circumferential/central) and bicuspid (often raphe-centered, asymmetric) valve calcification, a distinction used clinically (e.g., in CT calcium scoring thresholds, which differ by sex and valve morphology).

Suggested UBERON terms: aortic valve (UBERON:0002137, verify); aortic valve leaflet (UBERON candidate, verify exact ID); left ventricle (UBERON:0002082); left ventricular myocardium; ascending aorta (UBERON:0001496, verify); left atrium (UBERON:0002079).

8. Temporal Development

Onset: - Congenital forms (unicuspid valve, severe neonatal critical AS) present at or shortly after birth, sometimes prenatally on fetal echocardiography. - BAV-associated AS most often becomes clinically significant in the 4th–6th decades of life, decades earlier than tricuspid degenerative AS, due to the additional mechanical stress of an abnormal two-cusp geometry. - Degenerative tricuspid calcific AS is an insidious, chronic process typically becoming hemodynamically severe after age 65–70, with prevalence rising steeply with each further decade of life. - Rheumatic AS onset is more variable, often presenting as clinically significant stenosis in the 3rd–5th decade in endemic, resource-limited regions, reflecting years of recurrent/subclinical rheumatic valvulitis following childhood acute rheumatic fever.

Progression: - Stages (echocardiographic, per current ACC/AHA staging framework): Stage A (at risk — e.g., BAV or early sclerosis without stenosis), Stage B (progressive, mild-moderate hemodynamic obstruction), Stage C (asymptomatic severe — C1 normal LV function, C2 LV dysfunction), Stage D (symptomatic severe — D1 high-gradient, D2 low-flow/low-gradient with reduced EF, D3 low-flow/low-gradient with preserved EF/paradoxical low-flow). - Progression rate: generally slow (years), quantifiable as annualized increase in peak velocity/mean gradient and decrease in valve area, but with substantial inter-individual variability; BAV, higher baseline calcium burden, CKD, and elevated Lp(a) are associated with faster progression. - Course pattern: typically unidirectional and progressive (no spontaneous regression of established calcific stenosis); asymptomatic patients can remain stable for years before relatively abrupt symptom onset once critical obstruction is reached, at which point the clinical trajectory changes sharply (a recognized "cliff-edge" prognostic transition, discussed further in Outcome/Prognosis). - Duration: chronic and, once truly severe and symptomatic, rapidly lethal without intervention (median survival on the order of ~2 years untreated after symptom onset, per classical natural-history literature, with more contemporary series estimating ~77% one-year survival in unoperated symptomatic patients, PMC3954323 area).

Patterns: - No spontaneous remission is described for calcific AS (unlike some inflammatory valvulopathies). - The key "critical period" from a management perspective is the transition from asymptomatic-severe to symptomatic disease — a major focus of intervention-timing guidelines and trials (e.g., debate over early intervention in asymptomatic severe AS, addressed by studies such as PMC8026050 and the JAMA Cardiology meta-analysis, doi:10.1001/jamacardio.2021.5528 area) — because outcomes worsen sharply once symptoms (or LV dysfunction/biomarker elevation) develop.

9. Inheritance and Population

Epidemiology: - Calcific/degenerative AS: prevalence rises steeply with age, generally cited in the range of a few percent of individuals over 65 and up to ~2–4% (severe AS specifically lower, on the order of 1–3%) in octogenarians in population-based echocardiographic screening cohorts (classic sources: Cardiovascular Health Study, Helsinki Aging Study, Framingham-related analyses — confirm exact contemporary percentages against a current source such as the JACC 2025 state-of-the-art review, doi:10.1016/j.jacc.2025.06.049, at curation time). - Global Burden of Disease-based estimates place non-rheumatic calcific aortic valve disease burden as rising substantially from 1990 to 2021 with further projected increases to 2050, tracking population aging (medRxiv 2025.02.05.25321722; JAHA 2024, doi:10.1161/JAHA.124.037991). - Aortic valve stenotic disease overall (all etiologies) is estimated to affect on the order of ~9 million people worldwide, with calcific disease dominant in high-sociodemographic-index (high-SDI) regions and rheumatic disease dominant in low-SDI regions (Nature Reviews Cardiology 2021, doi:10.1038/s41569-021-00570-z). - Bicuspid aortic valve: population prevalence ~0.9–1.36% by autopsy/screening series (up to ~4.6/1000 live births in a newborn screening cohort), making it the most common congenital heart defect.

Inheritance pattern (genetic forms): - NOTCH1-related AOVD1/BAV: autosomal dominant, with variable/incomplete penetrance and expressivity (some carriers have isolated BAV without stenosis; others develop severe calcific AS or thoracic aortic aneurysm). - Common-variant polygenic risk (LPA, PALMD, TEX41, ALPL, IL6, FADS1, etc.): complex/multifactorial inheritance — no single-gene Mendelian pattern; risk is cumulative and interacts with age and environmental exposures. - Williams-Beuren syndrome (ELN, supravalvular AS): autosomal dominant, typically due to a de novo 7q11.23 microdeletion (contiguous gene deletion syndrome), so usually not inherited from a parent but is transmissible at 50% risk if a parent is affected.

Penetrance/expressivity: Notably incomplete/variable for NOTCH1 and other BAV-associated genes — family members carrying the same variant may show isolated BAV, BAV with AS, BAV with aortopathy, or apparently normal valve morphology, motivating cascade echocardiographic screening in relatives of BAV probands.

Genetic anticipation: Not a recognized feature of AS (not a repeat-expansion disorder).

Founder effects / consanguinity: Not prominently described for common degenerative AS; may be locally relevant for specific rare Mendelian valvulopathy variants in genetically isolated populations, but this is not a well-characterized area in the mainstream AS literature.

Population demographics: - Sex ratio: BAV shows a strong male predominance (commonly cited 2:1 to 4:1 male:female across studies, with a newborn screening cohort reporting 4:1); however, sex differences in valve phenotype presentation exist — men with BAV more often present with aortic regurgitation, while women more often present with aortic stenosis (Circ Cardiovasc Imaging, PMID:28251911). Degenerative calcific AS in the elderly still shows a male predominance in incidence, though the gap narrows somewhat with the oldest age groups, and women may show relatively more fibrotic (versus purely calcific) valve remodeling patterns — an active area of sex-specific pathobiology research. - Turner syndrome (45,X): markedly elevated BAV prevalence (14–34% vs. 0.5–2% general population), making it an important syndromic subgroup for population-level AS risk. - Geographic distribution: rheumatic AS is concentrated in low- and middle-income countries (Sub-Saharan Africa, South Asia, Pacific Islander populations, Indigenous populations in some high-income countries) reflecting limited access to primary prevention (penicillin prophylaxis) and treatment of streptococcal pharyngitis/acute rheumatic fever; calcific AS predominates in aging high-income-country populations. - Age distribution: BAV-related AS peaks in middle age (40s–60s); degenerative tricuspid AS peaks in the elderly (>70–80); rheumatic AS varies by region but often presents younger than degenerative AS in endemic settings.

10. Diagnostics

Clinical/imaging tests: - Transthoracic echocardiography (TTE) is the primary diagnostic modality. Key parameters per current (2020 ACC/AHA and analogous ESC) guidelines: peak aortic jet velocity, mean transvalvular pressure gradient (MPG), and aortic valve area (AVA) by the continuity equation. Severe AS is defined by peak velocity ≥4 m/s, MPG ≥40 mmHg, and/or AVA ≤1.0 cm² (or indexed AVA ≤0.6 cm²/m²); "very severe" AS is increasingly recognized at peak velocity ≥5 m/s or ≥5.5 m/s, associated with markedly worse event-free survival (44%, 25%, 11%, 4% at 1–4 years in one cohort, AHA Circulation 2010-era study). - Four hemodynamic categories are defined when flow, gradient, and area are discordant: high-gradient severe AS; low-flow low-gradient AS with reduced LVEF (classical low-flow low-gradient); low-flow low-gradient AS with preserved LVEF (paradoxical low-flow, low-gradient); and normal-flow low-gradient AS with preserved LVEF — reflecting the complexity of grading in the presence of ventricular dysfunction or small ventricular cavities. - Dobutamine stress echocardiography helps distinguish truly severe AS with reduced contractile/flow reserve from pseudo-severe AS in low-flow, low-gradient, reduced-EF states. - Cardiac CT with aortic valve calcium (AVC) scoring (Agatston units) is a class-I-recommended adjunct in ACC/AHA/ESC guidelines specifically to resolve discordant/low-gradient grading, with established sex-specific severity thresholds (men and women have different calcium-score cutoffs for "severe" AS given differing valve calcification propensity). - Cardiac MRI for LV volumes/function, myocardial fibrosis (late gadolinium enhancement, T1 mapping) when echo is inconclusive or for research-grade fibrosis quantification. - Cardiac catheterization (invasive hemodynamic gradient measurement) reserved for cases of echo-catheterization discordance or when non-invasive data are inconclusive; coronary angiography (or coronary CTA) is routinely performed pre-intervention to assess concomitant CAD. - Biomarkers: BNP/NT-proBNP elevation supports symptomatic status/prognostic risk stratification and can help trigger earlier intervention in asymptomatic patients per guideline-endorsed thresholds. - Electrocardiography: may show LV hypertrophy pattern, left atrial abnormality, conduction disease (especially relevant peri-TAVR given proximity of the conduction system to the aortic annulus). - Histopathology (surgical/explanted valve specimens): shows fibrosis, dystrophic/nodular calcification predominantly on the aortic surface of the fibrosa layer, chronic inflammatory infiltrate, and neovascularization in advanced disease; rheumatic valves additionally show commissural fusion and characteristic fibrous thickening/retraction distinct from purely nodular calcific deposits.

Genetic testing: Not routine for typical sporadic degenerative or BAV-related AS, but recommended in the context of: familial clustering of BAV/thoracic aortic disease (first-degree relative screening echocardiography is guideline-recommended regardless of genetic testing; targeted gene panels including NOTCH1, ACTA2, TGFBR1/2, FBN1, SMAD3 etc. are used when a syndromic thoracic aortic aneurysm/BAV phenotype is suspected); suspected Williams-Beuren syndrome (chromosomal microarray/FISH for 7q11.23 deletion) in supravalvular AS; suspected homozygous familial hypercholesterolemia (LDLR/APOB/PCSK9 sequencing) in children/young adults with premature valvular/supravalvular calcific disease.

Clinical/differential diagnosis: Hypertrophic obstructive cardiomyopathy (dynamic subaortic/midcavitary obstruction, distinguished by echo features and provocative maneuvers), subvalvular/supravalvular aortic stenosis (fixed obstruction at a different anatomic level than the valve itself, important to distinguish since management differs — e.g., surgical membrane resection rather than valve replacement for discrete subvalvular membranes), aortic sclerosis (valve thickening/calcification without significant hemodynamic obstruction — the earliest point on the same disease continuum), and flow murmurs of other causes (anemia, hyperthyroidism, physiologic in young/athletic individuals) that can mimic the systolic ejection murmur without true stenosis.

Screening: No population-based screening program exists for degenerative AS given its age-related, largely non-preventable natural history; targeted echocardiographic screening is recommended for first-degree relatives of BAV/thoracic aortic aneurysm probands given the substantial heritable component, and for individuals with Turner syndrome given the markedly elevated BAV prevalence in that population.

11. Outcome/Prognosis

Survival/mortality: - Asymptomatic severe AS under watchful waiting: roughly 44% experience death or require valve replacement by 2 years in some cohorts; one comparative analysis found 1-year mortality of 5.2% (watchful waiting) vs. 4.7% (early surgery), and 2-year survival of 83.9% vs. 92.5% respectively, favoring earlier intervention in appropriately selected patients (Annals of Thoracic Surgery, PMID area referenced above). - "Very severe" AS (peak velocity ≥5.5 m/s): event-free survival of only 44%, 25%, 11%, and 4% at 1, 2, 3, and 4 years respectively if managed conservatively — among the strongest natural-history prognostic signals in cardiology (Circulation, PMID:20026779 area). - Symptomatic, unoperated severe AS: classically associated with a median survival around 2–3 years from symptom onset (angina ~5 years, syncope ~3 years, heart failure ~1–2 years, per the long-standing Ross-Braunwald natural-history framework); more recent series report ~77% one-year survival in unoperated symptomatic patients — still a markedly poor prognosis relative to treated disease. - Sudden cardiac death is a recognized risk in truly asymptomatic-but-severe AS (historically estimated around 1%/year), a key argument for evolving early-intervention strategies and biomarker/imaging-based risk stratification (JAMA Cardiology systematic review/meta-analysis on early intervention vs. watchful waiting in asymptomatic severe AS).

Post-intervention outcomes (TAVR/SAVR): - High surgical risk (PARTNER 1): 5-year mortality similar between TAVR (67.8%) and SAVR (62.4%), HR 1.04 (95% CI 0.86–1.24), demonstrating durable comparable outcomes in this population (Lancet 2015, PMID:25788234). - Intermediate risk (PARTNER 2): 24-month mortality 16.7% (TAVR) vs. 18.0% (SAVR) — non-inferior/comparable (NEJM 2016, PMID:27040324 area). - Low risk (PARTNER 3): TAVR superior to SAVR for the composite of death/stroke/rehospitalization at 1 year; by 7-year follow-up, TAVR and surgery show similar durability and valve function (NEJM 2025 7-year report, doi:10.1056/NEJMoa2509766) — a major, still-evolving evidence base extending TAVR's applicability across the full surgical-risk spectrum.

Morbidity/complications: heart failure, atrial fibrillation, stroke (both disease-related embolism and periprocedural), conduction system disease/need for permanent pacemaker (particularly post-TAVR, given proximity of the conduction system to the valve annulus), acquired von Willebrand syndrome with GI bleeding (Heyde syndrome, which characteristically resolves after valve replacement), and, for rheumatic disease, concomitant mitral valve disease compounding overall morbidity.

Quality of life: substantially improved after successful intervention (TAVR/SAVR), a primary endpoint across the PARTNER trial family and reflected in validated instruments (KCCQ, SF-36, EQ-5D).

Prognostic factors/biomarkers: symptom status (single strongest classical prognostic determinant), peak jet velocity/mean gradient severity ("very severe" category especially high-risk), LV ejection fraction and presence of low-flow states, degree of valve calcification (AVC score), elevated BNP/NT-proBNP, global longitudinal strain abnormalities (subclinical LV dysfunction), concomitant coronary artery disease, frailty and comorbidity burden (central to surgical/TAVR risk-scoring and candidacy decisions), and elevated Lp(a) (associated with both incident risk and, in some studies, faster hemodynamic progression).

12. Treatment

No effective pharmacotherapy modifies the natural history of the valvular lesion itself. Definitive treatment is mechanical relief of obstruction; medical therapy addresses risk-factor modification, symptom/heart-failure management, and comorbidities.

Pharmacotherapy (adjunctive/comorbidity management, not disease-modifying for the valve): - Standard heart failure and hypertension management (with caution regarding preload/afterload-sensitive agents in severe AS) once symptomatic or LV dysfunction present. - Statins/lipid-lowering: NOT disease-modifying for AS progression despite benefit for atherosclerotic risk reduction generally (SALTIRE, SEAS, ASTRONOMER — see Etiology/Protective Factors above); still indicated per standard cardiovascular risk criteria, just not "for" the valve disease itself. - Emerging investigational Lp(a)-lowering agents (e.g., pelacarsen, an antisense oligonucleotide, and lepodisiran, an siRNA) are in active clinical development primarily for atherosclerotic cardiovascular disease, with dedicated hypotheses/trials examining whether Lp(a) lowering can slow AS progression given the strong causal genetic evidence for Lp(a) in AS — specific trial identifiers, phase, and results should be confirmed against ClinicalTrials.gov/recent primary literature at curation time, as this is a fast-moving area. - Rheumatic AS: secondary antibiotic prophylaxis (penicillin) to prevent recurrent rheumatic fever/valvulitis is a cornerstone of preventing disease progression in that specific etiology (distinct from the calcific-disease pharmacology discussion above).

Surgical and interventional (definitive therapy): - Surgical aortic valve replacement (SAVR): long-standing gold-standard, using mechanical or bioprosthetic valves, with established durability data. - Transcatheter aortic valve replacement/implantation (TAVR/TAVI): catheter-based valve replacement, now guideline-supported across the low-to-high surgical risk spectrum based on the PARTNER trial program (PARTNER 1 high-risk PMID:25788234; PARTNER 2 intermediate-risk NEJM 2016; PARTNER 3 low-risk, 1-year superiority and 7-year comparable durability, NEJM 2019/2025) and parallel CoreValve/Evolut trial programs. TAVR has become the dominant intervention modality for symptomatic severe AS given its less invasive nature, with ongoing evidence generation on long-term (>10 year) valve durability, particularly relevant as TAVR is used in younger, lower-risk patients. - Balloon aortic valvuloplasty: a temporizing (not curative) procedure, used as a bridge to definitive TAVR/SAVR in hemodynamically unstable patients or those needing urgent noncardiac surgery, or in the pediatric/young congenital AS population where valve growth potential argues against prosthetic replacement. - Ross procedure (pulmonary autograft) — an option in select younger patients, particularly in congenital/pediatric AS, avoiding lifelong anticoagulation and allowing growth.

Rehabilitative/supportive care: cardiac rehabilitation post-intervention; standard heart-failure supportive management for those not undergoing intervention or awaiting it; endocarditis-prophylaxis counseling for prosthetic valve recipients per current guidelines.

Experimental/investigational: Lp(a)-lowering agents as above; osteoprotegerin/RANKL-pathway-targeted approaches remain preclinical (mouse model rationale from PMC3675204) rather than in clinical trials for AS specifically; anti-inflammatory strategies analogous to those tested in atherosclerosis (e.g., canakinumab-class IL-1β inhibition) are of mechanistic interest given the IL6 GWAS signal but are not established AS therapies.

Treatment outcomes: As detailed under Prognosis — TAVR and SAVR produce comparable survival across risk strata in randomized trials, with TAVR showing an early advantage in low-risk patients for the composite endpoint at 1 year and comparable long-term valve durability out to 7 years.

Personalized/precision approaches: risk-stratified selection between TAVR and SAVR based on surgical risk scores (STS-PROM, EuroSCORE II), frailty assessment, valve/annulus anatomy (including bicuspid-specific anatomic considerations that affect TAVR device selection and outcomes), and access-site/vascular anatomy; genotype-informed risk assessment (e.g., elevated Lp(a) or known familial NOTCH1 BAV) is increasingly used to guide surveillance intensity and cascade family screening rather than to select a specific drug therapy at present.

Suggested NCIT terms: Surgical Procedure (NCIT:C15329); Transcatheter Aortic Valve Replacement (confirm exact NCIT ID, candidate NCIT:C80324); Pharmacotherapy (NCIT:C15986); Organ/Valve Transplantation-adjacent procedure codes as applicable; Balloon Valvuloplasty (confirm NCIT ID); Cardiac Rehabilitation (NCIT candidate, confirm).

13. Prevention

Primary prevention: Modifiable-risk-factor control (blood pressure, LDL-cholesterol per general cardiovascular risk guidelines, smoking cessation, diabetes/metabolic-syndrome management) reduces atherosclerotic cardiovascular risk broadly but has not been shown to prevent the specific development of calcific AS, given the negative statin trials described above — this is an important, somewhat counterintuitive point distinguishing AS from coronary disease prevention. For rheumatic AS specifically, primary prevention of acute rheumatic fever via prompt antibiotic treatment of streptococcal pharyngitis is genuinely effective and central to reducing global RHD-attributable AS incidence, particularly in low-resource, high-incidence settings.
Secondary prevention: Secondary antibiotic (penicillin) prophylaxis after acute rheumatic fever prevents recurrent valvulitis and thus limits progression to (or worsening of) rheumatic aortic/mitral stenosis — a well-established, guideline-endorsed intervention. For calcific AS, "secondary prevention" in practice means surveillance echocardiography at guideline-recommended intervals (frequency scaled to severity stage) to detect progression to severe/symptomatic disease at the optimal point for intervention, since no medical therapy prevents progression once the process has begun.
Tertiary prevention: Timely valve replacement (TAVR/SAVR) prevents the downstream complications of untreated severe symptomatic AS (heart failure, sudden death); post-intervention care (endocarditis prophylaxis for prosthetic valves, anticoagulation management for mechanical valves, periodic prosthetic valve surveillance) prevents intervention-related complications.
Screening/early detection: targeted (not population-wide) echocardiographic screening of first-degree relatives of BAV/thoracic-aortopathy probands and of individuals with Turner syndrome, given markedly elevated baseline risk in these groups; risk stratification using AVC scoring and biomarkers (BNP/NT-proBNP) to identify asymptomatic patients who may benefit from earlier intervention.
Genetic counseling: relevant for families with NOTCH1-associated autosomal dominant BAV/AOVD1, Williams-Beuren syndrome (recurrence risk essentially that of a de novo microdeletion, low for future pregnancies unless germline mosaicism), and homozygous familial hypercholesterolemia (autosomal codominant, with defined recurrence risk counseling for LDLR/APOB/PCSK9 pathogenic variants).
Public health interventions: for rheumatic AS, public-health-level investment in access to primary care/antibiotics for streptococcal pharyngitis, improved living conditions (reducing overcrowding-driven GAS transmission), and RHD control programs (echocardiographic screening programs for latent RHD in endemic regions, WHO-endorsed) represent the most effective population-level prevention strategy for this etiology globally.
Prophylaxis: infective endocarditis antibiotic prophylaxis is recommended for patients with prosthetic aortic valves (and select other high-risk categories) undergoing specified dental/procedural exposures, per current AHA/ESC guidelines.

14. Other Species / Natural Disease

Taxonomy: naturally occurring aortic/subaortic valvular stenosis is well described in domestic dogs (NCBITaxon:9615, Canis lupus familiaris), particularly as subvalvular aortic stenosis (SAS), a congenital fixed left ventricular outflow tract obstruction with strong breed predisposition.
Breed: Newfoundlands, Golden Retrievers, Rottweilers, Boxers, and German Shepherd Dogs are classically over-represented for canine subvalvular/aortic stenosis (breed-specific Vertebrate Breed Ontology/VBO identifiers should be confirmed at curation time; this is a well-established heritable condition in Newfoundlands specifically, with published pedigree/heritability analyses).
Gene: the specific causal genetic variant(s) for canine SAS are less definitively characterized than the human NOTCH1/LPA loci, though it is recognized as heritable with a complex/polygenic inheritance pattern in most studied breeds; orthology to human developmental valve genes (e.g., NOTCH1 pathway members) is biologically plausible but not established as the confirmed canine mechanism in the literature reviewed here — flag for targeted OMIA/veterinary literature confirmation if curating this comparative angle in detail.
Natural disease and veterinary relevance: canine SAS is one of the most common congenital cardiac defects in dogs and a significant cause of exercise intolerance, syncope, and sudden cardiac death in affected large-breed dogs, giving it substantial veterinary clinical importance and making affected dogs a naturally-occurring (rather than experimentally induced) comparative model.
Comparative pathology: the fixed left ventricular outflow obstruction, compensatory LV hypertrophy, and risk of sudden death parallel human congenital/valvular AS pathophysiology, though the anatomic level (frequently subvalvular fibrous ridge/membrane in dogs) and degenerative-calcific biology differ from adult human calcific AS — better viewed as a comparative model for congenital/subvalvular obstruction than for the lipid-driven calcific pathway.
Transmission/zoonotic potential: not applicable — this is a non-infectious structural cardiac disease in the calcific/congenital forms; note that the infectious trigger for rheumatic AS (Group A Streptococcus) is itself a human-adapted pathogen without a natural zoonotic reservoir relevant to this disease pathway.

15. Model Organisms

Genetically engineered and diet-induced mouse models (the dominant experimental system for calcific AS mechanism research): - Ldlr⁻/⁻ mice: develop aortic/vascular calcification with a distribution paralleling human disease; used with micro-CT quantification as a model for aortic calcification generally (PMID:22051553). - Ldlr⁻/⁻ApoB100/100 mice: hypercholesterolemic model prone to aortic valve calcification and oxidative stress with functional valvular disease mimicking the clinical syndrome; a customized diabetogenic/procalcific diet further accelerates calcification, hyperglycemia, and obesity in this model, directly modeling gene(lipid handling)×diet(metabolic syndrome) interaction (PMID:29539583). - Notch1⁺/⁻ heterozygous mice (on high-cholesterol diet): an established small-animal model of calcific aortic valve disease reflecting the human NOTCH1-haploinsufficiency mechanism; used, for example, to test genetic ablation of serotonin receptor 2B (Htr2b), which improved aortic valve hemodynamics in this model (PMC7688160), illustrating the model's utility for testing candidate modifier genes/pathways. - Aged hypercholesterolemic mice (without additional genetic valve-specific lesions): develop calcific AS with aging plus hypercholesterolemic diet, supporting age as an independent, non-genetic experimental variable (PMID:17075015). - Hypercholesterolemic/hypertensive combined mouse models: develop a more fibrotic (versus purely calcific) valve stenosis phenotype, useful for modeling the fibrotic component of human CAVD and potentially for sex- or subtype-specific human disease correlates (PMC4767592). - Osteoprotegerin (Opg) pathway models: OPG administration/genetic manipulation in hypercholesterolemic mice modulates valve calcification and preserves valve function, supporting OPG/RANK/RANKL as a therapeutic target axis (PMC3675204).

Model characteristics: - Phenotype recapitulation: these models reproduce key histopathologic features (lipid deposition, macrophage infiltration, osteogenic marker expression, calcific nodule formation) and, in several models, measurable hemodynamic valve dysfunction (reduced valve area, increased velocity by echocardiography), giving reasonable face validity for the initiation/inflammatory/early-osteogenic phases of human disease. - Model limitations: mice do not naturally develop the degree of leaflet macro-calcification and hemodynamically severe stenosis seen in elderly humans without genetic/dietary manipulation and prolonged time courses; the mouse valve is anatomically smaller and structurally distinct; models largely capture the LDL/cholesterol-driven and Notch-pathway-driven arms but less fully recapitulate the Lp(a)-driven arm (mice do not naturally express an LPA-orthologous gene generating human-like Lp(a) particles, a recognized cross-species translational gap given how central Lp(a) is to human genetic risk — a candidate HUMAN_MODEL_MISMATCH-type caveat if this disease were curated into a mechanism module framework); rheumatic-etiology AS has no direct standard rodent model given its human-adapted streptococcal/autoimmune basis. - Research applications: these models are used to dissect the initiating lipid/inflammatory phase, test candidate therapeutic targets (OPG/RANKL, serotonin receptor 2B, and others) before human trials, and to generate mechanistic hypotheses for pathways (e.g., IL6, ALPL) subsequently supported by human GWAS. - Resources: Mouse Genome Informatics (MGI) for strain/allele records (e.g., Ldlr and Notch1 alleles), International Mouse Phenotyping Consortium (IMPC) for systematic knockout phenotyping data potentially relevant to candidate valve-calcification genes, and GEO for deposited transcriptomic datasets from these valve-calcification mouse models.

Summary for Knowledge-Base Curation

This disease is best modeled with at least two distinct etiologic pathophysiology chains given its heterogeneous causation: (1) a degenerative/calcific chain (endothelial injury → lipid/Lp(a) infiltration → chronic inflammation → VIC osteoblastic transdifferentiation → nodular calcification → mechanical obstruction → LV hypertrophy/heart failure), strongly analogous to — but mechanistically distinct from — the dismech atherogenesis module, and a plausible candidate for its own dedicated "calcific valvulopathy" mechanism module given its recurrence pattern (it would also be a strong candidate to conforms_to a future cardiomyopathy_maladaptive_remodeling node for the downstream LV-hypertrophy-to-heart-failure arm); and (2) a rheumatic/autoimmune chain (GAS pharyngitis → molecular mimicry autoimmune valvulitis → commissural fusion/fibrosis → stenosis), which is mechanistically distinct and should not be conflated with the calcific pathway in a single pathophysiology chain. Congenital/BAV forms sit partly upstream of the calcific chain (as an "at-risk" structural predisposition, Stage A in the ACC/AHA framework) rather than being a wholly separate mechanism. The strongest, most rigorously evidenced single risk factor for curation priority is the LPA/Lp(a) axis (Mendelian-randomization-supported causality); NOTCH1 is the best-evidenced Mendelian congenital driver; and the negative statin trial evidence (SALTIRE/SEAS/ASTRONOMER) is an important, well-documented "expected but disconfirmed" treatment hypothesis worth explicitly capturing as a mechanistic_hypotheses/discussion entry rather than omitting.

Ask OpenScientist

OpenScientist Report

Inheritance

Subtypes

Mechanistic Hypotheses

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Biochemical Markers

Diagnosis

Progression

Prevalence

Epidemiology

Clinical Trials

Experimental Models

Animal Models

Source YAML

References & Deep Research

References

Deep Research

Aortic Valve Stenosis: Comprehensive Disease Characteristics Research Report

1. Disease Information

2. Etiology

2a. Disease Causal Factors

2b. Risk Factors

2c. Protective Factors

3. Phenotypes

4. Genetic/Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

Causal chain (degenerative calcific AS — the dominant adult mechanism)

Rheumatic mechanism (distinct pathway)

Molecular profiling / omics evidence

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome/Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Summary for Knowledge-Base Curation

Sources